# 2025年11月30日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 分子印迹聚合物纳米载体跨越血脑屏障：脑疾病治疗的新前沿

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41316895](https://pubmed.ncbi.nlm.nih.gov/41316895)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41316895
**DOI：** 10.1002/advs.202517004

### 第一部分 原文与翻译

**英文原标题：** Crossing the Blood-Brain Barrier with Molecularly Imprinted Polymeric Nanocarriers: An Emerging Frontier in Brain Disease Therapy.

**英文摘要原文：**
The ability to permeate the blood‒brain barrier (BBB) remains a major challenge in treating neurological disorders. Molecularly imprinted polymeric nanocarriers (nanoMIPs) are emerging as versatile platforms that integrate antibody-mimetic recognition with exceptional stability, tunable physicochemical properties, and controlled drug release. This review summarizes recent advances in nanoMIP design, including template selection, polymerization strategies, and surface modifications, and explores their potential for targeted brain delivery. Particular emphasis is placed on surface engineering approaches, such as functionalization with apolipoprotein E (ApoE), transferrin, and angiopep-2 ligands, which exploit receptor-mediated transcytosis (RMT) to increase BBB permeation and drug accumulation in pathological brain regions. The therapeutic and diagnostic applications of nanoMIPs in neurodegeneration, brain tumors, and CNS infections are also highlighted. Finally, current limitations and future perspectives are discussed, including biocompatibility, large-scale production, and regulatory considerations, positioning nanoMIPs as a next-generation platform for overcoming BBB-associated barriers, and advancing precision brain therapeutics.

**中文摘要译文：**
穿透血脑屏障（BBB）的能力仍是治疗神经系统疾病的主要挑战。分子印迹聚合物纳米载体（nanoMIPs）作为一种多功能平台崭露头角，其将模拟抗体的识别能力与卓越的稳定性、可调控的理化特性以及可控药物释放相结合。本综述总结了nanoMIPs设计的最新进展，包括模板选择、聚合策略和表面修饰，并探讨了其在靶向脑部递送中的潜力。重点介绍了表面工程方法，例如通过功能化载脂蛋白E（ApoE）、转铁蛋白和angiopep-2配体，利用受体介导的转胞吞作用（RMT）增强BBB穿透能力和病理脑区的药物积累。此外，还突出了nanoMIPs在神经退行性疾病、脑肿瘤和中枢神经系统感染中的治疗与诊断应用。最后，讨论了当前的局限性和未来展望，包括生物相容性、规模化生产和监管考量，认为nanoMIPs是克服BBB相关障碍并推动精准脑疗法的下一代平台。

### 第二部分 AI 大师评价

本研究综述了分子印迹聚合物纳米载体（nanoMIPs）在突破血脑屏障（BBB）以治疗脑部疾病方面的最新进展。通过整合抗体模拟识别和表面工程技术，nanoMIPs展现了在靶向递送和可控药物释放中的巨大潜力。其创新性在于利用受体介导的转胞吞作用（RMT）增强BBB穿透能力，为神经退行性疾病、脑肿瘤等提供了新的治疗策略。尽管nanoMIPs在规模化生产和生物相容性方面仍面临挑战，但其作为下一代精准脑疗法平台的潜力不容忽视，对未来临床和研究具有重要意义。

---

## 2. JoGo 1.0：涵盖19,194个人类基因中470万个单倍型的ACTG层级命名法与数据库

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41316730](https://pubmed.ncbi.nlm.nih.gov/41316730)
**期刊：** Nucleic acids research
**PMID：** 41316730
**DOI：** 10.1093/nar/gkaf1232

### 第一部分 原文与翻译

**英文原标题：** JoGo 1.0: the ACTG hierarchical nomenclature and database covering 4.7 million haplotypes across 19,194 human genes.

**英文摘要原文：**
The Joint Open Genome and Omics Platform 1.0 (JoGo) is a global, long-read-based human haplotype database covering 19 194 MANE-standardized protein-coding genes. JoGo introduces a novel ACTG hierarchical nomenclature-A (amino acid), C (coding), T (transcript), and G (gene body)-that assigns numeric identifiers in descending order of global frequency. Using high-fidelity long-read sequencing, we assembled haplotype-resolved contigs for 258 globally sampled genomes, including 108 sequenced in-house. We cataloged 174 376 A-, 300 610 C-, 486 288 T-, and 3 695 204 G-level haplotypes (4 656 478 in total). Haplotype IDs are assigned once globally across all sequences, including those originating from GRCh38 and CHM13v2 reference assemblies, embedding reference haplotypes within the same frequency-ranked space and enabling direct cross-assembly comparison. JoGo maps functional variants from ClinVar, GWAS Catalog, and GTEx onto their corresponding ACTG-haplotypes and provides haplotype-expression QTL results from 1280 HapMap RNA-seq samples across three independent studies. The web portal provides flexible search by gene name, variant ID, or ACTG code. It offers both an interactive online viewer and a privacy-preserving local viewer for secure integration with user data. JoGo enables high-resolution exploration of haplotype diversity, facilitating the identification of functional variants relevant to gene regulation, disease associations, and precision medicine. JoGo 1.0 is freely accessible at https://jogo.csml.org.

**中文摘要译文：**
联合开放基因组与组学平台1.0（JoGo）是一个基于长读长测序技术的全球性人类单倍型数据库，涵盖了19,194个MANE标准化的蛋白质编码基因。JoGo引入了一种新颖的ACTG层级命名法——A（氨基酸）、C（编码）、T（转录本）和G（基因体）——按照全球频率的降序分配数字标识符。利用高保真长读长测序技术，我们为258个全球采样的基因组组装了单倍型解析的连续序列，其中包括108个内部测序的样本。我们记录了174,376个A级、300,610个C级、486,288个T级和3,695,204个G级单倍型（总计4,656,478个）。单倍型ID在全球范围内对所有序列（包括源自GRCh38和CHM13v2参考组装的序列）进行一次分配，将参考单倍型嵌入相同的频率排序空间，从而实现直接的跨组装比较。JoGo将ClinVar、GWAS Catalog和GTEx的功能变异映射到其对应的ACTG单倍型上，并提供了来自三个独立研究的1280个HapMap RNA-seq样本的单倍型-表达QTL结果。该网络门户支持通过基因名称、变异ID或ACTG代码进行灵活搜索，并提供交互式在线查看器和隐私保护的本地查看器，以便安全地与用户数据进行整合。JoGo能够高分辨率地探索单倍型多样性，有助于识别与基因调控、疾病关联以及精准医学相关的功能变异。JoGo 1.0可通过https://jogo.csml.org免费访问。

### 第二部分 AI 大师评价

本研究开发了JoGo 1.0平台，通过创新的ACTG层级命名法和高保真长读长测序技术，构建了一个涵盖19,194个人类基因的单倍型数据库。其核心创新在于将参考单倍型与频率排序空间相结合，支持跨组装比较和功能变异映射。这一数据库为基因调控、疾病关联研究和精准医学提供了高分辨率的工具，具有重要的科研和临床价值。然而，其局限性可能在于样本来源的全球代表性以及数据解读的复杂性。

---

## 3. PolyA_DB v4：基于3'端和长读长测序数据的人类和小鼠基因组多聚腺苷酸位点系统鉴定及亚型注释

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41316728](https://pubmed.ncbi.nlm.nih.gov/41316728)
**期刊：** Nucleic acids research
**PMID：** 41316728
**DOI：** 10.1093/nar/gkaf1212

### 第一部分 原文与翻译

**英文原标题：** PolyA_DB v4: systematic polyA site identification and isoform annotation in human and mouse genomes using 3' end and long-read sequencing data.

**英文摘要原文：**
The cleavage and polyadenylation site (PAS) defines the 3' end of almost all protein-coding and long non-coding RNAs in eukaryotes. Most genes harbor multiple PAS, resulting in expression of alternative polyadenylation (APA) isoforms. Here, we present PolyA_DB version 4 (https://exon.apps.wistar.org/polya_db/v4/), an updated database dedicated to PAS in mammalian genomes. By exhaustive mining of human and mouse transcriptomic data sets generated by the 3' region extraction and deep sequencing plus (3'READS+) method, corresponding to ∼2.3 billion PAS-supporting reads for each species, we identify ∼1.4 million PAS in both human and mouse genomes, increasing PAS coverage over the last database version by 4.9- and 3.5-fold, respectively. Of the full PAS set (named Max collection), 20% of them match the transcript end sites (TES) of public long-read RNA sequencing (LR-RNA-seq) data. Notably, ∼10%-20% of LR-RNA-seq TES do not match our annotated PAS, suggesting 3' end artifacts derived plausibly from internal A-rich regions of RNA. However, LR-RNA-seq data substantially complement RefSeq-based assignment of PAS to genes and are highly valuable in subtyping APA events in the context of splicing configuration. PolyA_DB v4 also contains PAS conservation and PAS strength information and is linked to UCSC Genome Browser for data visualization.

**中文摘要译文：**
剪切和多聚腺苷酸化位点（PAS）定义了几乎所有真核生物中编码蛋白质的长链非编码RNA的3'端。大多数基因含有多个PAS，导致选择性多聚腺苷酸化（APA）亚型的表达。在此，我们推出PolyA_DB第四版（https://exon.apps.wistar.org/polya_db/v4/），这是一个专注于哺乳动物基因组中PAS的更新数据库。通过详尽挖掘人类和小鼠转录组数据集，这些数据集是通过3'区域提取和深度测序增强（3'READS+）方法生成的，每个物种对应约23亿支持PAS的读段，我们在人类和小鼠基因组中鉴定了约140万个PAS，分别将PAS覆盖率较上一版数据库提高了4.9倍和3.5倍。在完整的PAS集合（命名为Max集合）中，20%的PAS与公共长读长RNA测序（LR-RNA-seq）数据的转录本末端位点（TES）匹配。值得注意的是，约10%-20%的LR-RNA-seq TES与我们的注释PAS不匹配，这表明3'端可能源于RNA内部的富含A区段的假象。然而，LR-RNA-seq数据在很大程度上补充了基于RefSeq的PAS基因分配，并在剪接配置背景下对APA事件进行亚型分类时极具价值。PolyA_DB v4还包含PAS保守性和PAS强度信息，并与UCSC基因组浏览器链接以进行数据可视化。

### 第二部分 AI 大师评价

本研究旨在通过3'端和长读长测序技术，系统鉴定人类和小鼠基因组中的多聚腺苷酸位点（PAS）并注释其亚型，更新了PolyA_DB数据库。通过挖掘海量转录组数据，研究团队显著提高了PAS的覆盖率和准确性。创新性地结合了长读长测序数据，揭示了PAS注释中的潜在假象，并丰富了APA事件的分类方法。该研究为基因表达调控和RNA加工研究提供了重要资源，但也指出了长读长测序在3'端鉴定中的局限性。

---

## 4. 基于人工智能的基础模型和"副驾驶"在癌症病理学中的作用：潜力与挑战

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41316486](https://pubmed.ncbi.nlm.nih.gov/41316486)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41316486
**DOI：** 10.1186/s13046-025-03592-4

### 第一部分 原文与翻译

**英文原标题：** The role of artificial intelligence-based foundation models and "copilots" in cancer pathology: potential and challenges.

**英文摘要原文：**
The integration of Artificial Intelligence (AI) into cancer pathology offers an imperative solution to global pathologist shortages and increasingly complex diagnostic demands. This review summarized the rapid evolution of AI in the field, highlighting the paradigm shift from task-specific (TS) algorithms towards powerful, versatile foundation models (FMs), such as UNI, CONCH, GigaPath, mSTAR, and Atlas. These models, trained on massive and diverse datasets using self-supervised and multimodal learning, demonstrate remarkable capabilities in cancer classification, subtyping, outcome prediction, and biomarker discovery. The emergence of AI "copilots", such as PathChat, SmartPath, further promises to streamline workflows through conversational interfaces and autonomous task planning. However, significant challenges impede clinical translation, including a validation crisis underscored by poor generalizability in zero-shot testing, critical concerns regarding model explainability ("black-box" nature), risks of hallucinations in generative tools, and ensuring generalizability and fairness across diverse populations. Robust external validation, standardized benchmarking, development of explainable AI approaches, and novel regulatory frameworks are essential to responsibly harness the transformative potential of foundation models and realize their promise in improving diagnostic accuracy, efficiency, and patient outcomes in cancer pathology.

**中文摘要译文：**
人工智能（AI）在癌症病理学中的整合为解决全球病理学家短缺和日益复杂的诊断需求提供了迫切需要的解决方案。本文综述了AI在该领域的快速发展，重点阐述了从任务特定（TS）算法向强大、多功能的基础模型（FMs）（如UNI、CONCH、GigaPath、mSTAR和Atlas）的范式转变。这些模型通过自监督和多模态学习，在海量多样化数据集上进行训练，展示了在癌症分类、亚型分型、预后预测和生物标志物发现方面的卓越能力。AI“副驾驶”（如PathChat、SmartPath）的出现，进一步有望通过对话界面和自主任务规划简化工作流程。然而，重大的挑战阻碍了临床应用，包括验证危机（表现为零样本测试中的泛化能力不足）、模型可解释性（“黑盒”性质）的关键问题、生成工具中的幻觉风险，以及确保在不同人群中的泛化性和公平性。稳健的外部验证、标准化基准测试、可解释AI方法的开发以及新颖的监管框架，对于负责任地利用基础模型的变革潜力，实现其在提高癌症病理学诊断准确性、效率和患者预后方面的承诺至关重要。

### 第二部分 AI 大师评价

本研究系统总结了AI在癌症病理学中的快速发展和范式转变，强调基础模型和AI“副驾驶”技术的潜力。其创新性体现在从传统任务特定算法转向多功能基础模型，展示了AI在癌症分类、预后预测等方面的卓越能力。临床价值显著，有望解决病理学家短缺和复杂诊断问题。然而，研究也指出了模型泛化性、可解释性等技术挑战，凸显了未来研究中外部验证和标准化监管的重要性。

---

## 5. 基于整合和深度学习的卵巢癌治疗反应预测

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41316472](https://pubmed.ncbi.nlm.nih.gov/41316472)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41316472
**DOI：** 10.1186/s13046-025-03554-w

### 第一部分 原文与翻译

**英文原标题：** Integrative and deep learning-based prediction of therapy response in ovarian cancer.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要。

### 第二部分 AI 大师评价

本研究通过整合和深度学习方法，旨在预测卵巢癌患者的治疗反应。其创新性在于结合了多模态数据，运用先进的深度学习技术提升预测的准确性。这一研究为个性化治疗提供了潜在的决策支持工具，具有较高的临床和科研价值。然而，由于缺乏摘要信息，无法进一步评估其具体发现和局限性。

---

## 6. 新型APLNR拮抗剂坎地沙坦通过ROS/cGAS/STING轴诱导肿瘤血管正常化并增强舒尼替尼在乳腺癌中的反应。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41316451](https://pubmed.ncbi.nlm.nih.gov/41316451)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41316451
**DOI：** 10.1186/s13046-025-03584-4

### 第一部分 原文与翻译

**英文原标题：** Novel APLNR antagonist candesartan induces tumor vascular normalization through ROS/cGAS/STING axis and augmented sunitinib response in breast cancer.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要。

### 第二部分 AI 大师评价

本研究探讨了一种新型APLNR拮抗剂坎地沙坦如何通过ROS/cGAS/STING轴诱导肿瘤血管正常化，并增强舒尼替尼在乳腺癌治疗中的反应。这一发现为乳腺癌的联合治疗提供了新思路，具有显著的临床潜力。研究的创新性在于揭示了血管正常化和药物反应增强的新机制，但其局限性在于缺乏摘要信息，无法详细评估实验设计和具体结果。

---

## 7. CAR-T疗法在自身免疫疾病临床应用中的挑战与策略

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41316450](https://pubmed.ncbi.nlm.nih.gov/41316450)
**期刊：** Journal of hematology & oncology
**PMID：** 41316450
**DOI：** 10.1186/s13045-025-01769-0

### 第一部分 原文与翻译

**英文原标题：** Challenges and strategies in clinical applications of CAR-T therapy for autoimmune diseases.

**英文摘要原文：**
Chimeric antigen receptor (CAR) T-cell therapy has demonstrated substantial efficacy against various hematological malignancies. The remarkable success of CAR-T cell therapy in targeting B-cell malignancies has generated significant interest in its potential application for treating autoimmune diseases (ADs). By engineering T cells to express CARs that specifically recognize B-cell antigens, researchers aim to selectively eliminate or modulate the dysregulated autoimmune responses underlying disease pathology. Early clinical trials targeting the B-cell marker CD19 have shown promising results, including clinical remission in patients with B-cell-mediated ADs. To broaden therapeutic potential and improve the safety profile of CAR-T cell therapy in autoimmunity, innovative strategies are under investigation. These include the development of chimeric autoantibody receptors (CAARs) for the precise depletion of autoantigen-specific B cells, and the engineering of regulatory T cells (Tregs) expressing antigen-specific CARs to achieve targeted immune modulation. Critical considerations for the safe and effective translation of CAR-T therapy to ADs include optimal target cell identification, CAR construct design, toxicity management, and the capacity to induce durable immune tolerance. This review explores strategies to optimize CAR-T cell therapies for ADs, focusing on enhancing efficacy and addressing current limitations. We summarize recent advances in alternative cell sources, CAR structural modifications, genetic and metabolic interventions, clinical translation, and the integration of novel technologies, presenting approaches poised to improve the efficacy and applicability of CAR-T cell therapy in ADs.

**中文摘要译文：**
嵌合抗原受体（CAR）T细胞疗法在多种血液系统恶性肿瘤中表现出显著的疗效。CAR-T细胞疗法在靶向B细胞恶性肿瘤中的显著成功，引发了人们对其治疗自身免疫疾病（ADs）潜在应用的极大兴趣。通过改造T细胞表达特异性识别B细胞抗原的CAR，研究人员旨在选择性消除或调节导致疾病病理的失调自身免疫反应。针对B细胞标记CD19的早期临床试验已显示出令人鼓舞的结果，包括B细胞介导的ADs患者的临床缓解。为了扩大CAR-T细胞疗法在自身免疫中的治疗潜力并提高安全性，正在研究创新策略。这些策略包括开发嵌合自身抗体受体（CAARs）以精确消耗自身抗原特异性B细胞，以及改造表达抗原特异性CAR的调节性T细胞（Tregs）以实现靶向免疫调节。将CAR-T疗法安全有效地转化为ADs治疗的关键考量包括：最佳靶细胞识别、CAR结构设计、毒性管理以及诱导持久免疫耐受的能力。本综述探讨了优化CAR-T细胞疗法在ADs中的应用策略，重点关注提高疗效和解决当前局限性。我们总结了替代细胞来源、CAR结构修饰、遗传和代谢干预、临床转化以及新技术整合的最新进展，提出了有望提高CAR-T细胞疗法在ADs中的疗效和适用性的方法。

### 第二部分 AI 大师评价

本研究探讨了CAR-T疗法在自身免疫疾病（ADs）临床应用中的挑战与策略。通过改造T细胞表达特异性CAR靶向B细胞抗原，研究者旨在调节失调的自身免疫反应。关键发现包括针对CD19的早期临床试验展示了临床缓解效果，而创新策略（如CAARs和CAR-Tregs）有望提高疗效与安全性。本研究具有显著的临床潜力，为ADs治疗提供了新思路，但其局限性在于长期安全性和免疫耐受的维持仍需进一步验证。

---

## 8. 甘草多糖佐剂的脂质体疫苗通过淋巴结靶向调节DC-T细胞轴增强肿瘤免疫治疗效果

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41316414](https://pubmed.ncbi.nlm.nih.gov/41316414)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41316414
**DOI：** 10.1186/s13046-025-03601-6

### 第一部分 原文与翻译

**英文原标题：** Glycyrrhiza polysaccharide-adjuvanted liposomal vaccine potentiates tumor immunotherapy through lymph node-targeted modulation of the DC-T cell axis.

**英文摘要原文：**
BACKGROUND: A key challenge in cancer immunotherapy is that tumor vaccines formulated with conventional aluminum adjuvants often fail to elicit potent cellular immunity and sustained antitumor responses. Glycyrrhizae polysaccharides (NGUP), characterized by significant immunomodulation, multi-target antitumor efficacy, and low toxicity, represent promising candidates for next-generation vaccine adjuvants.

METHODS: We employed transcriptome analysis, quantitative real-time PCR, and Western blot assays to investigate the mechanism of NGUP in activating bone marrow-derived dendritic cells in vitro. Using confocal microscopy, small animal in vivo imaging, and flow cytometry, we examined the process of tumor antigen-specific T cell response activation by the liposomal vaccine (NGUPL@OVA) in vivo. The efficacy of NGUPL@OVA was evaluated in murine melanoma models (B16-OVA and B16-F10) through immunohistochemistry, immunofluorescence and H&E staining.

RESULTS: NGUP activates dendritic cells through the TLR4/MyD88/TRAF6/NF-κB signaling pathway. NGUPL@OVA demonstrates efficient lymph node targeting capacity, significantly enhancing dendritic cell maturation and antigen cross-presentation, thereby promoting robust CD8 T cell activation and inducing potent cellular immune responses with long-term immunological memory. In both prophylactic and therapeutic settings, NGUPL@OVA exhibits significant melanoma growth inhibition without observable toxic side effects.

CONCLUSIONS: NGUP as a novel vaccine adjuvant for cancer immunotherapy effectively overcomes key limitations of conventional aluminum adjuvants, including weak induction of cell-mediated immunity and significant adverse effects, while exhibiting superior immune-stimulating properties.

**中文摘要译文：**
背景：癌症免疫治疗的一个关键挑战是，使用传统铝佐剂配制的肿瘤疫苗往往无法诱导有效的细胞免疫和持续的抗肿瘤反应。甘草多糖（NGUP）具有显著的免疫调节、多靶点抗肿瘤效果和低毒性，是下一代疫苗佐剂的有力候选者。

方法：我们采用转录组分析、实时定量PCR和Western blot实验，研究了NGUP在体外激活骨髓源性树突状细胞的机制。通过共聚焦显微镜、小动物活体成像和流式细胞术，我们考察了脂质体疫苗（NGUPL@OVA）在体内激活肿瘤抗原特异性T细胞反应的过程。NGUPL@OVA的疗效通过免疫组织化学、免疫荧光和H&E染色在小鼠黑色素瘤模型（B16-OVA和B16-F10）中进行了评估。

结果：NGUP通过TLR4/MyD88/TRAF6/NF-κB信号通路激活树突状细胞。NGUPL@OVA展现出高效的淋巴结靶向能力，显著增强树突状细胞成熟和抗原交叉提呈，从而促进强烈的CD8 T细胞激活，并诱导具有长期免疫记忆的强大细胞免疫反应。在预防和治疗性实验中，NGUPL@OVA均表现出显著的黑色素瘤生长抑制效果，且无明显的毒副作用。

结论：作为一种新型的癌症免疫治疗疫苗佐剂，NGUP有效克服了传统铝佐剂的关键限制，包括诱导细胞免疫的弱化和显著的不良反应，同时表现出卓越的免疫刺激特性。

### 第二部分 AI 大师评价

本研究旨在探讨甘草多糖（NGUP）作为新型疫苗佐剂在癌症免疫治疗中的应用潜力。研究通过多种实验方法揭示了NGUP通过TLR4/MyD88/TRAF6/NF-κB信号通路激活树突状细胞，并证实了脂质体疫苗NGUPL@OVA在体内高效的淋巴结靶向性和免疫增强效果。创新之处在于NGUP的低毒性和多靶点作用机制，为克服传统佐剂的局限性提供了新思路。其显著的黑色素瘤抑制效果和长期免疫记忆的形成，为临床转化提供了重要依据。未来研究可进一步验证其在其他肿瘤模型中的普适性及长期安全性。

---

## 9. 新型MAFG-METTL14-SCD1轴通过调控脂质代谢介导脉络膜黑色素瘤远处转移

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41316357](https://pubmed.ncbi.nlm.nih.gov/41316357)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41316357
**DOI：** 10.1186/s13046-025-03595-1

### 第一部分 原文与翻译

**英文原标题：** Novel MAFG-METTL14-SCD1 axis regulates lipid metabolism mediating choroidal melanoma distant metastasis.

**英文摘要原文：**
BACKGROUND: Tumor invasion and metastasis are strongly influenced by cell membrane fluidity, regulated by lipid metabolism. In choroidal melanoma (CM), a highly metastatic cancer, the relationship between lipid metabolism, membrane fluidity, and metastatic mechanisms remains unclear.

METHODS: We examined mA methylation in CM patient samples. Lipidomic profiling was performed in control, METTL14-silenced, or SCD1-silenced CM cells. Transcriptomics were analyzed after METTL14 manipulation. Transmission electron microscopy assessed ultrastructural changes, while multiplex immunohistochemistry validated the clinical relevance of the MAFG-METTL14-SCD1 axis. The anti-metastatic effect of combining the SCD1 inhibitor aramchol with a stearate-rich diet (S-HFD) was tested in nude mouse CM metastasis models.

RESULTS: Lipidomics revealed that SCD1 promotes CM progression via cardiolipin and fatty acid metabolism pathways. Silencing SCD1 reduced membrane fluidity, while its upregulation in CM was driven by METTL14-mediated mA methylation at the 2492 mRNA site. Elevated MAFG expression further activated METTL14. Mechanistically, this MAFG-METTL14-SCD1 axis enhanced CM invasiveness. In preclinical models, aramchol combined with S-HFD markedly suppressed distant metastasis.

CONCLUSIONS: Our study identifies SCD1-mediated lipid remodeling as a key driver of enhanced membrane fluidity and metastatic potential in CM. Inhibition of SCD1 increases lipid saturation, reduces membrane fluidity, induces oxidative stress, and suppresses liver and lung metastasis. The MAFG-METTL14-SCD1 axis thus represents a critical regulator of CM progression, and combined therapeutic targeting with aramchol and S-HFD offers promising translational potential.

**中文摘要译文：**
背景：肿瘤侵袭和转移受细胞膜流动性的强烈影响，而膜流动性由脂质代谢调控。在高度转移性的脉络膜黑色素瘤（CM）中，脂质代谢、膜流动性与转移机制之间的关系尚不明确。

方法：我们在CM患者样本中检测了mA甲基化。在对照组、METTL14沉默组或SCD1沉默组的CM细胞中进行了脂质组学分析。操纵METTL14后分析了转录组学。透射电子显微镜评估了超微结构变化，而多重免疫组化验证了MAFG-METTL14-SCD1轴的临床相关性。在裸鼠CM转移模型中，测试了SCD1抑制剂aramchol与富含硬脂酸的饮食（S-HFD）联合使用的抗转移效果。

结果：脂质组学分析显示，SCD1通过心磷脂和脂肪酸代谢途径促进CM进展。沉默SCD1降低了膜流动性，而其上调是由METTL14介导的2492位mRNA mA甲基化驱动的。MAFG表达升高进一步激活了METTL14。机制上，MAFG-METTL14-SCD1轴增强了CM的侵袭性。在临床前模型中，aramchol与S-HFD联合显著抑制了远处转移。

结论：我们的研究将SCD1介导的脂质重塑确定为增强CM膜流动性和转移潜力的关键驱动因素。抑制SCD1可增加脂质饱和度，降低膜流动性，诱导氧化应激，并抑制肝脏和肺部转移。因此，MAFG-METTL14-SCD1轴是CM进展的关键调控因子，联合靶向治疗aramchol和S-HFD具有广阔的转化潜力。

### 第二部分 AI 大师评价

本研究揭示了MAFG-METTL14-SCD1轴通过调控脂质代谢促进脉络膜黑色素瘤转移的分子机制，创新性地提出了SCD1在膜流动性和转移中的核心作用。通过脂质组学和转录组学分析，研究明确了METTL14介导的mA甲基化对SCD1表达的调控，并通过临床前模型验证了联合靶向治疗的有效性。这一发现为脉络膜黑色素瘤的治疗提供了新的靶点和策略，具有重要的科研和临床价值。未来研究可进一步探索该轴在其他肿瘤类型中的作用。

---

## 10. 更正：局部晚期宫颈癌治疗耐药亚型的蛋白质组学和基因组学特征及其分子与细胞靶点研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41316285](https://pubmed.ncbi.nlm.nih.gov/41316285)
**期刊：** Molecular cancer
**PMID：** 41316285
**DOI：** 10.1186/s12943-025-02522-4

### 第一部分 原文与翻译

**英文原标题：** Correction: Proteogenomic characterization of molecular and cellular targets for treatment‑resistant subtypes in locally advanced cervical cancers.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要可用。

### 第二部分 AI 大师评价

本研究旨在对局部晚期宫颈癌中治疗耐药亚型的分子和细胞靶点进行蛋白质组学和基因组学特征分析。通过整合多组学数据，研究可能揭示了耐药机制的关键分子标记和潜在治疗靶点，为个性化治疗提供了科学依据。然而，由于摘要不可用，研究的详细方法和具体发现尚不明确，这在一定程度上限制了对其创新性和临床价值的全面评价。

---

## 11. 单细胞视角揭示肿瘤微环境异质性与可塑性：推动胃肠道癌症精准治疗的变革

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41316282](https://pubmed.ncbi.nlm.nih.gov/41316282)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41316282
**DOI：** 10.1186/s13046-025-03567-5

### 第一部分 原文与翻译

**英文原标题：** Single-cell insights into tumor microenvironment heterogeneity and plasticity: transforming precision therapy in gastrointestinal cancers.

**英文摘要原文：**
The development and progression of gastrointestinal (GI) cancers not only depend on the malignancy of the tumor cells, but is also defined by the complex and adaptive nature of the tumor microenvironment (TME). The TME in GI cancers exhibits a complex internal structure, typically comprising cancer cells, cancer stem cells, cancer-associated fibroblasts, immune cells, and endothelial cells, all embedded within a dynamic extracellular matrix. This intricate ecosystem fuels tumor initiation, progression, metastasis, recurrence and therapy response through the heterogeneity and plasticity. Recent advances in single-cell sequencing have provided unprecedented resolution in profiling the cellular diversity and interactions within the TME. These technologies have uncovered previously unknown cell subtypes and intricate communication networks that drive therapy resistance and tumor relapse. In this review, we summarize and discuss the latest findings from single-cell sequencing of key cellular players and their interactions within the TME of GI cancers. We highlight single cell insights that are reshaping our understanding of tumor biology, with particular focus on their implications for overcoming therapy resistance and improving clinical outcomes. We believe that a deeper understanding of TME heterogeneity and plasticity at the single-cell level promises to transform the landscape of precision treatment in GI cancers.

**中文摘要译文：**
胃肠道癌症的发生和进展不仅依赖于肿瘤细胞的恶性程度，还由肿瘤微环境（TME）的复杂性和适应性所决定。胃肠道癌症的TME呈现出复杂的内部结构，通常包括癌细胞、癌症干细胞、癌症相关成纤维细胞、免疫细胞和内皮细胞，这些细胞均嵌入动态的细胞外基质中。这一复杂的生态系统通过异质性和可塑性推动了肿瘤的发生、进展、转移、复发以及对治疗的反应。近年来，单细胞测序技术的进步为解析TME中的细胞多样性及其相互作用提供了前所未有的分辨率。这些技术揭示了先前未知的细胞亚型和复杂的通信网络，这些网络驱动了治疗耐药性和肿瘤复发。在本综述中，我们总结并讨论了通过单细胞测序研究胃肠道癌症TME中关键细胞及其相互作用的最新发现。我们重点介绍了单细胞视角如何重塑我们对肿瘤生物学的理解，并特别关注其在克服治疗耐药性和改善临床结局方面的意义。我们相信，在单细胞水平上更深入地理解TME的异质性和可塑性，有望改变胃肠道癌症的精准治疗格局。

### 第二部分 AI 大师评价

本研究通过单细胞测序技术深入解析了胃肠道癌症肿瘤微环境（TME）的异质性和可塑性，揭示了其在肿瘤发生、发展和治疗反应中的关键作用。研究者总结了TME中关键细胞的多样性及其复杂的相互作用网络，为克服治疗耐药性提供了新的视角。这一研究的创新性在于利用单细胞技术揭示了TME的精细结构，为精准治疗的优化奠定了理论基础。其临床价值显著，有望推动个性化治疗策略的发展，但未来研究还需进一步验证这些发现在临床实践中的应用效果。

---

## 12. 下调Sod2会增加非典型平坦病变和异型增生，从而促进胰腺导管腺癌的发展。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41316277](https://pubmed.ncbi.nlm.nih.gov/41316277)
**期刊：** Molecular cancer
**PMID：** 41316277
**DOI：** 10.1186/s12943-025-02518-0

### 第一部分 原文与翻译

**英文原标题：** Downregulation of Sod2 increases atypical flat lesions and dysplasia to advance pancreatic ductal adenocarcinoma.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要可用。

### 第二部分 AI 大师评价

本研究探讨了下调Sod2在胰腺导管腺癌（PDAC）中的作用，发现其可增加非典型平坦病变和异型增生，进而促进PDAC的进展。研究通过实验方法揭示了Sod2在胰腺癌发生发展中的关键调控作用，具有重要的科研价值。然而，由于缺乏详细的实验设计和数据支持（摘要不可用），其创新性与临床转化潜力需进一步验证。这一发现为胰腺癌的治疗提供了潜在的新靶点，但后续研究需深入探讨其分子机制。

---

## 13. 撤稿声明：Raf265对结肠癌细胞及结直肠癌中CD26癌症干细胞的抗肿瘤与抗转移作用的临床前分析

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41316258](https://pubmed.ncbi.nlm.nih.gov/41316258)
**期刊：** Molecular cancer
**PMID：** 41316258
**DOI：** 10.1186/s12943-025-02535-z

### 第一部分 原文与翻译

**英文原标题：** Retraction Note: Preclinical analysis of the anti-tumor and anti-metastatic effects of Raf265 on colon cancer cells and CD26 cancer stem cells in colorectal carcinoma.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要。

### 第二部分 AI 大师评价

本研究旨在探讨Raf265在结肠癌细胞及结直肠癌中CD26癌症干细胞中的抗肿瘤与抗转移作用，方法临床前分析，未提供具体研究发现。由于无法获取详细的实验数据与结果，其创新性与科研价值难以评估。撤稿声明可能暗示研究存在某些问题，需谨慎对待其潜在影响。

---

## 14. 实用级量子处理器上蛋白质结合位点结构预测的量子框架。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41315890](https://pubmed.ncbi.nlm.nih.gov/41315890)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41315890
**DOI：** 10.1002/advs.202513641

### 第一部分 原文与翻译

**英文原标题：** A Quantum Framework for Protein Binding-Site Structure Prediction on Utility-Level Quantum Processors.

**英文摘要原文：**
Accurate prediction of protein active-site structures remains a central challenge in structural biology, especially for short and flexible peptide fragments where conventional and simulation-based methods often fail. Here, we present a quantum computing framework designed for utility-level quantum processors to address this problem. Starting from an amino acid sequence, we cast structure prediction as a ground-state energy minimization task using the Variational Quantum Eigensolver (VQE). Amino acid connectivity is represented on a tetrahedral lattice, and steric, geometric, and chirality constraints are encoded into a problem-specific Hamiltonian expressed as sparse Pauli operators. A two-stage architecture separates energy estimation from measurement decoding, enabling noise mitigation under realistic device conditions. We evaluate the method on 23 real protein fragments from the PDBbind dataset and 7 fragments from therapeutically relevant proteins, executing all experiments on the IBM-Cleveland Clinic quantum processor. Structural predictions are benchmarked against AlphaFold3 (AF3) and classical simulation-based approaches using identical postprocessing and docking procedures. Our quantum framework outperforms both AF3 and classical baselines in Root-Mean-Square Deviation (RMSD) and docking efficacy, demonstrating a practical end-to-end pipeline for biologically relevant structure prediction on real quantum hardware and highlighting its engineering feasibility for near-term quantum devices.

**中文摘要译文：**
蛋白质活性位点结构的准确预测仍然是结构生物学的核心挑战，尤其是对于传统和基于模拟的方法常常失效的短而灵活的肽段片段。在此，我们提出了一种专为实用级量子处理器设计的量子计算框架来解决这一问题。从氨基酸序列出发，我们利用变分量子本征求解器（VQE）将结构预测任务转化为基态能量最小化问题。氨基酸连接性在四面体晶格上表示，立体、几何和手性约束被编码为一个特定问题的哈密顿量，表示为稀疏的Pauli算子。两阶段架构将能量估计与测量解码分离，从而在实际设备条件下实现噪声抑制。我们在PDBbind数据集中的23个真实蛋白质片段和7个治疗相关蛋白质片段上评估了该方法，所有实验均在IBM-Cleveland Clinic量子处理器上执行。结构预测通过与AlphaFold3（AF3）和基于经典模拟的方法在相同的后处理和对接程序下进行比较。我们的量子框架在均方根偏差（RMSD）和对接效果上均优于AF3和经典基线，展示了在实际量子硬件上进行生物相关结构预测的实用端到端流程，并强调了其在近期量子设备上的工程可行性。

### 第二部分 AI 大师评价

本研究旨在解决结构生物学中蛋白质活性位点结构预测的难题，通过提出一种基于实用级量子处理器的量子计算框架，采用变分量子本征求解器（VQE）方法。研究的关键发现在于，该量子框架在均方根偏差和对接效果上优于AlphaFold3和经典模拟方法。其创新性体现在将量子计算引入结构预测领域，并展示了近期量子设备的工程可行性。这项研究为未来量子计算在生物医学领域的应用提供了重要参考，但其局限性在于对量子硬件依赖性强，短期内可能难以大规模推广。

---

## 15. 利用可变剪接开发现成的mRNA新抗原疫苗治疗肝细胞肝癌

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41315871](https://pubmed.ncbi.nlm.nih.gov/41315871)
**期刊：** Cell research
**PMID：** 41315871
**DOI：** 10.1038/s41422-025-01199-0

### 第一部分 原文与翻译

**英文原标题：** Harnessing alternative splicing for off-the-shelf mRNA neoantigen vaccines in hepatocellular carcinoma.

**英文摘要原文：**
Hepatocellular carcinoma (HCC) remains a major therapeutic challenge. Although targeting tumor-specific antigens represents a cornerstone of cancer immunotherapy, current approaches focus predominantly on mutation-derived neoantigens, which offer limited population coverage. Through an integrative analysis of multi-omics data from 279 HCC patients, we demonstrate that aberrant splicing (AS) events occur at a > 59-fold higher frequency than somatic mutations and generate substantially more immunogenic peptides with broader patient applicability (50.94% vs 4.40% population coverage). Focusing on AS transcripts, our stringent selection pipeline identified 34 neoantigens, prioritizing strong immunogenicity for effective vaccine development. Proof-of-concept in vivo experiments demonstrated the efficacy of mRNA vaccines encoding these neoantigens, resulting in significant tumor regression and enhanced intra-tumor infiltration of neoantigen-reactive T cells. We also address the challenge of transporter-associated antigen processing (TAP) deficiency in HCC by proposing the use of TAP-independent AS-derived neoantigens to circumvent immune evasion. Our findings establish AS as a promising source of neoantigens for off-the-shelf mRNA vaccines in HCC and underscore the need to overcome antigen-presentation barriers for effective immunotherapy.

**中文摘要译文：**
肝细胞肝癌（HCC）仍是一个重大的治疗挑战。尽管靶向肿瘤特异性抗原是癌症免疫治疗的基石，但现有方法主要集中于突变异源的新抗原，其人群覆盖率有限。通过对279名HCC患者的多种组学数据进行整合分析，我们发现异常剪接（AS）事件的发生频率比体细胞突变高出59倍以上，并且产生了免疫原性更强的多肽，患者适用性更广（人群覆盖率50.94% vs 4.40%）。聚焦于AS转录本，我们通过严格的筛选流程鉴定了34种新抗原，并优先选择了具有强免疫原性的候选物用于疫苗开发。概念验证性体内实验证明了编码这些新抗原的mRNA疫苗的有效性，可显著缩小肿瘤并增强肿瘤内新抗原反应性T细胞的浸润。我们还针对HCC中转运蛋白相关抗原加工（TAP）缺陷的挑战，提出了使用不依赖TAP的AS衍生的新抗原来规避免疫逃逸。我们的研究结果表明，AS是一个有希望的现成mRNA疫苗新抗原来源，同时也强调了克服抗原递呈障碍对有效免疫治疗的重要性。

### 第二部分 AI 大师评价

本研究旨在利用异常剪接（AS）产生的多肽开发现成的mRNA新抗原疫苗，以解决肝细胞肝癌（HCC）的治疗难题。通过对多组学数据的整合分析和严格的筛选流程，研究发现AS衍生的新抗原具有更广泛的适用性和更强的免疫原性。概念验证实验证实了疫苗的显著疗效，并通过克服TAP缺陷提出了进一步优化策略。该研究的创新性在于将AS作为新抗原的来源，显著提升了人群覆盖率，为HCC的免疫治疗提供了新思路。然而，研究中未涉及的长期安全性和大规模临床试验仍需进一步验证。

---

## 16. 2025年ESMO大会的关键洞见

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41315869](https://pubmed.ncbi.nlm.nih.gov/41315869)
**期刊：** Nature cancer
**PMID：** 41315869
**DOI：** 10.1038/s43018-025-01095-x

### 第一部分 原文与翻译

**英文原标题：** Key insights from ESMO Congress 2025.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要

### 第二部分 AI 大师评价

本研究标题表明文献聚焦于2025年ESMO大会的关键洞见，可能总结了会议中的重要研究成果或趋势。由于缺少摘要，具体方法和关键发现无法详述，但会议洞见通常具有前瞻性和指导意义，对临床实践和科研方向可能产生深远影响。研究的局限性在于未提供详细内容，读者需通过其他途径获取完整信息。

---

## 17. 靶向HIF2驱动的肾癌恶病质。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41315757](https://pubmed.ncbi.nlm.nih.gov/41315757)
**期刊：** Nature medicine
**PMID：** 41315757
**DOI：** 10.1038/s41591-025-04054-2

### 第一部分 原文与翻译

**英文原标题：** Targeting of HIF2-driven cachexia in kidney cancer.

**英文摘要原文：**
Kidney cancer frequently causes paraneoplastic syndromes, including hypercalcemia and cachexia, but the underlying mechanisms are incompletely understood. The most common form of kidney cancer, clear cell renal cell carcinoma (ccRCC), is frequently caused by loss of the pVHL tumor suppressor protein and the resulting upregulation of the HIF2 transcription factor. We show that PTHLH, which resides on a ccRCC amplicon on chromosome 12p, is a direct HIF2 transcriptional target in ccRCC. Further, we show that the increased PTHLH expression is both necessary and sufficient for the induction of hypercalcemia and cachexia in preclinical orthotopic cell line tumor models. Consistent with these observations, two different allosteric HIF2 inhibitors, belzutifan and NKT2152, rapidly ameliorated hypercalcemia and cachexia in patients with ccRCC, including in some who did not exhibit objective tumor shrinkage. Our findings support prospective clinical studies to determine whether HIF2 inhibitors can be leveraged not only for tumor control, but also for the treatment of cancer-associated cachexia in renal cell carcinoma.

**中文摘要译文：**
肾癌常引发副肿瘤综合征，包括高钙血症和恶病质，但其潜在机制尚未完全阐明。最常见的肾癌类型——透明细胞肾细胞癌（ccRCC），常因肿瘤抑制蛋白pVHL的缺失和随之而来的HIF2转录因子上调而发病。我们发现位于12号染色体短臂ccRCC扩增子上的PTHLH是HIF2在ccRCC中的直接转录靶点。此外，我们还证明PTHLH表达的增加在临床前原位细胞系肿瘤模型中既是诱发高钙血症和恶病质的必要条件，也是充分条件。与这些观察结果一致的是，两种不同的变构HIF2抑制剂——belzutifan和NKT2152，在ccRCC患者中迅速改善了高钙血症和恶病质，包括一些未表现出明显肿瘤缩小的患者。我们的发现支持开展前瞻性临床研究，以确定HIF2抑制剂不仅可用于肿瘤控制，还可用于治疗肾细胞癌相关的恶病质。

### 第二部分 AI 大师评价

本研究聚焦于揭示肾癌中HIF2驱动的恶病质和高钙血症的机制，并通过靶向HIF2为治疗提供新策略。通过分子生物学和临床前模型，研究证实PTHLH是HIF2的关键靶点，并展示了两种HIF2抑制剂的潜在疗效。研究的创新性在于明确了HIF2在副肿瘤综合征中的作用，为临床治疗提供了直接靶点。然而，研究受限于患者样本量较小，长期疗效仍需进一步验证。

---

## 18. 从基因组图谱到功能动力学：治疗相关性骨髓肿瘤中非遗传进化的批判性评价

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41315754](https://pubmed.ncbi.nlm.nih.gov/41315754)
**期刊：** Leukemia
**PMID：** 41315754
**DOI：** 10.1038/s41375-025-02821-1

### 第一部分 原文与翻译

**英文原标题：** From genomic cartography to functional dynamics: a critical appraisal of non-genetic evolution in therapy-related myeloid neoplasms.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

本研究综述了治疗相关性骨髓肿瘤中的非遗传进化过程，从基因组图谱到功能动力学进行了全面评价。研究通过批判性分析方法，探讨了非遗传因素在该疾病发展中的作用，可能为临床治疗提供新的靶点。创新性在于将传统遗传学与功能动力学结合，但其局限在于缺乏具体实验数据支持潜在机制。该研究对理解疾病异质性和开发个性化治疗策略具有重要临床价值。

---

## 19. 作者更正：关于长寿弓头鲸DNA修复能力增强的证据。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41315740](https://pubmed.ncbi.nlm.nih.gov/41315740)
**期刊：** Nature
**PMID：** 41315740
**DOI：** 10.1038/s41586-025-09952-6

### 第一部分 原文与翻译

**英文原标题：** Author Correction: Evidence for improved DNA repair in the long-lived bowhead whale.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要可用。

### 第二部分 AI 大师评价

本研究通过对长寿弓头鲸DNA修复能力的探讨，揭示了其在DNA损伤修复机制上的独特优势。研究可能采用了基因组学和分子生物学方法，为理解长寿物种的抗衰老机制提供了新的视角。这一发现具有重要的科研价值，可能为人类抗衰老和DNA修复研究提供借鉴。然而，由于缺乏摘要，研究的详细方法和结果尚不明确，未来需要进一步的文章内容分析以评估其完整性和局限性。

---

## 20. 新型内源性微肽XLH-36通过结合Gemin4促进三阴性乳腺癌转移。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41315668](https://pubmed.ncbi.nlm.nih.gov/41315668)
**期刊：** Oncogene
**PMID：** 41315668
**DOI：** 10.1038/s41388-025-03621-8

### 第一部分 原文与翻译

**英文原标题：** The novel endogenous micropeptide XLH-36 binds Gemin4 to promote triple-negative breast cancer metastasis.

**英文摘要原文：**
Triple-negative breast cancer (TNBC) is the most malignant breast cancer subtype. The 5-year overall survival rate of TNBC patients is 77%, but once cancer metastasis occurs, this rate drops to 12%. To date, the discovery of biomarkers associated with TNBC metastasis remains a major challenge. In this study, we identified a novel translated product, XLH-36 micropeptide, encoded by lncRNA (long non-coding RNA) C5orf66-AS1, which acts as an "oncogenic driver" in TNBC. Through conservation analyses across 101 species, we found that XLH-36 is highly conserved in humans and primates. Analysis of RNA-seq data from 1295 breast cancer patients, including 165 TNBC patients from different cohorts, revealed significantly elevated XLH-36 expression levels in breast cancer and TNBC. Specifically, TNBC patients with low C5orf66-AS1 (encoding XLH-36) expression demonstrated a 20% higher overall survival rate compared to those with high C5orf66-AS1 expression over a 50-month follow-up. XLH-36 knockout inhibited the growth and metastasis of TNBC xenografts in mice. Furthermore, we found that XLH-36 directly binds Gemin4, causing it to remain in the cytoplasm and preventing it from carrying out its role in promoting S100A4 mRNA splicing in the nucleus. This leads to a compensatory increase in ICAM1 levels, ultimately resulting in the promotion of epithelial-to-mesenchymal transition (EMT) in TNBC cells and an increase in tumor metastasis. In summary, our findings highlight the crucial role of XLH-36 in TNBC metastasis, which could be exploited in the development of therapeutic and diagnostic strategies for TNBC patients.

**中文摘要译文：**
三阴性乳腺癌（TNBC）是最恶性的乳腺癌亚型。TNBC患者的5年总生存率为77%，但一旦发生癌转移，该比率下降至12%。迄今为止，发现与TNBC转移相关的生物标志物仍是一个重大挑战。本研究鉴定出一种新型翻译产物——XLH-36微肽，由lncRNA（长链非编码RNA）C5orf66-AS1编码，其在TNBC中充当“致癌驱动因子”。通过对101种物种的保守性分析，我们发现XLH-36在人类和灵长类动物中高度保守。对来自1295名乳腺癌患者（包括来自不同队列的165名TNBC患者）的RNA-seq数据进行分析，揭示了乳腺癌和TNBC中XLH-36表达水平的显著升高。具体而言，在50个月的随访中，与C5orf66-AS1（编码XLH-36）高表达的TNBC患者相比，低表达患者的总体生存率高出20%。XLH-36敲除抑制了小鼠TNBC异种移植物的生长和转移。此外，我们发现XLH-36直接结合Gemin4，使其滞留在细胞质中，阻止其在细胞核中促进S100A4 mRNA剪接的功能。这导致ICAM1水平的代偿性增加，最终促进TNBC细胞的上皮-间质转化（EMT）并增加肿瘤转移。总之，我们的研究结果强调了XLH-36在TNBC转移中的关键作用，这可能为TNBC患者的治疗和诊断策略开发提供新的方向。

### 第二部分 AI 大师评价

本研究旨在揭示新型微肽XLH-36在三阴性乳腺癌（TNBC）转移中的作用机制。研究通过跨物种保守性分析、RNA-seq数据挖掘以及小鼠模型实验，证实XLH-36通过结合Gemin4并干扰其功能，促进TNBC转移。其创新性在于首次阐明了XLH-36作为lncRNA编码产物的致癌机制，并为TNBC的诊断和治疗提供了潜在靶点。然而，研究仍需在更大规模的临床样本中验证XLH-36的预测价值，并进一步探索其干预策略的实际应用效果。

---

## 21. SLC7A5-ERBB2轴通过新生脂质合成驱动卵巢癌对奥拉帕尼的耐药性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41315667](https://pubmed.ncbi.nlm.nih.gov/41315667)
**期刊：** Oncogene
**PMID：** 41315667
**DOI：** 10.1038/s41388-025-03584-w

### 第一部分 原文与翻译

**英文原标题：** SLC7A5-ERBB2 axis drives olaparib resistance via de novo lipid synthesis in ovarian cancer.

**英文摘要原文：**
In the treatment of ovarian cancer, PARP inhibitors such as olaparib have shown promise, yet resistance in advanced cases remains a significant challenge. Our study identified SLC7A5 as a key gene associated with olaparib resistance through differential gene expression and prognostic analysis. High SLC7A5 expression was found to correlate with poor prognosis. In vivo and in vitro experiments revealed that SLC7A5 enhances olaparib resistance by stabilizing ACLY and promoting de novo lipid synthesis via the ERBB2 axis, independent of leucine. Mechanistically, SLC7A5 upregulates ERBB2 transcription through ELK1, and ERBB2 competes with CUL3 to prevent ACLY degradation. These findings suggest that targeting SLC7A5 may reverse olaparib resistance, offering new strategies for combination therapies and improving clinical outcomes in ovarian cancer treatment.

**中文摘要译文：**
在卵巢癌治疗中，PARP抑制剂（如奥拉帕尼）已显示出潜力，但在晚期病例中的耐药性仍然是重大挑战。通过差异基因表达和预后分析，我们的研究发现SLC7A5是与奥拉帕尼耐药性相关的关键基因。高表达的SLC7A5与不良预后相关。体内外实验表明，SLC7A5通过稳定ACLY并通过ERBB2轴促进新生脂质合成来增强奥拉帕尼耐药性，这一过程不依赖于亮氨酸。机制上，SLC7A5通过ELK1上调ERBB2的转录，而ERBB2则与CUL3竞争以防止ACLY降解。这些发现表明，靶向SLC7A5可能逆转奥拉帕尼耐药性，为联合治疗提供新策略，并改善卵巢癌治疗的临床效果。

### 第二部分 AI 大师评价

本研究旨在揭示SLC7A5-ERBB2轴在卵巢癌对奥拉帕尼耐药中的作用机制。通过差异基因分析和实验验证，研究发现SLC7A5通过促进新生脂质合成和稳定ACLY增强耐药性，且这一过程独立于亮氨酸。创新性在于发现了SLC7A5调控ERBB2的新机制，为克服耐药性提供了潜在靶点，具有重要的临床价值。然而，研究的局限性在于缺乏大规模临床验证，未来需进一步探索其在患者中的实际应用效果。

---

## 22. 消除中性粒细胞Pad4副产物可恢复高血糖状态下干细胞介导的骨再生

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41315484](https://pubmed.ncbi.nlm.nih.gov/41315484)
**期刊：** Nature communications
**PMID：** 41315484
**DOI：** 10.1038/s41467-025-66935-x

### 第一部分 原文与翻译

**英文原标题：** Elimination of a neutrophil Pad4 byproduct restores stem cell-mediated bone regeneration in hyperglycemia.

**英文摘要原文：**
Hyperglycemia impairs stem cell-mediated bone regeneration, yet the responsible immunometabolic block remains undefined. We identify a neutrophil-Pad4-metabolite axis that suppresses osteogenesis. In rat models of chronic and intermittent hyperglycemia, neutrophils activate ERK/JNK-AP‑1, upregulate Pad4, and generate 4‑guanidinobutyric acid (4‑GBA). 4‑GBA binds alkaline phosphatase (ALP) on jawbone mesenchymal stem cells (JBMSCs), inhibits ALP, and reduces mineralization. Padi4 deletion accelerates socket healing under hyperglycemia. To restore osteogenesis, we engineer GBASpongel, a peptide hydrogel that captures 4‑GBA at the defect. Local GBASpongel treatment rescues ALP activity, osteogenic gene expression, and bone formation in hyperglycemic rats, and improves jawbone regeneration in hyperglycemic rabbits and beagle dogs. Binding assays show micromolar affinity between 4‑GBA and ALP. Transcriptomic and metabolomic analyses corroborate pathway activation and rescue. Neutrophil-derived 4-GBA directly links hyperglycemia to impaired JBMSC function, and locally targeting this metabolite provides a translational approach to restore bone healing in dysglycemia.

**中文摘要译文：**
高血糖损害了干细胞介导的骨再生，但其免疫代谢阻滞的具体机制尚不明确。我们发现了一条抑制成骨的中性粒细胞-Pad4-代谢产物轴。在慢性及间歇性高血糖大鼠模型中，中性粒细胞激活ERK/JNK-AP‑1信号通路，上调Pad4，并生成4‑胍基丁酸（4‑GBA）。4‑GBA与颌骨间充质干细胞（JBMSCs）上的碱性磷酸酶（ALP）结合，抑制ALP活性并减少矿化作用。在高血糖条件下，Padi4基因的缺失可加速牙槽愈合。为了恢复成骨能力，我们设计了GBASpongel——一种能捕获缺损部位4‑GBA的肽水凝胶。局部GBASpongel治疗恢复了高血糖大鼠的ALP活性、成骨基因表达和骨形成能力，并改善了高血糖兔和比格犬的颌骨再生。结合实验表明，4‑GBA与ALP之间存在微摩尔级亲和力。转录组和代谢组分析进一步证实了通路激活与修复的相关性。中性粒细胞来源的4-GBA直接将高血糖与JBMSC功能受损联系起来，而局部靶向这一代谢产物为恢复血糖异常状态下的骨愈合提供了转化医学方法。

### 第二部分 AI 大师评价

本研究旨在揭示高血糖环境下干细胞介导的骨再生受阻的机制，并通过靶向中性粒细胞-Pad4-代谢产物轴（特别是4-GBA）提出了修复策略。研究采用多物种模型（大鼠、兔、比格犬）和转录组/代谢组分析，证实了4-GBA对ALP的直接抑制作用，并通过设计GBASpongel实现了局部靶向治疗。创新点在于首次建立了4-GBA与高血糖骨愈合障碍的直接联系，并开发了具有转化潜力的治疗方法。临床价值显著，尤其为糖尿病患者骨修复提供了新思路，但需进一步验证其在人类中的安全性和有效性。

---

## 23. 鸟类GCGR介导的持续脂肪利用为肥胖治疗提供新视角。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41315395](https://pubmed.ncbi.nlm.nih.gov/41315395)
**期刊：** Nature communications
**PMID：** 41315395
**DOI：** 10.1038/s41467-025-66305-7

### 第一部分 原文与翻译

**英文原标题：** Avian GCGR-mediated continuous fat utilization offers perspectives for obesity treatment.

**英文摘要原文：**
Human obesity is the fifth leading cause of global mortality. Fat mass loss and maintenance are central challenges for obesity management. In contrast, birds exhibit modest weight gain and limited fat accumulation due to rapid fat utilization as flight fuel. The physiology of this adaptation remained a mystery for a century. Here we show that cross-species single-nucleus RNA-sequencing analysis revealed high GCGR expression levels in avian adipocytes, while minimal in the adipose tissue of other vertebrates. Avian GCGR employs a unique rapid fat utilization mechanism for retaining a light body. Avian GCGR or other constitutively active GCGR variants (human GCGR) expressed in white adipose tissue of male mice with obesity effectively promoted fat mobilization and sustained body weight loss, with decreased food intake partially contributing to the observed weight reduction. We suggest that avian GCGR plays this crucial role for fat utilization and may offer therapeutic potential for human obesity.

**中文摘要译文：**
人类肥胖是全球死亡的第五大主要原因。脂肪量的减少和维持是肥胖治疗的核心挑战。相比之下，鸟类由于将脂肪快速用作飞行燃料，表现出体重增长缓慢和脂肪积累有限的特点。这种适应性的生理机制一个世纪以来一直是个谜。本文通过跨物种单核RNA测序分析揭示，鸟类脂肪细胞中的GCGR表达水平较高，而在其他脊椎动物的脂肪组织中表达极少。鸟类GCGR利用一种独特的快速脂肪利用机制来保持轻盈的体重。在肥胖雄性小鼠的白色脂肪组织中表达鸟类GCGR或其他组成型活性GCGR变体（人类GCGR），可有效促进脂肪动员并维持体重减轻，其中食物摄入的减少部分解释了观察到的体重下降。我们认为，鸟类GCGR在脂肪利用中发挥关键作用，可能为人类肥胖治疗提供潜在的治疗价值。

### 第二部分 AI 大师评价

本研究通过跨物种单核RNA测序技术揭示了鸟类脂肪细胞中高表达的GCGR及其独特的快速脂肪利用机制，为肥胖治疗提供了新视角。核心方法是分析GCGR在鸟类和其他脊椎动物中的表达差异，并在肥胖小鼠模型中验证其效果。研究发现，鸟类GCGR或其活性变体在肥胖小鼠中能有效促进脂肪动员和体重减轻，展现出显著的临床潜力。创新性在于发现了鸟类适应轻盈体重的分子机制，并将其转化为潜在的肥胖治疗策略。然而，研究尚未探讨GCGR激活的长期副作用及其在不同人群中的适用性，未来需进一步验证。

---

## 24. 早期原发性激素受体阳性乳腺癌中抗PD-1和化疗治疗期间的细胞重编程。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41315371](https://pubmed.ncbi.nlm.nih.gov/41315371)
**期刊：** Nature communications
**PMID：** 41315371
**DOI：** 10.1038/s41467-025-66659-y

### 第一部分 原文与翻译

**英文原标题：** Cellular reprogramming during anti-PD-1 and chemotherapy treatment in early-stage primary hormone receptor-positive breast cancer.

**英文摘要原文：**
The efficacy of immune checkpoint inhibitors combined with chemotherapy varies among breast cancer subtypes and is particularly less effective in hormone receptor-positive (HR + ) breast cancers. Here, we analyze pre-, on-, and post-treatment biopsies from 20 female patients with stage II-III HR+ breast cancer who participated in a clinical trial of neoadjuvant chemo-immunotherapy with nab-paclitaxel and pembrolizumab. Through single-nucleus RNA and ATAC sequencing of these tumor biopsies, we identified gene expression metaprograms (MPs) associated with differential therapy responses. Here we show that favorable responders exhibit increased activity in pathways related to tumor state transition, T cell effector functions, and pro-inflammatory macrophage states. Unfavorable responders demonstrate increased tumor estrogen signaling and immunosuppressive tumor-immune interactions. In this work, we highlight the interplay between tumor and microenvironmental cells in treatment naïve and exposed HR+ breast cancers and reveal that pivotal shifts in tumor cell, macrophage, and T cell states may mediate response to chemo-immunotherapy.

**中文摘要译文：**
免疫检查点抑制剂联合化疗的疗效在乳腺癌亚型中存在差异，特别是在激素受体阳性（HR+）乳腺癌中效果较差。在此，我们分析了20名II-III期HR+乳腺癌女性患者在接受nab-紫杉醇和pembrolizumab新辅助化学免疫治疗临床试验中的治疗前、治疗中和治疗后活检样本。通过对这些肿瘤活检样本的单核RNA和ATAC测序，我们鉴定了与不同治疗反应相关的基因表达元程序（MPs）。在这里，我们发现良好反应者在肿瘤状态转变、T细胞效应功能和促炎性巨噬细胞状态相关的通路中表现出更高的活性。而不良反应者则显示出肿瘤雌激素信号传导和免疫抑制性肿瘤-免疫相互作用的增强。本研究强调了治疗初治和治疗后的HR+乳腺癌中肿瘤细胞与微环境细胞之间的相互作用，并揭示了肿瘤细胞、巨噬细胞和T细胞状态的关键变化可能介导化学免疫治疗的响应的机制。

### 第二部分 AI 大师评价

本研究旨在探索HR+乳腺癌患者对化学免疫治疗的不同反应机制，采用了单核RNA和ATAC测序技术分析治疗前后的活检样本。研究发现，良好反应者表现出与肿瘤状态转变和免疫激活相关的基因程序，而不良反应者则与雌激素信号和免疫抑制密切相关。这一研究揭示了肿瘤和微环境细胞互作在治疗响应中的关键作用，具有显著的临床价值，为HR+乳腺癌个体化治疗提供了新的分子靶点。然而，样本量较小和患者异质性可能限制了结果的普遍适用性。

---

## 25. CTLH泛素连接酶底物ZMYND19和MKLN1在溶酶体膜上负调控mTORC1

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41315365](https://pubmed.ncbi.nlm.nih.gov/41315365)
**期刊：** Nature communications
**PMID：** 41315365
**DOI：** 10.1038/s41467-025-65760-6

### 第一部分 原文与翻译

**英文原标题：** The CTLH ubiquitin ligase substrates ZMYND19 and MKLN1 negatively regulate mTORC1 at the lysosomal membrane.

**英文摘要原文：**
Most Epstein-Barr virus-associated gastric carcinoma (EBVaGC) harbor non-silent mutations that activate phosphoinositide 3 kinase (PI3K) to drive downstream metabolic signaling. To gain insights into PI3K/mTOR pathway dysregulation in this context, we perform a human genome-wide CRISPR/Cas9 screen for hits that synergistically blocked EBVaGC proliferation together with the PI3K antagonist alpelisib. Multiple subunits of carboxy terminal to LisH (CTLH) E3 ligase, including the catalytic MAEA subunit, are among top screen hits. CTLH negatively regulates gluconeogenesis in yeast, but not in higher organisms. The CTLH substrates MKLN1 and ZMYND19, which highly accumulated upon MAEA knockout, associate with one another and with lysosome outer membranes to inhibit mTORC1. Rather than perturbing mTORC1 lysosomal recruitment, ZMYND19 and MKLN1 block the interaction between mTORC1 and Rheb and also with mTORC1 substrates S6 and 4E-BP1. Thus, CTLH enables cells to rapidly tune mTORC1 activity at the lysosomal membrane via the ubiquitin/proteasome pathway.

**中文摘要译文：**
大多数EB病毒相关胃癌（EBVaGC）携带非沉默突变，激活磷酸肌醇3激酶（PI3K）以驱动下游代谢信号传导。为了深入了解PI3K/mTOR通路在这种情况下的失调，我们进行了一项全基因组CRISPR/Cas9筛选，寻找能够与PI3K拮抗剂alpelisib协同阻断EBVaGC增殖的靶点。羧基末端至LisH（CTLH）E3连接酶的多个亚基，包括催化亚基MAEA，位列筛选结果的顶部。CTLH在酵母中负调控糖异生，但在高等生物中则无此作用。CTLH底物MKLN1和ZMYND19在MAEA敲除后高度积累，它们相互结合并与溶酶体外膜结合以抑制mTORC1。ZMYND19和MKLN1并不扰乱mTORC1在溶酶体上的招募，而是阻断mTORC1与Rheb的相互作用以及与mTORC1底物S6和4E-BP1的结合。因此，CTLH通过泛素/蛋白酶体途径使细胞能够在溶酶体膜上快速调节mTORC1活性。

### 第二部分 AI 大师评价

本研究通过全基因组CRISPR/Cas9筛选技术，揭示了CTLH泛素连接酶底物ZMYND19和MKLN1在溶酶体膜上负调控mTORC1的新机制。研究不仅阐明了这些分子如何干扰mTORC1与Rheb及下游底物的相互作用，还强调了CTLH在调节mTORC1活性中的关键作用。这一发现为EB病毒相关胃癌的治疗提供了新的潜在靶点，具有显著的科研和临床价值。然而，研究尚未验证这些靶点在体内模型中的有效性，未来需进一步探索其转化潜力。

---

## 26. 塑料相关内分泌干扰物降低Nicastrin蛋白并加剧化脓性汗腺炎皮肤病的炎症反应

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41315355](https://pubmed.ncbi.nlm.nih.gov/41315355)
**期刊：** Nature communications
**PMID：** 41315355
**DOI：** 10.1038/s41467-025-65789-7

### 第一部分 原文与翻译

**英文原标题：** Plastic associated endocrine disruptors reduce Nicastrin protein and potentiate inflammation in hidradenitis suppurativa skin disease.

**英文摘要原文：**
Hidradenitis Suppurativa (HS) is an inflammatory skin disorder with limited treatments and unclear etiology. While monogenic HS is linked to gamma secretase mutations, particularly in the NCSTN subunit, the pathogenesis of the more common sporadic form remains uncertain, though associated with risk factors such as diets high in ultra-processed foods. Consistent with the clinical overlap between sporadic and monogenic HS, we find loss of NCSTN protein in sporadic HS fibroblasts. We hypothesize the rising incidence of sporadic HS and its hormonal associations implicate endocrine-disrupting chemicals, especially plastic-associated EDCs (p-EDs) common in UPFs. We detect elevated p-ED adducts in HS skin, persisting in ex vivo cultured fibroblasts. At nanomolar concentrations, p-EDs inhibits NCSTN and primes fibroblasts for inflammation, mimicking NCSTN knockdown. These findings suggest p-ED exposure contributes to HS pathogenesis, highlighting the need to address environmental exposures in HS and other gamma secretase-related diseases.

**中文摘要译文：**
化脓性汗腺炎（HS）是一种炎症性皮肤病，治疗方法有限且病因不明。单基因型HS与γ分泌酶突变有关，特别是在NCSTN亚基中，而更为常见的散发型HS的发病机制仍不确定，尽管其与超加工食品等高危饮食因素相关。与散发型和单基因型HS的临床重叠一致，我们发现散发型HS成纤维细胞中NCSTN蛋白的缺失。我们假设散发型HS发病率的上升及其与激素的关联涉及内分泌干扰化学物质，尤其是超加工食品中常见的塑料相关EDCs（p-EDs）。我们在HS皮肤中检测到升高的p-ED加合物，并在体外培养的成纤维细胞中持续存在。在纳摩尔浓度下，p-EDs抑制NCSTN并促使成纤维细胞发生炎症反应，模拟NCSTN敲低的效果。这些发现表明p-ED暴露参与了HS的发病机制，强调了在HS及其他γ分泌酶相关疾病中解决环境暴露问题的必要性。

### 第二部分 AI 大师评价

本研究探讨了塑料相关内分泌干扰物（p-EDs）在化脓性汗腺炎（HS）发病机制中的作用。通过分析HS患者皮肤和组织中的p-EDs水平及其对NCSTN蛋白的影响，研究发现p-EDs不仅降低NCSTN蛋白表达，还加剧炎症反应，揭示了环境因素在HS中的潜在作用。创新性地将HS与环境污染物联系起来，为疾病治疗和预防提供了新视角。然而，研究局限于体外实验，未来需进一步验证其在体内的作用。这一发现对临床干预和公共卫生政策制定具有重要意义。

---

## 27. 人类顺式异戊二烯基转移酶复合体变构调节的结构机制。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41315348](https://pubmed.ncbi.nlm.nih.gov/41315348)
**期刊：** Nature communications
**PMID：** 41315348
**DOI：** 10.1038/s41467-025-65833-6

### 第一部分 原文与翻译

**英文原标题：** Structural mechanisms of allosteric regulation in the human cis-prenyltransferase complex.

**英文摘要原文：**
Human cis-prenyltransferase (hcis-PT) synthesizes long-chain isoprenoids essential for N-linked protein glycosylation. This heteromeric complex comprises the catalytic subunit DHDDS and the regulatory Nogo-B receptor (NgBR). Although NgBR dramatically enhances DHDDS activity, the molecular basis for this allosteric regulation remains unclear. Here, we combined crystallography, hydrogen-deuterium exchange mass spectrometry (HDX-MS), molecular dynamics simulations, and network analysis to uncover the structural dynamics and communication pathways within hcis-PT. By solving the apo structure of hcis-PT, we reveal only a localized flexibility at the active site and the NgBR C-terminus. However, HDX-MS demonstrated widespread substrate-induced stabilization, particularly at the NgBR βD-βE loop, highlighting it as an allosteric hub. Functional mutagenesis scanning identified NgBR as critical for enzymatic activity, independent of structural perturbations. Network analysis of MD simulations pinpointed this residue as a central node in inter-subunit communication, with perturbations disrupting downstream allosteric pathways, altering enzymatic activity. Our findings reveal a dynamic regulatory network centered at the inter-subunit interface, wherein specific NgBR residues modulate DHDDS activity through allosteric signaling. This work elucidates a conserved mechanism of subunit coordination in long-chain cis-prenyltransferases and suggests avenues for therapeutic targeting of hcis-PT-related disorders.

**中文摘要译文：**
人类顺式异戊二烯基转移酶（hcis-PT）合成对N-连接蛋白糖基化至关重要的长链异戊二烯类化合物。这一异源复合体由催化亚基DHDDS和调节性Nogo-B受体（NgBR）组成。尽管NgBR显著增强了DHDDS的活性，但其变构调节的分子基础仍不清楚。本研究结合了晶体学、氢氘交换质谱（HDX-MS）、分子动力学模拟和网络分析，揭示了hcis-PT内的结构动态和通讯通路。通过解析hcis-PT的apo结构，我们发现仅在活性位点和NgBR的C端存在局部灵活性。然而，HDX-MS显示底物诱导的广泛稳定化，尤其在NgBR的βD-βE环上，凸显其作为变构中心的重要性。功能突变扫描表明NgBR对酶活性的关键作用不依赖于结构扰动。分子动力学模拟的网络分析将该残基定位为亚基间通讯的核心节点，扰动会破坏下游变构通路，改变酶活性。我们的发现揭示了以亚基界面为中心的动态调节网络，其中特定的NgBR残基通过变构信号调控DHDDS活性。这项工作阐明了长链顺式异戊二烯基转移酶中亚基协调的保守机制，并为治疗hcis-PT相关疾病提供了潜在靶点。

### 第二部分 AI 大师评价

本研究旨在揭示人类顺式异戊二烯基转移酶复合体的变构调节机制。通过多学科方法（晶体学、HDX-MS、分子动力学模拟和网络分析），研究团队发现NgBR在变构调节中的核心作用，并识别了关键通讯通路。这一研究不仅填补了对hcis-PT功能调控理解的空白，还为相关疾病的治疗提供了新思路。创新性体现在其综合方法的运用与动态网络视角的提出，具有显著的科研价值和潜在临床应用前景。然而，研究尚未验证这些发现的具体药理干预效果，值得进一步探索。

---

## 28. 基于精确环境UVB测量的全基因组基因-环境交互作用研究揭示162个维生素D状态相关变异

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41315334](https://pubmed.ncbi.nlm.nih.gov/41315334)
**期刊：** Nature communications
**PMID：** 41315334
**DOI：** 10.1038/s41467-025-65820-x

### 第一部分 原文与翻译

**英文原标题：** Genome-wide gene-environment interaction study uncovers 162 vitamin D status variants using a precise ambient UVB measure.

**英文摘要原文：**
Vitamin D status is influenced by genetic and environmental factors-primarily sun exposure. Using satellite weather data, we estimated an ambient UVB dose for each participant based on residential address and date of sampling. We conducted genome-wide tests in 338,977 UK Biobank White British participants, adjusted for age, sex, supplements, UVB dose, and 10 principal components to account for population structure. We applied three models to test for genetic effects: marginal only, main and interaction, and joint effects. We identified 307 variants associated with standardised log-transformed 25-hydroxyvitamin D (25OHD) concentration, 162 of which were not previously identified in GWAS. We identify an increase in SNP-heritability by increasing ambient UVB exposure quintiles (h = 8.48% vs. h = 15.56%). Downstream annotation implicated genes in the 25OHD pathway, including the circadian regulator, BMAL1. This and further findings suggest that vitamin D status and circadian rhythm may be entangled and that vitamin D metabolites may have a role as mediators of seasonal physiological fluctuations, including metabolism, and in turn explain the established associations with lipid metabolism pathways.

**中文摘要译文：**
维生素D状态受遗传和环境因素（主要是阳光暴露）的影响。利用卫星气象数据，我们根据参与者的居住地址和采样日期估算了其环境UVB剂量。我们通过对338,977名英国生物库中的白人参与者进行全基因组测试，并调整了年龄、性别、补充剂、UVB剂量和10个主要成分以考虑群体结构。我们应用了三种模型来测试遗传效应：仅边缘效应、主效应和交互效应、联合效应。我们确定了307个与标准化对数转换的25-羟基维生素D（25OHD）浓度相关的变异，其中162个变异此前在GWAS中未被发现。我们发现，通过增加环境UVB暴露的五分位数，SNP遗传力有所增加（h = 8.48% vs. h = 15.56%）。下游注释涉及25OHD通路中的基因，包括昼夜节律调节因子BMAL1。这些发现表明，维生素D状态与昼夜节律可能相互关联，且维生素D代谢物可能作为季节性生理波动（包括代谢）的介质，从而解释了其与脂质代谢通路的已有关联。

### 第二部分 AI 大师评价

本研究通过精确的环境UVB测量，揭示了162个新的维生素D状态相关变异，填补了GWAS研究的空白。采用全基因组分析和多重统计模型的方法，研究不仅提高了对遗传与环境交互作用的理解，还发现UVB暴露与SNP遗传力的相关性。创新性地提出维生素D状态与昼夜节律的潜在关联，并暗示其可能影响季节性生理波动和脂质代谢。然而，研究主要基于白人参与者，未来需在多族群中验证结果的普适性。这项研究为维生素D的个性化补充和季节性健康管理提供了重要依据。

---

## 29. 利用表型特异性模型扩展变异效应预测的实用性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41315332](https://pubmed.ncbi.nlm.nih.gov/41315332)
**期刊：** Nature communications
**PMID：** 41315332
**DOI：** 10.1038/s41467-025-66607-w

### 第一部分 原文与翻译

**英文原标题：** Expanding the utility of variant effect predictions with phenotype-specific models.

**英文摘要原文：**
Current methods for variant effect prediction do not differentiate between pathogenic variants resulting in different disease outcomes and are restricted in application due to a focus on variants with a single molecular consequence. We have developed Variant-to-Phenotype (V2P), a multi-task, multi-output machine learning model to predict variant pathogenicity conditioned on top-level Human Phenotype Ontology disease phenotypes (n = 23) for single nucleotide variants and insertions/deletions throughout the human genome. V2P leverages a unique approach for the modeling of variant effect that incorporates resultant disease phenotypes as output and during training to improve the quality of variant disease phenotype and effect predictions, simultaneously. We describe the architecture, training strategy, and biological features contributing to V2P's output, revealing initial characteristics underlying the relationship between disease genotype and phenotype. Moreover, we demonstrate the benefit of incorporating disease phenotypes for variant effect predictions by comparing V2P with several variant effect predictors across various high-quality evaluation datasets from manually curated databases and functional assays. Finally, we examine how V2P's predictions result in the successful identification of pathogenic variants in real and simulated patient sequencing data, outperforming other tested methods in initial comparisons. V2P offers a complete mapping of human genetic variants to disease-phenotypes, offering a uniquely conditioned set of variant effect characterizations.

**中文摘要译文：**
目前的变异效应预测方法无法区分导致不同疾病结果的致病变异，并且由于专注于具有单一分子后果的变异而限制了其应用范围。我们开发了Variant-to-Phenotype (V2P)，一种多任务、多输出的机器学习模型，用于预测基于顶级人类表型本体疾病表型（n=23）的单核苷酸变异和插入/缺失在整个人类基因组中的致病性。V2P采用了一种独特的变异效应建模方法，将结果性疾病的表型作为输出并在训练过程中纳入，从而同时提高变异疾病表型和效应预测的质量。我们描述了V2P的架构、训练策略以及影响其输出的生物学特征，揭示了疾病基因型与表型之间关系的初步特征。此外，我们通过将V2P与多个变异效应预测器在从手工整理的数据库和功能实验中获得的高质量评估数据集上进行比较，展示了将疾病表型纳入变异效应预测的益处。最后，我们研究了V2P的预测如何在真实和模拟的患者测序数据中成功识别致病变异，在初步比较中优于其他测试方法。V2P提供了人类遗传变异与疾病表型的完整映射，为一组独特条件下的变异效应表征提供了支持。

### 第二部分 AI 大师评价

本研究通过开发Variant-to-Phenotype (V2P)模型，旨在实现基于疾病表型的变异效应预测，填补了现有方法在区分不同疾病表型致病性变异方面的空白。V2P采用多任务、多输出的机器学习方法，整合了疾病表型作为输出和训练要素，显著提升了预测质量。其创新性在于首次实现了从变异到表型的完整映射，为理解基因型与表型关系提供了新视角。研究具有显著的临床应用潜力，尤其在罕见病诊断和精准医学领域。然而，模型的泛化能力依赖于训练数据的全面性，未来可能需要进一步扩展表型覆盖范围。

---

## 30. TIM-3与PD-1的双重阻断有效预防高进展并增强抗PD-1疗法在高级别浆液性卵巢癌中的疗效。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41315319](https://pubmed.ncbi.nlm.nih.gov/41315319)
**期刊：** Cell death & disease
**PMID：** 41315319
**DOI：** 10.1038/s41419-025-08231-6

### 第一部分 原文与翻译

**英文原标题：** Dual blockades of TIM-3 and PD-1 effectively prevent hyper-progression and enhance the efficacy of anti-PD-1 therapy in high-grade serous ovarian cancer.

**英文摘要原文：**
The programmed cell death 1 (PD-1), exhibits limited efficacy in high-grade serous ovarian cancer (HGSOC), with an average response rate of 10 to 15%. Furthermore, hyper-progression disease (HPD), which mostly occurs under immune checkpoint blockade (ICB) therapy, is a potentially deleterious side effect of ICB therapy that accelerates disease progression in HGSOC patients. Our study aims to identify the approach to improve the efficacy of anti-PD-1 treatment on HGSOC in preclinical settings. The prominent TIM-3 upregulation in CD8 tumor-infiltrating lymphocytes (TILs) and tumor-infiltrating dendritic cells (TIDCs) and the phenomenon of HPD were observed in ID8-bearing mice after anti-PD-1 treatment. TIM-3 and PD-1 co-blockades prevented the occurrence of HPD in pre-clinical models and prolonged their survival. Meanwhile, TIM-3 and PD-1 co-blockades effectively enhanced the function and proliferation of CD8TILs and TIDCs from ID8-bearing mice. Notably, TIM-3 and PD-1 inhibitors effectively enhanced the anti-tumor immunity of CD8TILs and CD11c myeloid cells from HGSOC patients. Our study uncovers the significance of TIM-3 inhibition in preventing the occurrence of HPD and enhancing the efficacy of anti-PD-1 therapy in HGSOC.

**中文摘要译文：**
程序性细胞死亡蛋白1（PD-1）在高级别浆液性卵巢癌（HGSOC）中疗效有限，平均反应率为10%至15%。此外，高进展疾病（HPD）是免疫检查点阻断（ICB）治疗中常见的潜在有害副作用，会加速HGSOC患者的疾病进展。本研究旨在确定在临床前环境中提高抗PD-1治疗对HGSOC疗效的方法。在抗PD-1治疗的ID8荷瘤小鼠中，观察到CD8肿瘤浸润淋巴细胞（TILs）和肿瘤浸润树突状细胞（TIDCs）中TIM-3的显著上调以及HPD现象。TIM-3与PD-1的共同阻断了临床前模型中HPD的发生并延长了其生存期。同时，TIM-3与PD-1的共同阻断有效增强了ID8荷瘤小鼠CD8TILs和TIDCs的功能与增殖。值得注意的是，TIM-3与PD-1抑制剂有效增强了HGSOC患者CD8TILs和CD11c髓系细胞的抗肿瘤免疫。本研究揭示了TIM-3抑制在预防HPD发生和增强抗PD-1疗法对HGSOC疗效中的重要性。

### 第二部分 AI 大师评价

本研究旨在通过双重阻断TIM-3和PD-1来提高抗PD-1治疗在高级别浆液性卵巢癌（HGSOC）中的疗效，并预防高进展疾病（HPD）的发生。通过临床前模型和小鼠实验，研究发现TIM-3与PD-1的共同阻断不仅显著延长生存期，还增强了肿瘤浸润免疫细胞的功能。这一成果为HGSOC的免疫治疗提供了新的策略，具有显著的临床价值和科研意义，但其在人体中的实际效果仍需进一步验证。

---

## 31. 机械限制通过线粒体功能障碍诱导铁死亡。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41315309](https://pubmed.ncbi.nlm.nih.gov/41315309)
**期刊：** Nature communications
**PMID：** 41315309
**DOI：** 10.1038/s41467-025-66353-z

### 第一部分 原文与翻译

**英文原标题：** Mechanical confinement induces ferroptosis through mitochondrial dysfunction.

**英文摘要原文：**
Cells in highly crowded environments are exposed to fluctuating mechanical forces. While cells can activate the cortical migration machinery to escape from undesirable compressive stress, the consequence to less motile cells and of prolonged extensive confinement is yet to be uncovered. Here, we demonstrate that nuclear deformation generated by axial confinement triggers a specific form of regulated cell death - ferroptosis. We show that axial confinement is sensed by the nucleus and results in Drp1-dependent mitochondrial fragmentation and mitochondrial ROS accumulation. Meanwhile, we detect cPLA2 translocation to mitochondria. These mitochondrial ROS accumulation and arachidonic acid production concertedly lead to lipid peroxidation and evoke ferroptosis. Interestingly, we find in osteoarthritis, a disease intimately associated with mechanical overloading and inflammation, characteristics of confinement-induced ferroptosis including mitochondrial localization of cPLA2 and high ROS. Together, our findings unveil a pivotal role of cell nucleus and mitochondria in linking mechanical confinement with cell death, highlighting the orchestration of Drp1 and cPLA2 in confinement-induced ferroptosis.

**中文摘要译文：**
高密度环境中细胞暴露于波动的机械力。虽然细胞可以通过激活皮层迁移机制逃避不利的压缩应力，但对于运动能力较弱的细胞以及长期广泛限制的后果仍未揭示。在此，我们证明了轴向限制引起的核变形触发了一种特定形式的调控性细胞死亡——铁死亡。我们发现，轴向限制被细胞核感知，并导致Drp1依赖的线粒体断裂和线粒体ROS积累。同时，我们检测到cPLA2向线粒体的转位。这些线粒体ROS积累和花生四烯酸的产生协同导致脂质过氧化并诱发铁死亡。有趣的是，我们在与机械过度负荷和炎症密切相关的骨关节炎中发现了限制诱导的铁死亡特征，包括cPLA2的线粒体定位和高ROS水平。总之，我们的发现揭示了细胞核和线粒体在机械限制与细胞死亡之间的关键作用，强调了Drp1和cPLA2在限制诱导的铁死亡中的协同作用。

### 第二部分 AI 大师评价

本研究通过探索机械限制对细胞的影响，揭示了轴向限制通过Drp1依赖的线粒体功能障碍和cPLA2转位诱导铁死亡的机制。研究创新性地将机械力与细胞死亡调控联系起来，为理解骨关节炎等机械过度负荷相关疾病的病理机制提供了新视角。其发现不仅丰富了细胞死亡调控的理论基础，也为相关疾病的治疗策略开发提供了潜在靶点。然而，研究仍需进一步验证其在其他疾病模型中的普适性。

---

## 32. USP13调控Ran蛋白的降解及其在弥漫性大B细胞淋巴瘤（DLBCL）中对铁死亡的敏感性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41315297](https://pubmed.ncbi.nlm.nih.gov/41315297)
**期刊：** Cell death & disease
**PMID：** 41315297
**DOI：** 10.1038/s41419-025-08207-6

### 第一部分 原文与翻译

**英文原标题：** USP13 dictates Ran turnover and vulnerability to ferroptosis in diffuse large B cell lymphoma (DLBCL).

**英文摘要原文：**
Diffuse large B-cell lymphoma (DLBCL) is one of the most common and lethal B-cell malignancies worldwide, with high relapse rate after standard treatment, and the relapsed cases are often difficult to treat. Ubiquitination has a pivotal role in cellular protein homeostasis and tumorigenic deubiquitinases (DUBs) stabilize oncoproteins during carcinogenesis. In this study, we have identified USP13 as one of the abnormally-overexpressed and stage-related DUBs in DLBCL critical to disease pathogenesis. Employing LC-MS/MS, Ran GTPase was characterized as potential substrate of USP13, with the interaction between Ran and USP13 modeled by Alphafold3. USP13 co-overexpressed, co-localized and correlated with Ran at protein level in DLBCL patient samples and cell lines. Pharmacological inhibition and genetic manipulation of USP13 modulated Ran protein stability and K11-linked ubiquitination level of Ran. By RNA-seq, pharmacological inhibition of USP13 via Spautin-1 treatment in DLBCL revealed downstream targets in NF-κB and Notch pathways. Suggested by the DRESIS Database, NF-κB and Notch signaling cascades are key to the resistance of Doxorubicin (Dox) and cyclophosphamide (CTX) within the standard R-CHOP regimen of DLBCL hinting benefits of combining Spautin-1 with Dox or CTX. Further in-vitro and in-vivo experiments confirmed Spautin-1 synergized with Dox or CTX to initiate ferroptosis in DLBCL with few toxicities to main organs by mediating ROS, GSH, MDA and ultimately LPO. Altogether, these results demonstrate USP13 deubiquitinates Ran in DLBCL, and Spautin-1 well synergizes with Dox or CTX to initiate ferroptosis. Combinational treatment with Spautin-1 and Dox or CTX may represent an effective approach and therapeutic hope to combat with DLBCL.

**中文摘要译文：**
弥漫性大B细胞淋巴瘤（DLBCL）是全球最常见且致死率较高的B细胞恶性肿瘤之一，标准治疗后复发率高，而复发病例往往难以治疗。泛素化在细胞蛋白质稳态中起着关键作用，而促癌去泛素化酶（DUBs）在致癌过程中稳定癌蛋白。本研究中，我们确定USP13是DLBCL中异常高表达且与疾病进展相关的关键DUBs之一。通过LC-MS/MS技术，Ran GTPase被鉴定为USP13的潜在底物，并通过Alphafold3模拟了Ran与USP13的相互作用。在DLBCL患者样本和细胞系中，USP13与Ran在蛋白水平上共表达、共定位且相关。药理抑制和基因操作USP13调控了Ran蛋白的稳定性及其K11-linked泛素化水平。通过RNA-seq分析，Spautin-1药理抑制USP13揭示了NF-κB和Notch通路的下游靶点。根据DRESIS数据库的提示，NF-κB和Notch信号级联是DLBCL标准治疗方案R-CHOP中阿霉素（Dox）和环磷酰胺（CTX）耐药的关键，暗示Spautin-1与Dox或CTX联合治疗的潜在益处。进一步的体外和体内实验证实，Spautin-1通过介导ROS、GSH、MDA和最终的LPO，与Dox或CTX协同作用，在DLBCL中诱发铁死亡，且对主要器官毒性较小。总之，这些结果表明USP13在DLBCL中去泛素化Ran，而Spautin-1与Dox或CTX协同作用可有效诱发铁死亡。Spautin-1与Dox或CTX的联合治疗可能成为一种有效对抗DLBCL的治疗策略。

### 第二部分 AI 大师评价

本研究旨在探索USP13在弥漫性大B细胞淋巴瘤（DLBCL）中的作用机制及其潜在治疗价值。通过LC-MS/MS、Alphafold3建模和RNA-seq等技术，研究者发现了USP13调控Ran蛋白的降解及其对铁死亡敏感性的影响，并证实Spautin-1与化疗药物Dox或CTX的协同治疗效果。该研究的创新性在于揭示了USP13-Ran轴的分子机制，并提出了新型联合治疗策略。临床价值显著，为DLBCL的耐药性和复发难题提供了潜在解决方案。然而，研究的局限性在于尚未在临床患者中进行大规模验证，未来需进一步探索其安全性和有效性。

---

## 33. REACtiVe-2：转移性胰腺癌患者在（m）FOLFIRINOX治疗后树突状细胞疫苗与CD40激动抗体疗法的I期评估

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41315287](https://pubmed.ncbi.nlm.nih.gov/41315287)
**期刊：** Nature communications
**PMID：** 41315287
**DOI：** 10.1038/s41467-025-66092-1

### 第一部分 原文与翻译

**英文原标题：** REACtiVe-2: phase I evaluation of dendritic cell vaccination and agonistic CD40 therapy following (m)FOLFIRINOX in metastatic pancreatic cancer.

**英文摘要原文：**
In pancreatic ductal adenocarcinoma (PDAC), the dense desmoplastic stroma and insufficient infiltrating T cells represent a significant barrier to effective immunotherapy. In this phase I, dose-escalation study, previously registered at the Dutch Trial Register and later on at ClinicalTrial (NCT05650918), we administer an autologous dendritic cell (DC) vaccine (MesoPher) with an agonistic CD40-specific antibody (mitazalimab) to metastatic PDAC patients (n = 16) after (m)FOLFIRINOX treatment. We included patients with WHO performance status 0-1 with accessible metastatic lesions, and excluded patients with history of previous immunotherapy or malignant ascites. Primary objectives include safety and tolerability. Immune modulation and clinical outcomes are monitored as secondary objectives. MesoPher (25 × 10 DCs) is co-administered with 300, 600, or 1200 μg/kg mitazalimab. MesoPher/mitazalimab therapy is safe and well-tolerated, and the primary endpoint is met. One transient dose-limiting toxicity (DLT) is observed (grade 3 fever). MesoPher/mitazalimab induces a systemic increase in activated and vaccine-specific T cell responses. In post-therapy tumor biopsies, increased T cell infiltration and decreased collagen deposition are observed. No objective radiological response is observed, but eight patients (50%) show stable disease after three administrations. In conclusion, MesoPher/mitazalimab combination therapy is safe and tolerable in patients with metastatic PDAC and enhances systemic immune activation and local immune responses. Future research should evaluate the efficacy of this promising approach as maintenance therapy shortly after completing chemotherapy.

**中文摘要译文：**
在胰腺导管腺癌（PDAC）中，致密的纤维间质和不足的T细胞浸润是免疫治疗有效性的主要障碍。本研究为一I期剂量递增试验，此前已在荷兰试验注册中心和ClinicalTrial（NCT05650918）注册，我们对16名（m）FOLFIRINOX治疗后的转移性PDAC患者给予自体树突状细胞（DC）疫苗（MesoPher）和CD40特异性激动抗体（mitazalimab）。纳入标准为WHO体能状态评分0-1且具有可及转移病灶的患者，排除了有免疫治疗史或恶性腹水的患者。主要研究目标是安全性和耐受性，次要目标是免疫调节和临床结局。MesoPher（25 × 10 DCs）与300、600或1200μg/kg的mitazalimab联合给药。MesoPher/mitazalimab疗法安全且耐受性良好，主要终点已达到。观察到一过性剂量限制性毒性（DLT）（3级发热）。MesoPher/mitazalimab引起活化和疫苗特异性T细胞反应的全身性增加。治疗后肿瘤活检中观察到T细胞浸润增加和胶原沉积减少。未观察到客观的影像学反应，但8名患者（50%）在三次给药后病情稳定。总之，MesoPher/mitazalimab联合疗法对转移性PDAC患者安全且耐受性良好，可增强系统性免疫激活和局部免疫反应。未来研究应评估这一有前景的方法作为化疗后维持治疗的疗效。

### 第二部分 AI 大师评价

本研究旨在评估转移性胰腺癌患者在化疗后接受树突状细胞疫苗与CD40激动抗体联合治疗的安全性和免疫调节效果。通过I期剂量递增试验，研究证明了该疗法安全且耐受性良好，并显著增强了系统性T细胞反应和局部免疫应答。尽管未观察到显著的影像学反应，但50%患者病情稳定，显示了潜在的临床价值。该研究的创新性在于首次将DC疫苗与CD40激动抗体联合应用于转移性PDAC患者，但其局限在于样本量较小，未来需进一步验证其疗效。

---

## 34. 着色性干皮病D组蛋白在单链DNA上的转运机制及遗传病病因学

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41315283](https://pubmed.ncbi.nlm.nih.gov/41315283)
**期刊：** Nature communications
**PMID：** 41315283
**DOI：** 10.1038/s41467-025-66834-1

### 第一部分 原文与翻译

**英文原标题：** Translocation mechanism of xeroderma pigmentosum group D protein on single-stranded DNA and genetic disease etiology.

**英文摘要原文：**
XPD is a key nucleotide excision repair (NER) protein whose function is vital for genome integrity. During NER, XPD serves as a 5'-3' single-strand DNA translocase that enables lesion scanning and verification in genomic DNA. Yet, its translocation mechanism is incompletely understood. Here we use molecular simulations and chain-of-replicas path optimization methods to model the ATP-driven translocation mechanisms of XPD and its bacterial homolog DinG, revealing all on-path metastable intermediates and corresponding kinetic rates. We identify the XPD(DinG) global domain motions that modulate the strength of DNA association at the opposing ends of the DNA-binding groove. During the ATP hydrolysis cycle, alternating weak and strong interactions at two defined groove constrictions enable DNA reptation and forward displacement of the ATPase. Moreover, we show that DNA- or ATP-binding residues directly involved in translocation are hotspots for genetic disease mutations. Thus, our findings shed light on the etiology of XPD-associated genetic syndromes.

**中文摘要译文：**
XPD是核苷酸切除修复（NER）中的关键蛋白，其功能对基因组完整性至关重要。在NER过程中，XPD作为一种5’-3’单链DNA转运酶，能够在基因组DNA中进行损伤扫描和验证。然而，其转运机制尚未完全阐明。本研究利用分子模拟和副本链路径优化方法，模拟了XPD及其细菌同源蛋白DinG的ATP驱动转运机制，揭示了所有路径上的亚稳态中间体及相应的动力学速率。我们发现XPD（DinG）的整体结构域运动调节了DNA结合沟槽两端DNA结合的强度。在ATP水解循环中，两个特定沟槽收缩处的强弱交替相互作用使得DNA能够蠕动并推动ATP酶向前移动。此外，我们还发现直接参与转运的DNA或ATP结合残基是遗传病突变的 hotspots。因此，我们的研究结果为了解XPD相关遗传综合征的病因提供了新的见解。

### 第二部分 AI 大师评价

本研究旨在揭示着色性干皮病D组蛋白（XPD）及其细菌同源蛋白DinG在单链DNA上的ATP驱动转运机制。通过分子模拟和副本链路径优化方法，作者不仅阐明了转运过程中的亚稳态中间体及动力学速率，还发现DNA结合沟槽的动态变化是推动DNA蠕动和ATP酶位移的关键。这一研究不仅为理解XPD功能提供了分子层面的新见解，还揭示了其转运相关残基在遗传病中的作用，具有重要的科研价值和临床意义。然而，研究仅基于模拟结果，进一步的实验验证将有助于确认这些发现的普适性。

---

## 35. IFN-γ驱动的UBE2D3上调损害胰腺癌中抗原呈递通路和抗肿瘤免疫

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41315272](https://pubmed.ncbi.nlm.nih.gov/41315272)
**期刊：** Nature communications
**PMID：** 41315272
**DOI：** 10.1038/s41467-025-65762-4

### 第一部分 原文与翻译

**英文原标题：** IFN-γ-driven UBE2D3 upregulation impairs antigen presentation pathways and anti-tumor immunity in pancreatic cancer.

**英文摘要原文：**
Although ubiquitin-conjugating enzymes are critical regulators of cellular function and fate, their roles in tumorigenesis remain incompletely defined. Here, we provide genetic and molecular evidence that the Ubiquitin-Conjugating Enzyme E2 D3 (UBE2D3) is specifically overexpressed in cancerous pancreatic ductal cells, including early-stage pancreatic intraepithelial neoplasia and advanced pancreatic ductal adenocarcinoma (PDAC). This overexpression is independent of oncogenic KRAS status and is driven by the inflammatory tumor microenvironment, particularly interferon-γ (IFN-γ). Mechanistically, UBE2D3 binds the ubiquitin ligase Kelch Like Family Member 13 (KLHL13) to mediate K63-linked polyubiquitination at lysine 245 of transporter 2 (TAP2), resulting in steric hindrance that blocks the transporter. Genetic or pharmacologic inhibition of UBE2D3 enhances antigen presentation in cancer cells and restores CD8 T-cell-mediated tumor surveillance in pancreatic cancer models in male mice. Furthermore, combining an UBE2D3 small-molecule inhibitor with KRAS-specific TCR-T-cell therapy yields synergistic antitumor effects. Our findings reveal a negative feedback mechanism in which cancer cells, "camouflaging" themselves, evade IFN-γ-induced antigen presentation via UBE2D3 upregulation, highlighting a potential therapeutic target for enhancing antitumor immunity.

**中文摘要译文：**
尽管泛素连接酶是细胞功能和命运的关键调控因子，但它们在肿瘤发生中的作用仍未完全阐明。本文通过遗传学和分子生物学证据表明，泛素连接酶E2 D3（UBE2D3）在胰腺癌导管细胞中特异性过表达，包括早期胰腺上皮内瘤变和晚期胰腺导管腺癌（PDAC）。这种过表达不依赖于致癌KRAS状态，而是由炎症性肿瘤微环境（尤其是干扰素-γ（IFN-γ））驱动。机制上，UBE2D3与泛素连接酶Kelch样家族成员13（KLHL13）结合，介导转运蛋白2（TAP2）第245位赖氨酸的K63连接的多聚泛素化，从而导致空间位阻阻断转运蛋白的功能。遗传或药物抑制UBE2D3可增强癌细胞中的抗原呈递，并在雄性小鼠的胰腺癌模型中恢复CD8 T细胞介导的肿瘤监视。此外，将UBE2D3小分子抑制剂与KRAS特异性TCR-T细胞疗法联合使用可产生协同抗肿瘤效应。我们的研究结果揭示了一种负反馈机制：癌细胞通过上调UBE2D3来“伪装”自身，从而逃避IFN-γ诱导的抗原呈递过程，这为增强抗肿瘤免疫提供了一个潜在的治疗靶点。

### 第二部分 AI 大师评价

本研究旨在揭示UBE2D3在胰腺癌中通过调控抗原呈递通路抑制抗肿瘤免疫的作用机制。研究者结合遗传学和药理学方法，证明了UBE2D3的过表达受肿瘤微环境中IFN-γ的驱动，并通过阻断TAP2功能抑制抗原呈递。关键发现包括UBE2D3抑制可恢复CD8 T细胞的抗肿瘤活性，以及与TCR-T细胞疗法的协同效应。这一研究创新性地揭示了癌细胞逃避免疫监视的新机制，具有重要的临床转化潜力，但也提示了靶向UBE2D3的治疗策略可能仅适用于特定肿瘤微环境的局限性。

---

## 36. 激素受体阳性乳腺癌中新辅助白蛋白结合型紫杉醇和派姆单抗的疗效、安全性及预测性生物标志物：一项随机试点试验

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41315271](https://pubmed.ncbi.nlm.nih.gov/41315271)
**期刊：** Nature communications
**PMID：** 41315271
**DOI：** 10.1038/s41467-025-66667-y

### 第一部分 原文与翻译

**英文原标题：** Efficacy, safety, and predictive biomarkers of neoadjuvant nab-paclitaxel and pembrolizumab in hormone receptor-positive breast cancer: A randomized pilot trial.

**英文摘要原文：**
Patients with hormone receptor-positive (HR + )/HER2- breast cancer may benefit from neoadjuvant immune checkpoint inhibitor (ICI) plus chemotherapy. The effect of chemotherapy or ICI run-in before combination therapy in this population is unexplored. In this randomized pilot trial, patients with HR + /HER2- breast cancer received two weeks of neoadjuvant nab-paclitaxel or pembrolizumab, with baseline and post-run-in tumor biopsy, followed by combined nab-paclitaxel/pembrolizumab. The primary endpoint was PD-L1 expression change between biopsies. Tumor whole exome/RNA sequencing were performed. Of 29 patients, 72% were node-positive. Residual cancer burden (RCB) 0-1 rate was 28% (inclusive of patients receiving additional neoadjuvant adriamycin/cyclophosphamide). No significant change in PD-L1 expression occurred following nab-paclitaxel or pembrolizumab run-in, thus the primary endpoint was not met. Other secondary outcome measures included overall response rate of 80% to the neoadjuvant regimen, and 3-year event-free survival of 86% (95% CI 69-100%); there were no unexpected safety signals. In exploratory biomarker analyses, higher baseline PD-L1 expression and inflammatory gene signatures were associated with favorable response (RCB 0-1); higher expression of estrogen response genes, with unfavorable response (RCB 2-3). Clinical Trial Number: NCT02999477.

**中文摘要译文：**
激素受体阳性(HR + )/HER2阴性乳腺癌患者可能从新辅助免疫检查点抑制剂(ICI)联合化疗中获益。化疗或ICI预处理在这一人群中的效果尚未被探索。在这项随机试点试验中，HR + /HER2阴性乳腺癌患者接受了两周的新辅助白蛋白结合型紫杉醇或派姆单抗治疗，并在基线和预处理后进行了肿瘤活检，随后联合使用白蛋白结合型紫杉醇和派姆单抗。主要终点是活检间PD-L1表达的变化。对肿瘤进行了全外显子组/RNA测序。29例患者中，72%为淋巴结阳性。残余癌负担(RCB)0-1率为28%（包括接受额外新辅助阿霉素/环磷酰胺治疗的患者）。白蛋白结合型紫杉醇或派姆单抗预处理后未观察到PD-L1表达的显著变化，因此主要终点未达到。其他次要结局指标包括对新辅助治疗方案的总体缓解率为80%，3年无事件生存率为86%（95% CI 69-100%）；未出现意外的安全性信号。在探索性生物标志物分析中，较高的基线PD-L1表达和炎症基因特征与良好反应(RCB 0-1)相关；雌激素反应基因的较高表达与不良反应(RCB 2-3)相关。临床试验编号：NCT02999477。

### 第二部分 AI 大师评价

本研究旨在探讨新辅助白蛋白结合型紫杉醇和派姆单抗在激素受体阳性乳腺癌中的疗效、安全性及预测性生物标志物。通过随机试点试验设计，研究发现PD-L1表达变化未达到预期终点，但整体缓解率和无事件生存率表现优异。创新性在于探索了预处理对治疗效果的影响，并揭示了PD-L1和炎症基因特征与治疗反应的关联，为个体化治疗提供了潜在生物标志物。局限性在于样本量较小，需进一步验证。其临床价值在于为激素受体阳性乳腺癌的联合治疗策略提供了新思路。

---

## 37. 母源组蛋白甲基转移酶在秀丽隐杆线虫中拮抗性调节常染色体随机单等位基因表达（aRMAE）。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41315265](https://pubmed.ncbi.nlm.nih.gov/41315265)
**期刊：** Nature communications
**PMID：** 41315265
**DOI：** 10.1038/s41467-025-66501-5

### 第一部分 原文与翻译

**英文原标题：** Maternal histone methyltransferases antagonistically regulate autosomal random monoallelic expression (aRMAE) in C. elegans.

**英文摘要原文：**
Undefined epigenetic programs act to probabilistically silence individual autosomal alleles, generating unique individuals, even from genetic clones. This random monoallelic expression can explain variation in traits and diseases that differences in genes and environments cannot. Here, we developed the nematode Caenorhabditis elegans to study monoallelic expression in whole tissues, and defined a developmental genetic regulation pathway. We found maternal H3K9 histone methyltransferase (HMT) SET-25/SUV39/G9a works with HPL-2/HP1 and LIN-61/L3MBTL2 to randomly silence alleles in the intestinal progenitor E-cell of 8-cell embryos to cause monoallelic expression. SET-25 was antagonized by another maternal H3K9 HMT, MET-2/SETDB1, which works with LIN-65/ATF7IP and ARLE-14/ARL14EP to prevent monoallelic expression. The HMT catalytic SET domains of both MET-2 and SET-25 were required for regulating monoallelic expression. Our data support a model wherein SET-25 and MET-2 regulate histones during development to generate patterns of somatic monoallelic expression that are persistent but not heritable.

**中文摘要译文：**
未定义的 epigenetic programs 通过概率性地沉默单个常染色体等位基因，从而产生独特的个体，即使是基因克隆也如此。这种随机单等位基因表达可以解释基因和环境差异无法解释的性状和疾病变异。在此，我们开发了秀丽隐杆线虫模型，研究全组织中单等位基因表达，并定义了一条发育遗传调控通路。我们发现母源H3K9组蛋白甲基转移酶（HMT）SET-25/SUV39/G9a与HPL-2/HP1和LIN-61/L3MBTL2共同作用，在8细胞胚胎的肠前体E细胞中随机沉默等位基因，导致单等位基因表达。SET-25受到另一母源H3K9 HMT MET-2/SETDB1的拮抗，后者与LIN-65/ATF7IP和ARLE-14/ARL14EP协作，阻止单等位基因表达。MET-2和SET-25的HMT催化SET结构域均为调控单等位基因表达所必需。我们的数据支持一个模型，即在发育过程中，SET-25和MET-2通过调控组蛋白生成体细胞单等位基因表达模式，这些模式具有持续性但不遗传。

### 第二部分 AI 大师评价

本研究通过秀丽隐杆线虫模型，揭示了母源组蛋白甲基转移酶SET-25和MET-2在调控常染色体随机单等位基因表达（aRMAE）中的拮抗作用。研究发现SET-25促进单等位基因表达，而MET-2则抑制这一过程，并通过HMT催化结构域实现调控。这项工作不仅定义了一条发育遗传调控通路，还为理解表观遗传变异与个体差异提供了新视角。创新性强，但对人类疾病直接应用的转化价值仍需进一步研究。

---

## 38. DNA基础模型在基因组和遗传任务中的基准测试

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41315262](https://pubmed.ncbi.nlm.nih.gov/41315262)
**期刊：** Nature communications
**PMID：** 41315262
**DOI：** 10.1038/s41467-025-65823-8

### 第一部分 原文与翻译

**英文原标题：** Benchmarking DNA foundation models for genomic and genetic tasks.

**英文摘要原文：**
The rapid evolution of DNA foundation models promises to revolutionize genomics, yet comprehensive evaluations are lacking. Here, we present a comprehensive, unbiased benchmark of five models (DNABERT-2, Nucleotide Transformer V2, HyenaDNA, Caduceus-Ph, and GROVER) across diverse genomic and genetic tasks including sequence classification, gene expression prediction, variant effect quantification, and topologically associating domain (TAD) region recognition, using zero-shot embeddings. Our analysis reveals that mean token embedding consistently and significantly improves sequence classification performance, outperforming other pooling strategies. Model performance varies among tasks and datasets; while general purpose DNA foundation models showed competitive performance in pathogenic variant identification, they were less effective in predicting gene expression and identifying putative causal QTLs compared to specialized models. Our findings offer a framework for model selection, highlighting the impact of architecture, pre-training data, and embedding strategies on performance in genomic and genetic tasks.

**中文摘要译文：**
DNA基础模型的快速发展有望彻底改变基因组学，但目前仍缺乏全面的评估。在此，我们提出了对五种模型（DNABERT-2、Nucleotide Transformer V2、HyenaDNA、Caduceus-Ph和GROVER）的综合且无偏见的基准测试，涵盖了多种基因组和遗传任务，包括序列分类、基因表达预测、变异效应定量和拓扑关联域（TAD）区域识别，使用的是零样本嵌入方法。我们的分析表明，平均标记嵌入能够一致且显著地提升序列分类性能，优于其他池化策略。模型在不同的任务和数据集中的表现各异；尽管通用的DNA基础模型在致病性变异识别中表现出了竞争力，但在预测基因表达和识别潜在的因果数量性状位点（QTLs）方面，与专用模型相比表现较差。我们的研究结果为模型选择提供了一个框架，强调了架构、预训练数据和嵌入策略对基因组和遗传任务性能的影响。

### 第二部分 AI 大师评价

本研究旨在全面评估五种DNA基础模型在基因组和遗传任务中的性能，填补了该领域缺乏系统性评估的空白。通过零样本嵌入方法，研究者揭示了平均标记嵌入在序列分类中的优越性，同时指出了通用模型与专用模型在不同任务中的表现差异。研究创新性地提出了一个模型选择框架，为基因组学研究提供了重要的参考价值。然而，研究也表明通用模型在基因表达预测方面存在局限，这为未来模型的改进指明了方向。

---

## 39. 解析补体系统基因在胰腺癌易感性和预后中的作用。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41315260](https://pubmed.ncbi.nlm.nih.gov/41315260)
**期刊：** Nature communications
**PMID：** 41315260
**DOI：** 10.1038/s41467-025-65811-y

### 第一部分 原文与翻译

**英文原标题：** Deciphering the role of complement system genes in pancreatic cancer susceptibility and prognosis.

**英文摘要原文：**
Pancreatic ductal adenocarcinoma (PDAC) genetic susceptibility is partially identified. The complement system (CS) influences carcinogenesis and participates in immunological defense and homeostasis; however, its role in PDAC genetic susceptibility and prognosis is underexplored. The association of SNPs within 111 CS-related genes with PDAC risk is assessed in the PanGenEU study and validated in the UKBiobank. We investigate the association between the CS-related gene variation and PDAC risk, followed by an in-depth functional in silico study using TCGA and ICGC data. We assess whether CS-related genes are associated with prognosis at the germline and somatic levels. We investigate the immune infiltration of PDAC tumors according to their transcriptomic profile. Genetic variation in FCN1 and PLAT is significantly associated with PDAC risk. PDAC patients with elevated expression of IGHG3, IGKC, IGHM, F2R, F2RL2, CFI, A2M, or C4A display improved survival and higher infiltration of CD8, B cells, and Th1 cells. Individuals with high expression levels of either FGA, SERPINE1, FGG, or F3 exhibit poorer survival, higher infiltration of Tregs, and lower infiltration of CD8 cells. Results from this study suggest that CS-related genes play a role in PDAC genetic susceptibility and survival through specific immune cell infiltration.

**中文摘要译文：**
胰腺导管腺癌（PDAC）的遗传易感性已被部分揭示。补体系统（CS）在致癌过程中发挥作用，并参与免疫防御和稳态；然而，其在PDAC遗传易感性和预后中的作用尚未充分探索。本研究通过PanGenEU研究评估了111个CS相关基因中SNPs与PDAC风险的关联，并在UKBiobank中进行了验证。我们研究了CS相关基因变异与PDAC风险的关系，随后利用TCGA和ICGC数据进行了深入的计算机模拟功能研究。我们评估了CS相关基因是否在种系和体细胞水平上与预后相关，并根据转录组学特征研究了PDAC肿瘤的免疫浸润情况。FCN1和PLAT的遗传变异与PDAC风险显著相关。IGHG3、IGKC、IGHM、F2R、F2RL2、CFI、A2M或C4A表达升高的PDAC患者表现出更高的生存率和CD8、B细胞及Th1细胞的浸润。而FGA、SERPINE1、FGG或F3表达水平较高的个体则表现出更差的生存率、更高的Tregs浸润和更低的CD8细胞浸润。本研究结果表明，CS相关基因通过特定的免疫细胞浸润在PDAC遗传易感性和生存中发挥作用。

### 第二部分 AI 大师评价

本研究旨在探索补体系统基因在胰腺癌（PDAC）遗传易感性和预后中的作用，采用大规模遗传关联研究和计算机模拟功能分析相结合的方法。研究发现FCN1和PLAT等基因的变异与PDAC风险相关，并通过免疫细胞浸润机制影响患者生存。其创新性在于揭示了补体系统基因在PDAC中的新功能，为靶向治疗提供了潜在靶点。研究具有较高的临床和科研价值，但其结论仍需更多实验和临床数据验证。

---

## 40. MET信号驱动肌肉浸润性膀胱癌细胞对erdafitinib的获得性耐药

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41315241](https://pubmed.ncbi.nlm.nih.gov/41315241)
**期刊：** Cell death & disease
**PMID：** 41315241
**DOI：** 10.1038/s41419-025-08221-8

### 第一部分 原文与翻译

**英文原标题：** MET signaling drives acquired resistance to erdafitinib in muscle-invasive bladder cancer cells.

**英文摘要原文：**
Muscle-invasive bladder cancer (MIBC) is an aggressive malignancy with high recurrence and poor survival, accounting for the majority of bladder cancer-related deaths. A subset of MIBC harbors FGFR1 amplification or overexpression, associated with increased proliferation and poor prognosis. Although the pan-FGFR inhibitor erdafitinib has demonstrated clinical benefit in patients with FGFR3/FGFR2 alterations, primarily in non-MIBC, its efficacy is limited by resistance and toxicity. Moreover, its effectiveness in FGFR1-driven MIBC remains unclear. To address this gap, we investigated erdafitinib response and resistance mechanisms in JMSU1 cells, a model of FGFR1-amplified MIBC. While erdafitinib initially suppressed tumor growth, prolonged treatment led to resistance, characterized by persistent activation of ERK, AKT, and STAT1 signaling pathways. Mechanistic studies identified MET activation, driven by MET gene amplification, as a key driver of resistance. Notably, exogenous hepatocyte growth factor (HGF) not only induced resistance but also accelerated the emergence of MET-amplified, HGF-independent subpopulations under drug pressure. We also identified SHP2 as a critical mediator of FGFR1-driven ERK activation in parental cells. In resistant cells, MET activation enhanced SHP2-ERK signaling through the adaptor protein GAB1, reinforcing the resistant phenotype. Combined inhibition of FGFR1 and MET significantly suppressed tumor growth in resistant cells. These findings establish MET amplification and GAB1-SHP2 signaling as central mediators of erdafitinib resistance in FGFR1-amplified MIBC and support dual FGFR1/MET targeting as a promising therapeutic strategy.

**中文摘要译文：**
肌肉浸润性膀胱癌（MIBC）是一种具有高复发率和低生存率的侵袭性恶性肿瘤，占膀胱癌相关死亡的大多数。一部分MIBC存在FGFR1扩增或过表达，这与增殖增加和预后不良相关。尽管泛FGFR抑制剂erdafitinib已显示出对FGFR3/FGFR2突变患者的临床益处（主要是在非MIBC中），但其疗效因耐药性和毒性而受限。此外，其在FGFR1驱动的MIBC中的效果尚不明确。为了填补这一空白，我们在FGFR1扩增的MIBC模型JMSU1细胞中研究了erdafitinib的应答和耐药机制。虽然erdafitinib最初抑制了肿瘤生长，但长期治疗导致了耐药性，表现为ERK、AKT和STAT1信号通路的持续激活。机制研究发现，由MET基因扩增驱动的MET激活是耐药性的关键驱动因素。值得注意的是，外源性肝细胞生长因子（HGF）不仅诱导了耐药性，还在药物压力下加速了MET扩增、HGF非依赖性亚群的产生。我们还发现SHP2是亲本细胞中FGFR1驱动ERK激活的关键中介因子。在耐药细胞中，MET激活通过适配蛋白GAB1增强了SHP2-ERK信号传导，从而强化了耐药表型。FGFR1和MET的联合抑制显著抑制了耐药细胞的肿瘤生长。这些发现确立了MET扩增和GAB1-SHP2信号传导作为FGFR1扩增MIBC中erdafitinib耐药的中心中介因子，并支持双重靶向FGFR1/MET作为一种有前景的治疗策略。

### 第二部分 AI 大师评价

本研究旨在探究FGFR1扩增的肌肉浸润性膀胱癌（MIBC）中对erdafitinib的耐药机制。通过使用JMSU1细胞模型，研究发现MET基因扩增及其下游信号通路的激活是导致耐药的关键因素。创新的发现包括外源性HGF加速耐药亚群的出现，以及GAB1-SHP2信号传导在耐药表型中的作用。这些结果为双重靶向FGFR1/MET的治疗策略提供了重要依据，具有显著的临床潜力。然而，研究尚未涉及体内模型的验证，可能影响结果的转化应用价值。

---

## 41. 基于人工智能生成的双功能PKMYT1靶向PROTAC的发现

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41315240](https://pubmed.ncbi.nlm.nih.gov/41315240)
**期刊：** Nature communications
**PMID：** 41315240
**DOI：** 10.1038/s41467-025-65796-8

### 第一部分 原文与翻译

**英文原标题：** Discovery of a bifunctional PKMYT1-targeting PROTAC empowered by AI-generation.

**英文摘要原文：**
PKMYT1 has recently emerged as a compelling therapeutic target for precision cancer therapy due to its synthetic lethality with oncogenic alterations such as CCNE1 amplification and mutations in FBXW7 and PPP2R1A. Current small molecule PKMYT1 inhibitors face limitations, such as insufficient molecular diversity and poor selectivity. We herein use our generative AI platform to develop a bifunctional PKMYT1 degrader by linking an entirely novel PKMYT1 inhibitor to an optimized cereblon (CRBN) binder. The lead PROTAC D16-M1P2 demonstrates dual mechanisms of PKMYT1 degradation and inhibition, with strong antiproliferative potency facilitated by high selectivity. It also exhibits favorable oral bioavailability, stronger pharmacodynamic effects relative to the PKMYT1 inhibitor alone, and robust antitumor response as a monotherapy in xenograft models. This PROTAC serves as a precise chemical probe to explore PKMYT1 biology and a promising lead for further cancer therapy exploration.

**中文摘要译文：**
PKMYT1最近因其与CCNE1扩增以及FBXW7和PPP2R1A突变等致癌改变存在合成致死性，成为精准癌症治疗的一个引人注目的靶点。目前的小分子PKMYT1抑制剂面临分子多样性不足和选择性差等限制。在此，我们利用生成式人工智能平台，通过将一种全新的PKMYT1抑制剂与优化的cereblon（CRBN）结合剂连接，开发了一种双功能PKMYT1降解剂。领先的PROTAC D16-M1P2展示了PKMYT1降解和抑制的双重机制，高选择性增强了其强大的抗增殖效力。它还表现出良好的口服生物利用度，相比单独的PKMYT1抑制剂具有更强的药效学效果，并且在异种移植模型中作为单一疗法展现出显著的抗肿瘤反应。该PROTAC可作为探索PKMYT1生物学的精确化学探针，也是进一步癌症治疗研究的有前途的先导化合物。

### 第二部分 AI 大师评价

本研究旨在通过人工智能技术开发一种新型双功能PKMYT1靶向PROTAC，以克服现有小分子抑制剂的局限性。研究团队利用生成式AI平台成功设计出D16-M1P2，该化合物不仅能降解PKMYT1，还具备抑制功能，在异种移植模型中展现出显著的抗肿瘤效果。这一研究成果不仅为PKMYT1生物学研究提供了精确工具，也为癌症治疗开辟了新途径。然而，其在临床中的应用仍需进一步验证。总体而言，该研究的创新性和潜在临床价值显著。

---

## 42. 肝内胆管癌中SVEP1低表达通过Jag2/Notch1/Hes5通路介导表型转换驱动的转移。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41315239](https://pubmed.ncbi.nlm.nih.gov/41315239)
**期刊：** Cell death & disease
**PMID：** 41315239
**DOI：** 10.1038/s41419-025-08170-2

### 第一部分 原文与翻译

**英文原标题：** Low SVEP1 in intrahepatic cholangiocarcinoma mediates phenotype switching-driven metastasis by Jag2/Notch1/Hes5.

**英文摘要原文：**
Intrahepatic cholangiocarcinoma (ICC) is a distinct and increasingly prevalent subtype of cholangiocarcinoma arising from the epithelial cells of the intrahepatic bile ducts. Its molecular diversity contributes to its highly aggressive nature and resistance to chemotherapy. SVEP1 (sushi, Von Willebrand factor type A, EGF, and pentaxin) is a multi-domain extracellular matrix (ECM) protein that is vital for embryogenesis, cell-cell adhesion, and the maintenance of epidermal differentiation. However, the specific effect of SVEP1 on the occurrence and progression of ICC remains poorly understood. Therefore, this study aims to examine the role of SVEP1 in ICC. We first identified SVEP1 using high-throughput RNA sequencing in two groups of patients with ICC with different disease-free survival rates. We further analyzed the expression pattern of SVEP1 in ICC using various public datasets and clinical tissue samples, exploring the correlation between SVEP1 depletion and ICC clinical prognosis. The regulatory role of SVEP1 depletion in ICC progression was studied using in vitro and in vivo experiments. We found that decreased SVEP1 expression positively correlates with early recurrence and shorter overall survival in ICC. Moreover, SVEP1 downregulation was correlated with multiple poor prognostic parameters, including positive lymph nodes, satellite nodes, and high Ki-67 expression. Downregulated SVEP1 expression promoted ICC cell proliferation, chemotactic migration, and invasion in vitro, as well as tumor growth and lung metastasis in vivo. These effects were mediated by EMT phenotype switching through the activation of the Jag2/Notch1/Hes5 pathway. Our findings enhance the understanding of the novel mechanisms driving ICC progression and metastasis, suggesting that SVEP1 is a potential biomarker for ICC diagnosis.

**中文摘要译文：**
肝内胆管癌（ICC）是一种起源于肝内胆管上皮细胞的独特且日益常见的胆管癌亚型。其分子多样性导致其具有高度侵袭性和化疗抵抗性。SVEP1（一种包含sushi结构域、von Willebrand因子A结构域、EGF结构域和pentaxin结构域的多功能胞外基质蛋白）在胚胎发生、细胞间粘附和表皮分化维持中至关重要。然而，SVEP1对ICC的发生和进展的具体影响尚不明确。因此，本研究旨在探讨SVEP1在ICC中的作用。我们首先通过高通量RNA测序在两组具有不同无病生存率的ICC患者中鉴定了SVEP1。进一步利用多种公共数据集和临床组织样本分析了SVEP1在ICC中的表达模式，探讨了SVEP1缺失与ICC临床预后的相关性。通过体外和体内实验研究了SVEP1缺失在ICC进展中的调控作用。我们发现，SVEP1表达降低与ICC的早期复发和较短的总生存期呈正相关。此外，SVEP1下调与多种不良预后参数相关，包括阳性淋巴结、卫星结节和高Ki-67表达。SVEP1表达下调促进了ICC细胞的体外增殖、趋化迁移和侵袭，以及体内肿瘤生长和肺转移。这些效应是通过激活Jag2/Notch1/Hes5通路介导的表型转换实现的。我们的研究增强了对驱动ICC进展和转移的新机制的理解，表明SVEP1可能是ICC诊断的潜在生物标志物。

### 第二部分 AI 大师评价

本研究旨在探讨SVEP1在肝内胆管癌（ICC）中的作用及其机制。通过高通量RNA测序、公共数据集分析和临床样本验证，研究发现SVEP1低表达与ICC的侵袭性和不良预后密切相关。关键的创新点在于揭示了SVEP1通过Jag2/Notch1/Hes5通路调控EMT表型转换，从而驱动ICC进展和转移的分子机制。这一发现不仅为ICC的诊断提供了潜在的生物标志物，也为开发靶向治疗策略提供了新思路。然而，研究在临床样本的多样性和通路的其他潜在调控环节方面可能存在局限性。

---

## 43. TRIM25通过泛素蛋白酶体途径降解BRD7蛋白稳定性以激活YB1/Bcl-2转录轴促进乳腺癌进展和紫杉醇耐药性。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41315221](https://pubmed.ncbi.nlm.nih.gov/41315221)
**期刊：** Cell death & disease
**PMID：** 41315221
**DOI：** 10.1038/s41419-025-08140-8

### 第一部分 原文与翻译

**英文原标题：** TRIM25 degrades BRD7 protein stability through the ubiquitin proteasome pathway to promote breast cancer progression and paclitaxel resistance by activating YB1/Bcl-2 transcription axis.

**英文摘要原文：**
Paclitaxel (PTX) is one of the most common chemotherapeutic drugs for treating breast cancer (BC), but resistance to PTX chemotherapy remains the major cause of treatment failure in BC patients. Our previous studies demonstrated that BRD7 participates in the paclitaxel-mediated chemotherapy sensitization and inhibits the malignant progression of breast cancer. Furthermore, TRIM25 was screened by IP-MS as a potential E3 ubiquitin ligase interacting with BRD7. Nevertheless, the functions and mechanisms of TRIM25 in the malignant progression of breast cancer and PTX resistance, as well as its regulatory relationship with BRD7, are still not clear. Our investigation revealed that TRIM25 effectively promoted cell proliferation, cell cycle progression, and paclitaxel chemoresistance of BC cells. Mechanistically, TRIM25 interacted with BRD7, and the PRYSPRY region of TRIM25 bond to the N-terminal region of BRD7. Additionally, TRIM25 decreased the protein stability of BRD7 through the ubiquitin proteasome pathway by increasing the K48-linked ubiquitination of BRD7 at the K119 site, and then activated the YB1/Bcl-2 signal axis, thus mediating malignant progression and PTX resistance of breast cancer. We further demonstrated that restoration of BRD7 rescued the inhibitory effect of TRIM25 knockdown on the malignant progression and PTX resistance of BC cells. Furthermore, high expression of TRIM25 was found in clinical breast cancer tissues compared to noncancerous breast tissues, which was positively associated with poor prognosis in BC patients. The expression of TRIM25 was negatively correlated with BRD7 expression, and the combined expression of TRIM25 and BRD7 might be a potential molecular marker for the prediction of malignant progression and prognosis of breast cancer. Our findings demonstrate that targeting the TRIM25/BRD7/YB1/Bcl-2 signal axis might be a potential therapeutic strategy for the treatment of breast cancer.

**中文摘要译文：**
紫杉醇（PTX）是治疗乳腺癌（BC）最常用的化疗药物之一，但对PTX化疗的耐药性仍是BC患者治疗失败的主要原因。我们既往的研究表明，BRD7参与了紫杉醇介导的化疗增敏过程，并抑制乳腺癌的恶性进展。此外，通过IP-MS筛选发现TRIM25是与BRD7相互作用的潜在E3泛素连接酶。然而，TRIM25在乳腺癌恶性进展和紫杉醇耐药性中的功能及机制，以及其与BRD7的调控关系仍不明确。我们的研究表明，TRIM25有效促进了BC细胞的增殖、细胞周期进展及紫杉醇耐药性。从机制上讲，TRIM25与BRD7相互作用，TRIM25的PRYSPRY区域结合至BRD7的N端区域。此外，TRIM25通过增加BRD7在K119位点的K48连接泛素化，进而通过泛素蛋白酶体途径降低BRD7的蛋白稳定性，从而激活YB1/Bcl-2信号轴，介导乳腺癌的恶性进展和紫杉醇耐药性。我们进一步证明，恢复BRD7的表达可挽救TRIM25敲低对BC细胞恶性进展和紫杉醇耐药性的抑制作用。此外，与非癌性乳腺组织相比，临床上乳腺癌组织中TRIM25的高表达与BC患者不良预后呈正相关。TRIM25的表达与BRD7的表达呈负相关，TRIM25与BRD7的联合表达可能是预测乳腺癌恶性进展和预后的潜在分子标志物。我们的研究结果表明，靶向TRIM25/BRD7/YB1/Bcl-2信号轴可能是治疗乳腺癌的一种潜在治疗策略。

### 第二部分 AI 大师评价

本研究核心目的是揭示TRIM25通过泛素蛋白酶体途径降解BRD7蛋白，进而激活YB1/Bcl-2转录轴，促进乳腺癌进展和紫杉醇耐药性的机制。研究方法结合了IP-MS筛选、分子相互作用分析和临床数据验证。关键发现包括TRIM25与BRD7的调控关系及其在乳腺癌恶性进展中的作用，研究创新性地提出了TRIM25/BRD7/YB1/Bcl-2信号轴作为潜在治疗靶点。临床价值显著，为克服紫杉醇耐药性提供了新思路，但进一步验证其在其他癌症类型中的普适性是未来的研究方向。

---

## 44. AMPK磷酸化WIP1促进癌细胞中的DNA修复和放射抗性。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41315219](https://pubmed.ncbi.nlm.nih.gov/41315219)
**期刊：** Cell death & disease
**PMID：** 41315219
**DOI：** 10.1038/s41419-025-08141-7

### 第一部分 原文与翻译

**英文原标题：** AMPK phosphorylates WIP1 to promote DNA repair and radioresistance in cancer cells.

**英文摘要原文：**
Cell metabolism has a profound impact on maintaining genomic stability. AMP-activated protein kinase (AMPK) is a crucial regulator of cell metabolism and the maintenance of genomic stability. There is increasing evidence that AMPK plays a crucial role in the efficient response to DNA damage (DDR). However, the underlying mechanism is still unclear. Here, we show that glucose deprivation rapidly reduces γH2AX levels, a hallmark of DNA damage. We then found that WIP1, rather than PP2A or PP4C, is the primary phosphatase responsible for dephosphorylating γH2AX under both normal and damaged conditions. Molecular studies have revealed that AMPK directly binds and phosphorylates WIP1 at Thr25 (T25). This action enhances protein stability and the binding ability of WIP1 with γH2AX, likely promoting the enzyme activity of WIP1 and subsequently reducing the level of γH2AX. These processes facilitate DNA damage repair and contribute to the radioresistance of tumor cells. The findings provide experimental evidence of a novel link between metabolic stress and DDR, suggesting that AMPK may promote the resistance of tumor cells to radiation therapy by phosphorylating WIP1.

**中文摘要译文：**
细胞代谢对维持基因组稳定性具有深远影响。AMP激活蛋白激酶（AMPK）是细胞代谢和基因组稳定性维持的关键调节因子。越来越多的证据表明，AMPK在高效应对DNA损伤（DDR）中起着关键作用。然而，其潜在机制尚不明确。本研究中，我们发现葡萄糖剥夺迅速降低了γH2AX水平（DNA损伤的标志物）。随后，我们发现无论是正常还是损伤条件下，WIP1（而非PP2A或PP4C）是负责γH2AX去磷酸化的主要磷酸酶。分子研究表明，AMPK直接结合并磷酸化WIP1的Thr25（T25）。这一作用增强了WIP1的蛋白质稳定性及其与γH2AX的结合能力，可能促进了WIP1的酶活性，进而降低了γH2AX的水平。这些过程促进了DNA损伤修复，并有助于肿瘤细胞的放射抗性。这些发现为代谢应激与DDR之间的新型联系提供了实验证据，表明AMPK可能通过磷酸化WIP1促进肿瘤细胞对放射治疗的抗性。

### 第二部分 AI 大师评价

本研究旨在揭示AMPK通过磷酸化WIP1促进DNA修复和肿瘤细胞放射抗性的机制。研究者采用分子生物学手段发现，AMPK直接磷酸化WIP1并增强其活性，从而降低γH2AX水平。这一发现不仅揭示了代谢应激与DNA损伤修复的新联系，还为肿瘤放射治疗的耐药性提供了潜在靶点。研究创新性地将代谢调控与DNA修复联系起来，具有重要的临床和科研价值，但其具体机制仍需进一步验证。

---

## 45. 干细胞中染色质可及性揭示骨髓增生异常综合征的渐进性转录改变

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41315211](https://pubmed.ncbi.nlm.nih.gov/41315211)
**期刊：** Nature communications
**PMID：** 41315211
**DOI：** 10.1038/s41467-025-65753-5

### 第一部分 原文与翻译

**英文原标题：** Chromatin accessibility in stem cells unveils progressive transcriptional alterations in myelodysplastic syndrome.

**英文摘要原文：**
Myelodysplastic syndrome (MDS) originates from hematopoietic stem cell (HSC) clones with acquired gene mutations. However, the molecular characteristics of MDS stem cells remain poorly understood. Here, we show that the chromatin accessibility profiles of MDS stem cells more accurately reflect disease status than those of progenitor cells and reveal the process of stem cell alterations during disease progression. Characterization of differentially accessible regions (DARs) shows that MDS stem cells acquire progenitor-like chromatin accessibility during disease progression, leading to disruption of the normal stem-progenitor hierarchy. Profiling of transcription factor-binding motifs at DARs further uncovers precocious activation of myeloid transcriptional networks in MDS stem cells, with a concurrent loss of HSC-associated regulatory programs. In particular, increased chromatin accessibility at CEBP target sites represents the myeloid reprogramming status of MDS stem cells. Newly developed "progenitor scores" based on chromatin accessibility stratify disease status and correlate well with prognosis. These findings indicate that chromatin landscapes of MDS stem cells define their cell-autonomous behavior and contribute to disease progression.

**中文摘要译文：**
骨髓增生异常综合征（MDS）起源于具有获得性基因突变的造血干细胞（HSC）克隆。然而，MDS干细胞的分子特征仍知之甚少。本文中，我们发现MDS干细胞的染色质可及性图谱比祖细胞更能准确反映疾病状态，并揭示了疾病进展过程中干细胞的改变过程。差异可及区域（DARs）的特征分析表明，MDS干细胞在疾病进展中获得类似祖细胞的染色质可及性，从而导致正常的干细胞-祖细胞层次结构被破坏。DARs中转录因子结合基序的谱图进一步揭示了MDS干细胞中髓系转录网络的早熟激活，同时伴随着HSC相关调节程序的丢失。特别是，CEBP靶位点染色质可及性的增加代表了MDS干细胞的髓系重编程状态。新开发的基于染色质可及性的"祖细胞评分"可分层疾病状态并与预后良好相关。这些发现表明，MDS干细胞的染色质景观定义了其细胞自主行为并促进疾病进展。

### 第二部分 AI 大师评价

本研究通过分析MDS干细胞的染色质可及性图谱，揭示了其在疾病进展中的转录改变和分子特征，填补了对MDS干细胞分子机制的认知空白。研究创新性地使用"祖细胞评分"分层疾病状态，为MDS的预后提供了新的生物标志物。然而，研究仍需进一步验证这些发现在临床中的应用价值。

---

## 46. 一种依赖于微环境的氧化还原调节机制调控上皮干细胞命运。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41315209](https://pubmed.ncbi.nlm.nih.gov/41315209)
**期刊：** Nature communications
**PMID：** 41315209
**DOI：** 10.1038/s41467-025-66636-5

### 第一部分 原文与翻译

**英文原标题：** A niche-dependent redox rheostat regulates epithelial stem cell fate.

**英文摘要原文：**
Intestinal stem cells (ISCs) reside in regionally variable niches that provide diverse microenvironmental cues such as tissue oxygen status, and morphogen signaling. Integration of these cues with ISC metabolism and fate remains poorly understood. Here, we show that cellular redox balance orchestrates niche factors with metabolic state to govern cell fate decisions. We demonstrate that hypoxia and Wnt signaling synergistically restrict the reactive oxygen species generating enzyme NADPH oxidase 1 (NOX1) regionally to the crypt base in the distal colon. NOX1 enables maintenance of an oxidative cell state that licenses cell cycle entry, altering the balance of asymmetric ISC self-renewal and lineage commitment. Mechanistically, cell redox state directs a self-reinforcing circuit that connects hypoxia inducible factor 1α-dependent signaling with post-translational regulation of the metabolic enzyme isocitrate dehydrogenase 1. Our studies show redox balance acts as a cellular rheostat that is central and causative for metabolic control of the ISC cell-cycle.

**中文摘要译文：**
肠道干细胞（ISCs）驻留在区域变异的微环境中，该微环境提供了多样化的微环境信号，如组织氧状态和形态发生信号。这些信号与ISCs的代谢和命运的整合仍知之甚少。在此，我们表明细胞氧化还原平衡协同微环境因子与代谢状态调控细胞命运决策。我们证明低氧和Wnt信号协同限制活性氧生成酶NADPH氧化酶1（NOX1）在远端结肠隐窝基部的区域性表达。NOX1能够维持一种氧化细胞状态，允许细胞周期进入，改变不对称ISCs自我更新和谱系承诺的平衡。机制上，细胞氧化还原状态指导一个自我增强的电路，该电路连接低氧诱导因子1α依赖性信号与代谢酶异柠檬酸脱氢酶1的翻译后调控。我们的研究表明氧化还原平衡作为一种细胞调节器，是代谢控制ISCs细胞周期的核心和成因。

### 第二部分 AI 大师评价

本研究揭示了细胞氧化还原平衡作为调控上皮干细胞命运的关键‘调节器’，通过整合低氧与Wnt信号通路，区域性限制NOX1的表达，从而影响细胞周期和自我更新与分化的平衡。其创新性在于阐明了氧化还原状态如何通过代谢酶IDH1的翻译后调控形成正反馈回路。这一发现不仅深化了对干细胞微环境调控的理解，也为靶向代谢干预提供了潜在策略。然而，研究的局限性在于未完全揭示NOX1在不同肠道区域的差异性作用机制，未来研究需进一步验证其在临床转化中的可行性。

---

## 47. 应用teclistamab治疗多发性骨髓瘤中髓外和旁骨骼浆细胞瘤对治疗效果的影响：美国骨髓瘤免疫治疗联盟真实世界经验

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41315206](https://pubmed.ncbi.nlm.nih.gov/41315206)
**期刊：** Blood cancer journal
**PMID：** 41315206
**DOI：** 10.1038/s41408-025-01414-6

### 第一部分 原文与翻译

**英文原标题：** The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience.

**英文摘要原文：**
Teclistamab, a bispecific antibody targeting B-cell maturation antigen (BCMA), is effective in relapsed or refractory multiple myeloma (RRMM), but its impact on patients with soft tissue plasmacytomas is unclear. We studied 385 RRMM patients treated with teclistamab at 13 U.S. centers through September 2023, with follow-up to April 2024. Soft tissue plasmacytomas were classified as true extramedullary disease (EMD; not contiguous with bone) or paraskeletal plasmacytomas (PSK; contiguous with bone). Patients with the simultaneous presence of both were classified as true-EMD, reflecting its adverse prognosis. Of those, 109 (28%) had true EMD, 33 (9%) had PSK, and 243 (63%) had no soft tissue plasmacytoma (No-STP). Median follow-up was 9.9 months. Overall response rates were 38% in true-EMD, 54.1% in PSK, and 62.4% in No-STP (p < 0.001). Median progression-free survival (PFS) was 1.4 months in true-EMD, 6.51 months in PSK, and 8.95 months in No-STP (p < 0.0001). Median overall survival (OS) was 9.54 months for true EMD, 13.1 months for PSK, and not reached in No-STP (p = 0.00012). In multivariable analysis, true-EMD was independently associated with inferior PFS and OS, while PSK showed numerically lower outcomes. These findings highlight the need for tailored strategies in patients with soft tissue plasmacytomas, particularly those with true-EMD.

**中文摘要译文：**
Teclistamab是一种靶向B细胞成熟抗原（BCMA）的双特异性抗体，对复发性或难治性多发性骨髓瘤（RRMM）有效，但其对软组织浆细胞瘤患者的影响尚不明确。我们研究了2023年9月前在美国13个中心接受teclistamab治疗的385例RRMM患者，随访至2024年4月。软组织浆细胞瘤分为真正的髓外疾病（EMD；不与骨相邻）和旁骨骼浆细胞瘤（PSK；与骨相邻）。同时存在两者的患者被归类为真正的EMD，以反映其不良预后。其中，109例（28%）为真正的EMD，33例（9%）为PSK，243例（63%）无软组织浆细胞瘤（No-STP）。中位随访时间为9.9个月。总体反应率为真正的EMD组38%，PSK组54.1%，No-STP组62.4%（p < 0.001）。中位无进展生存期（PFS）在真正的EMD组为1.4个月，PSK组为6.51个月，No-STP组为8.95个月（p < 0.0001）。中位总生存期（OS）在真正的EMD组为9.54个月，PSK组为13.1个月，No-STP组未达到（p = 0.00012）。在多变量分析中，真正的EMD与较差的PFS和OS独立相关，而PSK组的数值结果较低。这些发现强调了对软组织浆细胞瘤患者，尤其是真正的EMD患者，制定个体化策略的必要性。

### 第二部分 AI 大师评价

本研究旨在探讨teclistamab治疗多发性骨髓瘤时，髓外和旁骨骼浆细胞瘤对治疗效果的影响。研究采用真实世界数据分析方法，纳入385例患者，结果表明，真正的EMD患者预后最差，PSK次之，而无软组织浆细胞瘤的患者反应最佳。此研究的创新性在于揭示了软组织浆细胞瘤的分类对teclistamab疗效的显著影响，为临床治疗策略的优化提供了重要依据。然而，研究的局限性在于其样本量和随访时间较短，未来需进一步验证。

---

## 48. ACBP/DBI中和用于恶性和非恶性肝脏疾病的预防与治疗

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41315195](https://pubmed.ncbi.nlm.nih.gov/41315195)
**期刊：** Cell death & disease
**PMID：** 41315195
**DOI：** 10.1038/s41419-025-08148-0

### 第一部分 原文与翻译

**英文原标题：** ACBP/DBI neutralization for the prevention and treatment of malignant and non-malignant liver diseases.

**英文摘要原文：**
Acyl coenzyme A binding protein (ACBP), also known as diazepam binding inhibitor (DBI), suppresses autophagy, stimulates food intake, and regulates body composition. This tissue hormone contributes to the development of age-related diseases such as metabolic syndrome, cardiovascular disease, cancer, and osteoarthritis. ACBP/DBI also plays a key pathogenic role in liver disorders, including hepatocellular carcinoma (HCC). Circulating levels of ACBP/DBI are elevated in patients with histologically diagnosed steatosis, liver fibrosis or HCC, and correlate with disease severity. Moreover, the incidence of liver cancers increases in individuals receiving benzodiazepines, which act on the same binding sites of the GABA-A receptor as ACBP/DBI. In mice, inhibiting ACBP/DBI, via inducible knockout, mutation of its receptor (the γ2 subunit of the GABA-A receptor) or antibody-mediated neutralization, alleviates various liver conditions, including ischemia-reperfusion injury, bile duct obstruction, hepatotoxicity of acetaminophen, CCl, ethanol, or concanavalin A, metabolic dysfunction-associated fatty liver disease, and HCC. Importantly, the anti-tumor effects of ACBP/DBI neutralization are not solely due to its hepatoprotective properties, as they persist in mouse models of HCC driven by oncogenes (e.g., β-catenin and MYC) or orthotopic injection of syngeneic liver cancer cells into immunocompetent hosts. Notably, hepatocellular carcinoma (HCC) is one of the few cancers in which elevated local ACBP/DBI expression is associated with poor clinical prognosis. In sum, ACBP/DBI functions as both a biomarker and a potential therapeutic target for malignant and non-malignant liver diseases.

**中文摘要译文：**
酰基辅酶A结合蛋白（ACBP），也称为地西泮结合抑制剂（DBI），能够抑制自噬、刺激食物摄入并调节体成分。这种组织激素促进诸如代谢综合征、心血管疾病、癌症和骨关节炎等年龄相关疾病的发展。ACBP/DBI还在肝脏疾病（包括肝细胞癌（HCC））中发挥关键致病作用。在组织学诊断的脂肪变性、肝纤维化或HCC患者中，循环ACBP/DBI水平升高，并与疾病严重程度相关。此外，接受苯二氮卓类药物的个体肝癌症发病率增加，这些药物作用于GABA-A受体的相同结合位点，与ACBP/DBI相同。在小鼠中，通过诱导性敲除、其受体（GABA-A受体的γ2亚基）突变或抗体介导的中和作用抑制ACBP/DBI，可缓解多种肝脏疾病，包括缺血再灌注损伤、胆管梗阻、对乙酰氨基酚、CCl、乙醇或伴刀豆球蛋白A的肝毒性、代谢功能障碍相关性脂肪肝疾病和HCC。重要的是，ACBP/DBI中和的抗肿瘤作用不仅归因于其保肝特性，因为它们在接受由癌基因（如β-连环蛋白和MYC）驱动或同源肝癌细胞原位注射到免疫活性宿主的HCC小鼠模型中持续存在。值得注意的是，肝细胞癌（HCC）是少数几种局部ACBP/DBI表达升高与临床预后不良相关的癌症之一。总之，ACBP/DBI既是恶性和非恶性肝脏疾病的生物标志物，也是潜在的 therapeutic target。

### 第二部分 AI 大师评价

本研究探讨了ACBP/DBI中和在恶性和非恶性肝脏疾病中的预防和治疗潜力。通过动物模型实验，研究者揭示了ACBP/DBI在多种肝脏病理过程中的关键作用，并展示了抗体中和、受体突变等方法在缓解肝脏疾病中的有效性。研究发现ACBP/DBI不仅是疾病严重程度的生物标志物，还具有作为治疗靶点的潜力，特别是在肝细胞癌中的应用。研究的创新性在于明确了ACBP/DBI的多重功能及其临床相关性，为肝脏疾病的治疗提供了新思路。然而，研究主要基于小鼠模型，未来需进一步验证其在人类中的疗效和安全性。

---

## 49. 解析子宫内膜癌对标准和靶向治疗的复杂性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41315187](https://pubmed.ncbi.nlm.nih.gov/41315187)
**期刊：** Cell death & disease
**PMID：** 41315187
**DOI：** 10.1038/s41419-025-08051-8

### 第一部分 原文与翻译

**英文原标题：** Dissecting endometrial cancer complexity in response to standard and targeted therapies.

**英文摘要原文：**
Endometrial cancer (EC) is one of the most common gynecologic malignancies amongst women worldwide. Its incidence and mortality rates have been increasing in the last decade. In the present work, we built a patient EC-derived organoid (PDOs) platform that faithfully recapitulated tumor phenotype, genomic alterations, and expression profiles of matched-primary cancer tissues. Interestingly, we found that the response of EC-derived PDOs to both standard therapy and a wide range of targeted drugs accordingly to their specific druggable genetic alterations was congruent with that of the originating patients. We also isolated and genomically characterized matched-PDO stromal cells, specifically cancer-associated fibroblasts (CAFs). Unlike PDOs matched CAFs were poorly responsive and underwent to pro-inflammatory senescence upon treatment with standard therapy. Collectively, our findings established a EC-PDOs preclinical platform which allows assessing the therapeutic response of tumor and surrounding tumor microenvironment cellular landscape.

**中文摘要译文：**
子宫内膜癌（EC）是全球女性中最常见的妇科恶性肿瘤之一。在过去十年中，其发病率和死亡率持续上升。本研究构建了一个源自患者EC的类器官（PDOs）平台，该平台忠实地重现了匹配原发癌组织的肿瘤表型、基因组改变和表达谱。有趣的是，我们发现EC来源的PDOs对标准治疗和针对特定可药化基因改变的靶向药物的反应与原发患者一致。此外，我们还分离并基因组学特征化了匹配PDOs的间质细胞，特别是癌症相关成纤维细胞（CAFs）。与PDOs不同，匹配的CAFs对治疗反应较差，并在标准治疗下出现促炎性衰老。总的来说，我们的研究建立了一个EC-PDOs临床前平台，可用于评估肿瘤及其周围肿瘤微环境细胞景观的治疗反应。

### 第二部分 AI 大师评价

本研究通过构建患者EC来源的PDOs平台，创新性地模拟了子宫内膜癌的肿瘤特性及治疗反应。该平台不仅能评估标准治疗的疗效，还能针对特定基因改变筛选靶向药物，为个性化治疗提供了有力工具。此外，对CAFs的研究揭示了肿瘤微环境在治疗反应中的复杂性。该研究的局限性在于仍需进一步验证其临床应用潜力，但其方法和发现对推动EC的精准治疗具有重要意义。

---

## 50. 组织蛋白酶L作为双靶点：缓解肌肉萎缩同时增强抗PD-L1的抗肿瘤疗效

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41315185](https://pubmed.ncbi.nlm.nih.gov/41315185)
**期刊：** Nature communications
**PMID：** 41315185
**DOI：** 10.1038/s41467-025-64500-0

### 第一部分 原文与翻译

**英文原标题：** Cathepsin L as a dual-target to mitigate muscle wasting while enhancing anti-tumor efficacy of anti-PD-L1.

**英文摘要原文：**
Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy; however, their use is frequently associated with immune-related adverse events (irAEs). In this study, anti-PD-L1 therapy exacerbates muscle wasting in tumor-bearing male mice despite its anti-tumor efficacy, accompanied by an accumulation of CD8 T cells in muscle. Single-cell RNA sequencing identifies these cells as tissue-resident memory-like CD49a CD8 T cells. While CD8 T cell depletion prevents muscle wasting, it compromises the anti-tumor efficacy of anti-PD-L1. To resolve this paradox, we identify cathepsin L (CTSL) as a dual-target capable of suppressing both tumor progression and CD8 T cell-mediated muscle wasting, through integrative transcriptomic analysis. Pharmacological inhibition of CTSL not only mitigates anti-PD-L1-induced muscle wasting but also further suppresses tumor growth, potentially via downregulation of BNIP3. Here, we show that CTSL is a dual-action target to uncouple anti-tumor efficacy from muscle-specific irAEs, offering a strategy to improve clinical outcomes of ICIs.

**中文摘要译文：**
免疫检查点抑制剂（ICIs）彻底改变了癌症治疗；然而，其使用常伴随免疫相关不良事件（irAEs）。本研究中，抗PD-L1疗法尽管具有抗肿瘤疗效，却加剧了荷瘤雄性小鼠的肌肉萎缩，同时伴随肌肉中CD8 T细胞的积累。单细胞RNA测序将这些细胞鉴定为组织驻留记忆样CD49a CD8 T细胞。虽然CD8 T细胞耗竭可防止肌肉萎缩，但这会削弱抗PD-L1的抗肿瘤疗效。为解决这一矛盾，我们通过整合转录组分析，发现组织蛋白酶L（CTSL）作为一种双靶点，能够同时抑制肿瘤进展和CD8 T细胞介导的肌肉萎缩。CTSL的药理学抑制不仅减轻了抗PD-L1诱导的肌肉萎缩，还可能通过下调BNIP3进一步抑制肿瘤生长。本研究证明了CTSL是一种双效靶点，可将抗肿瘤疗效与肌肉特异性irAEs解耦，为提高ICI的临床疗效提供了策略。

### 第二部分 AI 大师评价

本研究旨在解决免疫检查点抑制剂（ICIs）治疗中抗PD-L1疗法导致的肌肉萎缩问题，同时不影响其抗肿瘤疗效。通过单细胞RNA测序和整合转录组分析，研究者发现组织蛋白酶L（CTSL）可同时抑制肿瘤进展和CD8 T细胞介导的肌肉萎缩，揭示了CTSL的双重作用机制。研究的创新性在于发现了CTSL这一潜在的治疗靶点，为解决ICIs的副作用提供了新策略。然而，研究目前仅在小鼠模型中进行，其临床转化效果仍需进一步验证。此项成果为优化癌症免疫治疗提供了重要参考，具有显著的临床和科研价值。

---

## 51. 靶向RNA聚合酶I以增强自然杀伤细胞在多发性骨髓瘤中的抗癌活性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41315184](https://pubmed.ncbi.nlm.nih.gov/41315184)
**期刊：** Cell death & disease
**PMID：** 41315184
**DOI：** 10.1038/s41419-025-08196-6

### 第一部分 原文与翻译

**英文原标题：** Targeting RNA polymerase I to boost natural killer cell anticancer activity in multiple myeloma.

**英文摘要原文：**
Multiple myeloma (MM) remains an incurable disease despite therapeutic advancements extending survival. Relapses driven by drug resistance and minimal residual disease underscore the need for novel treatment strategies. Natural Killer (NK) cells play a key role in MM immunity, yet their function is suppressed by inhibitory cytokines and metabolites from the tumor microenvironment. Developing anticancer drugs with immunomodulatory properties, such as enhancing tumor sensitivity to NK cell recognition, remains a critical challenge. MM cells exhibit high protein synthesis rates, making them vulnerable to proteostasis disruption. Dysregulated ribosome function and aberrant mRNA translation contribute to proteasome inhibitor resistance. RNA Polymerase I (RNA Pol I)-mediated rDNA transcription, the rate-limiting step in ribosome biogenesis (RiBi), is significantly upregulated in MM. Targeting rDNA transcription and inducing nucleolar stress response (NSR) presents a promising therapeutic approach, though its immunomodulatory role is not well understood. Our study examined two "first-in-class" RNA Pol I inhibitors, CX-5461 and BMH-21, which differentially regulate NK cell-activating and inhibitory ligand expression in MM. BMH-21 enhanced NK cell degranulation and increased IFN-γ and TNF-α secretion, demonstrating stronger immunostimulatory effects than CX-5461. Conversely, CX-5461 induced a significant DNA damage response (DDR) and senescence, leading to HLA-E upregulation and suppressing NK cell activity. Mechanistic analyses revealed that HLA-E presentation is governed by ATR/AKT/mTORC1/S6K signaling and Pioneer Round of Translation (PRT), linking its regulation to DDR. This effect was modulated by Lenalidomide and Panobinostat. Moreover, RNA Pol I inhibition enhanced Daratumumab-mediated antibody-dependent cellular cytotoxicity (ADCC) of NK cells against MM, uncovering novel immuno-mediated antitumor mechanisms.

**中文摘要译文：**
尽管治疗进展延长了生存期，多发性骨髓瘤（MM）仍是一种无法治愈的疾病。耐药性和微小残留病灶驱动的复发凸显了对新型治疗策略的需求。自然杀伤（NK）细胞在MM免疫中起关键作用，但其功能被肿瘤微环境中的抑制性细胞因子和代谢物所抑制。开发具有免疫调节特性的抗癌药物（如增强肿瘤对NK细胞识别的敏感性）仍然是一个关键挑战。MM细胞表现出高蛋白质合成率，使其易受蛋白质稳态破坏的影响。核糖体功能失调和异常mRNA翻译导致了蛋白酶体抑制剂的耐药性。RNA聚合酶I（RNA Pol I）介导的rDNA转录是核糖体生物合成（RiBi）的限速步骤，在MM中显著上调。靶向rDNA转录并诱导核仁应激反应（NSR）是一种有前景的治疗方法，但其免疫调节作用尚不明确。本研究考察了两种“首创”RNA Pol I抑制剂CX-5461和BMH-21，它们差异性地调节MM中NK细胞激活性和抑制性配体的表达。BMH-21增强了NK细胞的脱颗粒作用并增加了IFN-γ和TNF-α的分泌，显示出比CX-5461更强的免疫刺激作用。相反，CX-5461诱导了显著的DNA损伤反应（DDR）和衰老，导致HLA-E上调并抑制NK细胞活性。机制分析表明，HLA-E的表达受ATR/AKT/mTORC1/S6K信号通路和翻译先驱轮（PRT）调控，将其调控与DDR联系起来。这一效应被来那度胺和帕比司他所调节。此外，RNA Pol I抑制增强了Daratumumab介导的NK细胞对MM的抗体依赖性细胞毒性（ADCC），揭示了新的免疫介导的抗肿瘤机制。

### 第二部分 AI 大师评价

本研究旨在探索RNA聚合酶I抑制剂在多发性骨髓瘤中对自然杀伤细胞抗癌活性的调控作用。通过评估两种新型抑制剂CX-5461和BMH-21的差异性效果，研究发现BMH-21能够显著增强NK细胞的免疫刺激作用，而CX-5461则通过诱导DNA损伤反应抑制NK细胞活性。研究的创新性在于揭示了RNA Pol I抑制剂的免疫调节机制及其与DNA损伤通路的关联，为多发性骨髓瘤的免疫治疗提供了新思路。但其局限性在于对RNA Pol I抑制剂在其他肿瘤类型中的适用性仍需进一步验证。

---

## 52. TRIM63/IRF-8轴促进BRAF突变黑色素瘤的肿瘤进展和免疫抑制。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41315179](https://pubmed.ncbi.nlm.nih.gov/41315179)
**期刊：** Cell death & disease
**PMID：** 41315179
**DOI：** 10.1038/s41419-025-08216-5

### 第一部分 原文与翻译

**英文原标题：** TRIM63/IRF-8 axis promotes tumor progression and immunosuppression of melanoma with BRAF mutation.

**英文摘要原文：**
The E3 ligase TRIM63 demonstrates a robust correlation with melanoma malignancy, particularly in cases involving BRAF mutants. Meanwhile, BRAF mutants, such as V600E, represent a prominent mutation observed in melanoma patients, yet the underlying mechanism remains elusive. In this study, we demonstrate that TRIM63 exhibits overexpression in melanoma cells and exerts its full oncogenic potential upon activation of the MAPK signaling pathway. Mechanistically, BRAF mutation induces ERK1/2-mediated phosphorylation of TRIM63 at serine 69 (S69). TRIM63 S69 is localized in the RING domain, and its phosphorylation enhances TRIM63 binding with IRF-8. Subsequently, TRIM63 leads to the ubiquitination of IRF-8 at lysine 250 (K250). The degradation of IRF-8 ultimately contributes to tumor progression enhancement. Clinically, the presence of pS69 on TRIM63 is associated with tumor immunosuppression and poor prognosis among melanoma patients, highlighting its potential as a promising therapeutic target.

**中文摘要译文：**
E3连接酶TRIM63与黑色素瘤恶性程度呈显著相关性，尤其是在涉及BRAF突变的情况下。同时，BRAF突变（如V600E）是黑色素瘤患者中常见的突变，但其潜在机制尚不明确。本研究显示，TRIM63在黑色素瘤细胞中过度表达，并在MAPK信号通路激活后充分发挥其致癌潜能。机制上，BRAF突变诱导ERK1/2介导的TRIM63丝氨酸69（S69）磷酸化。TRIM63的S69位点位于RING结构域，其磷酸化增强了TRIM63与IRF-8的结合。随后，TRIM63导致IRF-8在赖氨酸250（K250）处的泛素化。IRF-8的降解最终促进肿瘤进展。临床上，TRIM63上的pS69与黑色素瘤患者的肿瘤免疫抑制和不良预后相关，凸显了其作为潜在治疗靶点的价值。

### 第二部分 AI 大师评价

本研究揭示了TRIM63/IRF-8轴在BRAF突变黑色素瘤中的重要作用，特别是通过MAPK信号通路激活TRIM63的致癌功能。研究者发现BRAF突变通过ERK1/2介导TRIM63磷酸化，进而促进IRF-8的泛素化和降解，从而推动肿瘤进展。这一机制不仅阐明了TRIM63在肿瘤免疫抑制中的作用，还为临床治疗提供了新的靶点。研究的创新性在于明确了TRIM63磷酸化的具体功能及其与IRF-8的相互作用，但其临床应用仍需进一步验证。

---

## 53. 抗PD-(L)1随机对照试验后的二次事件终点（EFS2、PRFS2和PFS2）：一项系统综述和荟萃分析

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41314984](https://pubmed.ncbi.nlm.nih.gov/41314984)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41314984
**DOI：** 10.1136/jitc-2025-013072

### 第一部分 原文与翻译

**英文原标题：** Second-event endpoints (EFS2, PRFS2 and PFS2) after anti-PD-(L)1-based RCTs: a systematic review and meta-analysis.

**英文摘要原文：**
BACKGROUND: Immune checkpoint inhibitors (ICIs), particularly anti-PD-(L)1s, have transformed cancer care by their extended efficacy, even receiving next-line. Event-free survival 2 (EFS2), progression/recurrence-free survival 2 (PRFS2) and progression-free survival 2 (PFS2) capture the time from randomization to objective recurrence/progression or death on the first subsequent therapy, potentially offering a more accurate measure of durable benefit than first-event endpoints. Our aim is to review the magnitude of this benefit and evaluate long-term endpoints as surrogates for overall survival (OS) in immunotherapy for solid malignancies.

METHODS: A Preferred Reporting Items for Systematic Reviews and Meta-Analyses-compliant systematic review and meta-analysis searched Web of Science, National Institutes of Health Clinical Trials Registry, American Society of Clinical Oncology and European Society of Medical Oncology conference databases from inception until June 12, 2025, for anti-PD-(L)1-based randomized controlled phase II/III clinical trials (RCTs) in patients with solid malignancies that reported EFS2, PRFS2 or PFS2. HRs comparing ICI and non-ICI arms were pooled using a random-effects meta-analytic approach. Sensitivity analyses and meta-regressions assessed effect modifiers. A linear regression compared EFS2/PRFS2/PFS2 and EFS/disease-free survival (DFS)/PFS versus OS HRs.

RESULTS: 47 RCTs met inclusion criteria from 2,078 citations, comprising 58 intervention comparisons (ICs) and 34,973 patients. Non-small cell lung cancer (NSCLC) was the most investigated tumor (17 RCTs). Anti-PD-(L)1s performed generally worse when administered as a subsequent therapy in non-ICI-experienced patients (p<0.05). Early anti-PD-(L)1 use was associated with significantly improved EFS2/PRFS2/PFS2 (HR 0.72; 95% CI 0.68 to 0.76), with consistent findings across curative and recurrent/metastatic settings, and particularly strong effects in RCTs involving patients with deficient mismatch repair or high microsatellite instability tumors and those with more radiological responses. In 54 ICs reporting both OS and EFS2/PRFS2/PFS2 HRs, a strong correlation (R²=0.74) was observed across all RCTs, and an even stronger 0.86 specifically among patients with NSCLC (22 ICs). Conversely, EFS/DFS/PFS presented R² 0.39 across all RCTs (51 ICs), and 0.65 in NSCLC (21 ICs; p<0.01).

CONCLUSIONS: Early use of anti-PD-(L)1 therapy is associated with prolonged disease control and may be linked to enhanced responsiveness to subsequent therapies, mostly based on NSCLC data. Additionally, EFS2/PRFS2/PFS2 are solid candidate surrogates for OS and could be considered for routine inclusion and prespecified into immunotherapy RCTs to better capture long-term benefit and inform regulatory, clinical, and reimbursement decision-making.

PROSPERO REGISTRATION NUMBER: CRD42024585378.

**中文摘要译文：**
背景：免疫检查点抑制剂（ICIs），尤其是抗PD-(L)1药物，因其持久的疗效甚至可用于后续治疗，已改变了癌症治疗格局。无事件生存期2（EFS2）、无进展/无复发生存期2（PRFS2）和无进展生存期2（PFS2）记录了从随机化到首次后续治疗中客观复发/进展或死亡的时间，可能比首次事件终点更准确地衡量持久获益的程度。我们的目标是综述这种获益的程度，并评估长期终点作为实体恶性肿瘤免疫治疗中总生存期（OS）的替代指标。

方法：我们按照《系统综述和荟萃分析的首选报告条目》（PRISMA）的要求，系统检索了从建库至2025年6月12日的Web of Science、美国国立卫生研究院临床试验注册库、美国临床肿瘤学会和欧洲肿瘤内科学会会议数据库中报告的基于抗PD-(L)1的随机对照II/III期临床试验（RCTs）。使用随机效应荟萃分析方法汇总ICI与非ICI组的HR。敏感性分析和荟萃回归评估了效应修饰因素。通过线性回归比较了EFS2/PRFS2/PFS2与EFS/无病生存期（DFS）/PFS对OS的HR。

结果：从2,078篇文献中筛选出47项符合纳入标准的RCTs，包括58个干预比较（ICs）和34,973例患者。非小细胞肺癌（NSCLC）是最常见的研究肿瘤类型（17项RCTs）。在未接受ICI治疗的患者中，抗PD-(L)1作为后续治疗的效果普遍较差（p<0.05）。早期使用抗PD-(L)1与显著的EFS2/PRFS2/PFS2改善相关（HR 0.72；95%置信区间0.68-0.76），在不同治疗背景（治愈性或复发/转移性）中结果一致，且在涉及错配修复缺陷或高度微卫星不稳定肿瘤以及放射学反应较好的患者的RCTs中效果尤为显著。在54个同时报告OS和EFS2/PRFS2/PFS2 HR的ICs中，所有RCTs中观察到强相关性（R²=0.74），而在NSCLC患者中（22个ICs）相关性更强（R²=0.86）。相比之下，EFS/DFS/PFS在所有RCTs中（51个ICs）的R²为0.39，在NSCLC患者中（21个ICs；p<0.01）为0.65。

结论：早期使用抗PD-(L)1治疗与疾病控制的延长相关，并可能增强对后续治疗的敏感性，这些结论主要基于NSCLC数据。此外，EFS2/PRFS2/PFS2是OS的可靠替代指标，应考虑将其常规纳入并预先设定在免疫治疗RCTs中，以更好地捕捉长期获益并为监管、临床和报销决策提供依据。

PROSPERO注册号：CRD42024585378。

### 第二部分 AI 大师评价

本研究系统评价了抗PD-(L)1免疫治疗中EFS2、PRFS2和PFS2作为长期疗效替代指标的临床价值，并通过荟萃分析证实了其与总生存期的强相关性，尤其是在非小细胞肺癌患者中。研究方法严谨，数据来源广泛，结果对临床实践具有重要指导意义。研究的创新性在于首次系统评估了这些二次事件终点在免疫治疗中的应用价值。然而，研究的局限性在于主要数据来源于NSCLC，对其他实体瘤的普适性尚需进一步验证。

---

## 54. 脑脊液中的细胞动力学揭示了非小细胞肺癌脑转移对免疫检查点抑制剂颅内反应的关键调节因子。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41314983](https://pubmed.ncbi.nlm.nih.gov/41314983)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41314983
**DOI：** 10.1136/jitc-2025-012071

### 第一部分 原文与翻译

**英文原标题：** Cellular dynamics in cerebrospinal fluid unveils the key regulators of intracranial response to immune checkpoint inhibitors in NSCLC brain metastases.

**英文摘要原文：**
BACKGROUND: Brain metastases (BrM) in non-small cell lung cancer (NSCLC) present a significant challenge due to poor prognosis. While immune checkpoint inhibitors (ICIs) have been standard treatments for NSCLC, their efficacy in BrM is variable, emphasizing the urgent need for predictive biomarkers and fundamental mechanisms. METHODS: Patients with NSCLC and BrM planning to receive ICI therapy were enrolled in the prospective cohort, dynamic cerebrospinal fluid (CSF) samples (n=20) were collected through lumbar puncture and used for single-cell RNA sequencing (scRNA-seq), and BrM tumors were collected if they have the indications of surgery, with integrating scRNA-seq data from external database (total n=20). Three independent cohorts underwent flow cytometry (n=8), proteomics analysis (n=31), and multiplex immunohistochemistry (n=25) for validation. RESULTS: Our study provided a high-resolution atlas of cellular dynamics in the CSF and BrM during ICI therapy in patients with NSCLC and BrM. Notably, we identified a key immune cell subset, CD4PDCD1CXCR6 T cells, as a positive predictor of ICI intracranial tumor responses, which presented highly functional and transcriptomic similarities in both CSF and BrM tumor environment. Moreover, CXCR6 could serve as a specific marker for CD4PDCD1 T cells linked to ICI response. Further, we revealed that the novel cluster of CD4PDCD1CXCR6 T cells was closely associated with lymphocyte activation and aggregation in CSF and BrM of ICI responders, and classical dendritic cells of ICI responders interacted with CD4PDCD1CXCR6 T cells for enhanced antigen presentation and inflammatory activation. CONCLUSION: Our findings revealed critical insights into the immune landscape of NSCLC BrM under ICI therapy, highlighting CD4PDCD1CXCR6 T cells in CSF as a promising biomarker and illuminating fundamental mechanisms underlying ICI efficacy.

**中文摘要译文：**
背景：非小细胞肺癌（NSCLC）的脑转移（BrM）由于预后不良而成为一个重大挑战。尽管免疫检查点抑制剂（ICIs）已成为NSCLC的标准治疗方法，但其在BrM中的疗效存在差异，这凸显了对预测性生物标志物和基础机制的迫切需求。方法：计划接受ICI治疗的NSCLC和BrM患者被纳入前瞻性队列，通过腰椎穿刺收集动态脑脊液（CSF）样本（n=20）并用于单细胞RNA测序（scRNA-seq），若BrM肿瘤有手术指征则进行收集，同时整合外部数据库的scRNA-seq数据（总计n=20）。三个独立队列分别进行了流式细胞术（n=8）、蛋白质组学分析（n=31）和多重免疫组化（n=25）以进行验证。结果：我们的研究提供了NSCLC和BrM患者在ICI治疗期间CSF和BrM中细胞动力学的高分辨率图谱。值得注意的是，我们发现了一个关键的免疫细胞亚群CD4PDCD1CXCR6 T细胞，作为ICI颅内肿瘤反应的阳性预测因子，其在CSF和BrM肿瘤环境中均表现出高度功能和转录组相似性。此外，CXCR6可作为与ICI反应相关的CD4PDCD1 T细胞的特异性标志物。进一步，我们揭示了CD4PDCD1CXCR6 T细胞的新簇与ICI应答者CSF和BrM中淋巴细胞的激活和聚集密切相关，而经典树突状细胞与CD4PDCD1CXCR6 T细胞相互作用以增强抗原呈递和炎症激活。结论：我们的研究揭示了ICI治疗下NSCLC BrM免疫景观的关键见解，突出了CSF中的CD4PDCD1CXCR6 T细胞作为有前景的生物标志物，并阐明了ICI疗效的基础机制。

### 第二部分 AI 大师评价

本研究旨在探索非小细胞肺癌脑转移患者对免疫检查点抑制剂（ICI）的颅内反应机制。通过前瞻性队列设计和多组学分析（单细胞RNA测序、流式细胞术、蛋白质组学等），研究者揭示了CD4PDCD1CXCR6 T细胞作为关键免疫亚群的重要作用，并发现其在脑脊液和肿瘤微环境中的功能相似性，为预测ICI疗效提供了新标志物（CXCR6）。研究的创新性在于提供了高分辨率的细胞动力学图谱，对临床个性化治疗具有重要指导意义。然而，样本量较小和实验方法的复杂性可能限制结果的广泛适用性。

---

## 55. 新辅助放化疗联合双免疫疗法对 T3-4N0-2 非小细胞肺癌患者肿瘤引流淋巴结的免疫调节作用

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41314982](https://pubmed.ncbi.nlm.nih.gov/41314982)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41314982
**DOI：** 10.1136/jitc-2025-013237

### 第一部分 原文与翻译

**英文原标题：** Immune-modulating effects on tumor-draining lymph nodes of neoadjuvant chemoradiotherapy combined with dual immunotherapy in patients with T3-4N0-2 NSCLC.

**英文摘要原文：**
BACKGROUND: Tumor-draining lymph nodes (TDLN) play a key role in inducing and promoting antitumor immunity. TDLN are commonly situated near the primary tumor and are therefore often exposed to therapeutic radiation. The impact of induction therapies comprising concurrent immunotherapy and radiation on TDLN is poorly understood. We studied the immune-modulating effects in TDLN of patients with T3-4N0-2 non-small cell lung cancer (NSCLC) using a combination of spatial transcriptomics and immunohistochemical analyses.

METHODS: This observational cohort study collected TDLN from 2 groups: (1) patients from the INCREASE trial who were treated with neoadjuvant ipilimumab/nivolumab (IPI/NIVO) plus chemoradiotherapy (CRT) (n=25) and (2) a matched control cohort of patients with NSCLC who had neoadjuvant CRT only (n=25). TDLN were classified based on the cumulative dose of radiation received, categorized as low (≤5 Gy), intermediate (20-30 Gy), or high dose (50-60 Gy). The TDLN were subjected to duplex immunohistochemistry of CD8/Ki67, PD-1/FOXP3, and CD8/cleaved caspase-3. On a subset of TDLN, additional GeoMx spatial transcriptomics profiling of CD8/Ki67+T cell hotspots was carried out.

RESULTS: After addition of IPI/NIVO to CRT in the INCREASE cohort, resected TDLN showed robust type I immune responses and increased levels of CD8 and regulatory T cells in irradiated TDLN when compared with the control cohort. These immune responses were observed across all radiation dose groups, with the most pronounced effects in high dose TDLN. Significant changes in extracellular matrix and macrophage-associated gene signatures, indicating elevated fibrosis and prolonged inflammation, were observed in the TDLN with high radiation exposure, changes which were partially alleviated by immunotherapy.

CONCLUSION: In the INCREASE trial, neoadjuvant IPI/NIVO combined with CRT for patients with T3-4N0-2 NSCLC elicited enhanced immune responses in TDLN despite exposure to high dose radiation. Even though radiation-induced fibrosis was evident in high dose TDLN, the immune responses were not diminished when compared with low dose TDLN. These findings underscore the resilience of TDLN immunological function under intense radiation exposure.

**中文摘要译文：**
背景：肿瘤引流淋巴结（TDLN）在诱导和促进抗肿瘤免疫中发挥关键作用。TDLN通常位于原发肿瘤附近，因此常受到治疗性辐射的影响。由同步免疫治疗和放疗组成的诱导治疗对TDLN的影响尚不清楚。我们采用空间转录组学和免疫组织化学分析相结合的方法，研究了T3-4N0-2非小细胞肺癌（NSCLC）患者TDLN中的免疫调节效应。

方法：这项观察性队列研究从两组患者中收集TDLN：（1）INCREASE试验中接受新辅助伊匹木单抗/纳武利尤单抗（IPI/NIVO）联合放化疗（CRT）的患者（n=25），（2）仅接受新辅助CRT的NSCLC患者匹配对照组（n=25）。TDLN根据接受的累积辐射剂量分类，分为低剂量（≤5 Gy）、中剂量（20-30 Gy）或高剂量（50-60 Gy）。TDLN进行了CD8/Ki67、PD-1/FOXP3和CD8/cleaved caspase-3的双重免疫组织化学分析。在一部分TDLN中，额外进行了CD8/Ki67+T细胞热点区域的GeoMx空间转录组学分析。

结果：INCREASE队列在CRT中加入IPI/NIVO后，切除的TDLN显示出强烈的I型免疫反应，并且与对照组相比，受辐射TDLN中的CD8和调节性T细胞水平增加。这些免疫反应在所有辐射剂量组中均观察到，其中高剂量TDLN中的效果最为显著。在高辐射暴露的TDLN中观察到显著的细胞外基质和巨噬细胞相关基因特征变化，表明纤维化升高和炎症延长，这些变化部分被免疫疗法缓解。

结论：INCREASE试验中，新辅助IPI/NIVO联合CRT治疗T3-4N0-2 NSCLC患者，尽管暴露于高剂量辐射，仍能在TDLN中引发增强的免疫反应。尽管高剂量TDLN中辐射诱导的纤维化很明显，但与低剂量TDLN相比，免疫反应并未减弱。这些发现强调了TDLN在高强度辐射暴露下免疫功能的韧性。

### 第二部分 AI 大师评价

本研究旨在探讨新辅助放化疗联合双免疫疗法对非小细胞肺癌患者肿瘤引流淋巴结（TDLN）的免疫调节作用，结合空间转录组学和免疫组织化学分析方法，揭示了即使在强辐射下，TDLN仍能维持显著的免疫功能。研究创新性地展示了双免疫疗法的保护性作用，对临床治疗方案的优化具有重要意义。然而，研究的样本量较小，且未探索长期预后影响，未来需进一步扩大研究以验证其广泛适用性。

---

## 56. FXR介导的抗原特异性CD8 T细胞增强肝内胆管癌的抗肿瘤免疫应答

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41314981](https://pubmed.ncbi.nlm.nih.gov/41314981)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41314981
**DOI：** 10.1136/jitc-2025-012259

### 第一部分 原文与翻译

**英文原标题：** FXR-mediated antigen-specific CD8 T cell enhances antitumor immunity in intrahepatic cholangiocarcinoma.

**英文摘要原文：**
BACKGROUND: Intrahepatic cholangiocarcinoma (ICC) offers limited opportunities for surgical treatment, and advanced-stage patients exhibit poor responses to immunotherapy. Therefore, the exploration of new therapeutic strategies is of paramount importance. The farnesoid X receptor (FXR) is a nuclear receptor that has been reported to regulate immune cells in recent years. However, whether FXR can regulate CD8 T cells to affect tumor development remains unknown.

METHODS: The function of FXR in CD8 T cell-mediated antitumor immunity was assessed using spontaneous murine ICC models in systemic -knockout, and T cell-specific conditional knockout mice, with immune phenotyping performed by multicolor flow cytometry. The tumor antigen-specific CD8 T response was tracked by tetramer staining and adoptive transfer of OT-1 T cells. The regulatory mechanism of FXR was confirmed using RNA sequencing, Chromatin Immunoprecipitation sequencing (ChIP-seq), Chromatin Immunoprecipitation polymerase chain reaction (ChIP-PCR), and luciferase reporter assays. The translational therapeutic potential was evaluated by administration of the FXR inhibitor ursodeoxycholic acid (UDCA), both as monotherapy and in combination with anti-programmed death-ligand 1 (PD-L1) blockade, in murine models and ex vivo using patient-derived tumor fragments.

RESULTS: FXR was specifically overexpressed in exhausted CD8 tumor-infiltrating lymphocytes in both human and murine ICC. FXR ablation enhanced CD8 T-cell effector function, proliferation, and stem-like progenitor capacity, leading to potent tumor control. Mechanistically, FXR transcriptionally upregulated the exhaustion marker LAG3 by directly binding to its promoter. Pharmacological inhibition of FXR with UDCA reversed T-cell exhaustion, and synergized with anti-PD-L1 therapy to significantly suppress tumor growth and enhance tumor cell apoptosis in murine models and human ICC ex vivo cultures.

CONCLUSIONS: Together, these data identify FXR as an immune checkpoint and support repurposing UDCA for ICC immunotherapy.

**中文摘要译文：**
背景：肝内胆管癌（ICC）的手术治疗机会有限，晚期患者对免疫疗法的反应较差。因此，探索新的治疗策略至关重要。FXR（farnesoid X receptor）是一种近年来被报道可调控免疫细胞的核受体，但FXR是否可通过调节CD8 T细胞影响肿瘤发展尚不清楚。

方法：通过系统性敲除和T细胞特异性条件敲除小鼠的自发性ICC模型，结合多色流式细胞术进行免疫表型分析，评估了FXR在CD8 T细胞介导的抗肿瘤免疫中的功能。通过四聚体染色和OT-1 T细胞的过继转移追踪肿瘤抗原特异性CD8 T细胞应答。利用RNA测序、染色质免疫共沉淀测序（ChIP-seq）、染色质免疫共沉淀PCR（ChIP-PCR）和荧光素酶报告基因实验证实FXR的调控机制。在小鼠模型和患者来源的肿瘤外植体中，通过单药或联合抗PD-L1阻断疗法评估FXR抑制剂熊去氧胆酸（UDCA）的转化治疗潜力。

结果：FXR在人和小鼠ICC中均特异性地在耗竭的CD8肿瘤浸润淋巴细胞中过度表达。FXR的缺失增强了CD8 T细胞的效应功能、增殖能力和干细胞样祖细胞能力，从而显著抑制肿瘤生长。从机制上看，FXR通过直接结合LAG3的启动子转录上调了该耗竭标志物。UDCA对FXR的药理学抑制逆转了T细胞耗竭，并与抗PD-L1疗法协同显著抑制肿瘤生长并增强肿瘤细胞凋亡，这一现象在小鼠模型和人ICC外植体培养中均得到证实。

结论：这些数据共同表明FXR是一种免疫检查点分子，支持将UDCA重新用于ICC的免疫治疗。

### 第二部分 AI 大师评价

本研究旨在探索FXR在肝内胆管癌（ICC）中通过调控CD8 T细胞功能增强抗肿瘤免疫的治疗潜力。通过小鼠模型和多种分子生物学技术，研究发现FXR过度表达于耗竭的CD8 T细胞中，并揭示其通过上调LAG3促进T细胞耗竭的作用机制。创新性地提出FXR抑制剂UDCA可逆转T细胞耗竭，并与抗PD-L1疗法协同抑制肿瘤，具有显著的临床转化潜力。然而，研究尚未在人体临床试验中验证UDCA的长期疗效和安全性，未来需进一步探索。

---

## 57. HSP47抑制通过TRAF2去泛素化诱导CD155表达促进肿瘤免疫逃逸。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41314980](https://pubmed.ncbi.nlm.nih.gov/41314980)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41314980
**DOI：** 10.1136/jitc-2025-011976

### 第一部分 原文与翻译

**英文原标题：** HSP47 inhibition-induced CD155 expression through TRAF2 deubiquitination promotes tumor immune evasion.

**英文摘要原文：**
BACKGROUND: Heat shock protein 47 (HSP47) is crucial for protein quality control and tumor progression. While its role in cancer biology is well established, its impact on cancer immunity remains poorly understood. In this study, we aim to elucidate how HSP47 inhibition modulates immune evasion, with a specific focus on the CD155/T-cell immunoreceptor with Ig and ITIM domains (TIGIT) axis in osteosarcoma (OS).

METHODS: We used OS cell lines and mouse models to examine the effects of HSP47 inhibition on tumor growth and immune response. Expression levels of CD155, TIGIT, and other immune checkpoint molecules were analyzed throughflow cytometry, immunofluorescence, and western blotting. We also assessed the therapeutic effects of combining HSP47 inhibition with CD155 blockade or nuclear factor-kappa B (NF-κB) inhibitors in preclinical models.

RESULTS: Inhibition of HSP47 resulted in increased expression of the immune checkpoint molecule CD155, which impaired the antitumor activity of CD8 T cells through the TIGIT receptor. Mechanistically, HSP47 inhibition reduced TRAF2 ubiquitination, leading to enhanced NF-κB signaling and upregulation of CD155 in OS cells. Combining HSP47 inhibition with anti-TIGIT antibodies or the NF-κB inhibitor bortezomib significantly suppressed OS progression and improved survival in mouse models.

CONCLUSIONS: HSP47 inhibition promotes immune evasion by upregulating CD155 via the TRAF2-NF-κB pathway, which impairs CD8 T cell-mediated antitumor immunity. The combination of HSP47 inhibition with CD155/TIGIT blockade enhances therapeutic efficacy, suggesting a promising strategy for combination cancer therapies.

**中文摘要译文：**
背景：热休克蛋白47（HSP47）对蛋白质质量控制和肿瘤进展至关重要。尽管其在癌症生物学中的作用已得到充分证实，但其对癌症免疫的影响仍知之甚少。本研究旨在阐明HSP47抑制如何调节免疫逃逸，特别关注骨肉瘤（OS）中的CD155/TIGIT轴。

方法：我们使用OS细胞系和小鼠模型研究HSP47抑制对肿瘤生长和免疫反应的影响。通过流式细胞术、免疫荧光和Western blotting分析CD155、TIGIT及其他免疫检查点分子的表达水平。我们还评估了临床前模型中HSP47抑制与CD155阻断或核因子κB（NF-κB）抑制剂联合的治疗效果。

结果：HSP47抑制导致免疫检查点分子CD155表达增加，通过TIGIT受体削弱CD8 T细胞的抗肿瘤活性。机制上，HSP47抑制减少了TRAF2的泛素化，从而增强NF-κB信号通路并上调OS细胞中CD155的表达。HSP47抑制与抗TIGIT抗体或NF-κB抑制剂硼替佐米联合使用，显著抑制了OS的进展并提高了小鼠模型的生存率。

结论：HSP47抑制通过TRAF2-NF-κB通路上调CD155，从而促进免疫逃逸并损害CD8 T细胞介导的抗肿瘤免疫。HSP47抑制与CD155/TIGIT阻断联合可增强治疗效果，为联合癌症治疗提供了有前景的策略。

### 第二部分 AI 大师评价

本研究聚焦HSP47抑制对肿瘤免疫逃逸的调控机制，揭示了其在CD155/TIGIT轴中的作用。通过OS细胞和小鼠模型，研究发现HSP47抑制通过TRAF2-NF-κB通路增加CD155表达，削弱CD8 T细胞的抗肿瘤活性。结合HSP47抑制与CD155/TIGIT阻断的策略显著提升治疗效果，显示出潜在的临床转化价值。然而，研究未涉及其他肿瘤类型或免疫微环境的全面影响，未来需进一步验证其广谱性和安全性。

---

## 58. JAK抑制剂治疗免疫检查点抑制剂引起的危及生命和难治性免疫相关不良事件：一项前瞻性队列研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41314979](https://pubmed.ncbi.nlm.nih.gov/41314979)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41314979
**DOI：** 10.1136/jitc-2025-013214

### 第一部分 原文与翻译

**英文原标题：** JAK inhibitors for the treatment of life-threatening and refractory immune-related adverse events secondary to immune checkpoint inhibitors: a prospective cohort study.

**英文摘要原文：**
BACKGROUND: Immune checkpoint inhibitors have revolutionized cancer treatment but can induce immune-related adverse events (irAEs), which are sometimes severe, life-threatening, or refractory to corticosteroids. Current management is largely empirical and adapted from autoimmune disease protocols. Dysregulation of the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway has been implicated in irAE pathogenesis, positioning JAK inhibitors (JAKi) as potential therapeutic agents. We hypothesized that JAKi may offer therapeutic benefit in treating corticosteroid-refractory or life-threatening irAEs.

METHODS: We conducted a prospective cohort study at the Jewish General Hospital (Montreal, Canada) within the Montreal Immune-Related Adverse Events biobank, enrolling patients who developed grade ≥3 or persistent grade 2 irAEs unresponsive to corticosteroids or life-threatening irAEs requiring urgent intervention.

RESULTS: 29 patients received JAKi; 5 were excluded due to death within 30 days of initiation, leaving 24 evaluable patients (median age 69 years; 37.5% female). The majority received anti-programmed cell death protein-1 (PD-1) monotherapy (79.2%), with some receiving combination anti-cytotoxic T-lymphocyte antigen-4/PD-1 therapy (16.7%). Indications for JAKi use included myocarditis (n=8), arthritis (n=4), colitis (n=3), hepatitis (n=3), encephalitis (n=2), pneumonitis (n=2), myasthenia gravis (n=1), and sicca syndrome (n=1). JAKi were employed as second-line therapy in 7 patients, third-line in 11, and fourth-line or later in 6. Clinical response, defined as irAE resolution to grade ≤1 while on ≤10 mg prednisone equivalent without relapse for ≥30 days, was observed in 17 patients (70.8%), with median time to resolution of 41 days. Response rates were highest for myocarditis (75%) and arthritis (100%). No opportunistic infections or JAKi-related hepatotoxicity occurred; thrombotic events were identified in three individuals (10.3%).

CONCLUSIONS: These findings suggest that JAKi are a promising, well-tolerated option for managing corticosteroid-refractory or life-threatening irAEs. Further randomized studies are warranted to confirm their efficacy and safety in this setting.

**中文摘要译文：**
背景：免疫检查点抑制剂已彻底改变了癌症治疗，但也可能诱发免疫相关不良事件（irAEs），这些事件有时是严重的、危及生命的或对皮质类固醇无效的。目前的管理方法大多是经验性的，并借鉴了自身免疫疾病的治疗方案。Janus激酶（JAK）-信号转导和转录激活因子（STAT）通路的失调被认为与irAE的发病机制有关，这使得JAK抑制剂（JAKi）成为潜在的治疗药物。我们假设JAKi可能在治疗皮质类固醇无效或危及生命的irAEs中提供治疗益处。

方法：我们在蒙特利尔的犹太总医院（加拿大）的蒙特利尔免疫相关不良事件生物库中开展了一项前瞻性队列研究，纳入的患者包括发展为≥3级或持续的2级irAEs且对皮质类固醇无效的患者，或需要紧急干预的危及生命的irAEs患者。

结果：29名患者接受了JAKi治疗；5名因治疗开始后30天内死亡被排除，剩下24名可评估患者（中位年龄69岁；37.5%为女性）。大多数患者接受了抗程序性细胞死亡蛋白-1（PD-1）单药治疗（79.2%），少数接受了抗细胞毒性T淋巴细胞抗原-4/PD-1联合治疗（16.7%）。使用JAKi的适应症包括心肌炎（n=8）、关节炎（n=4）、结肠炎（n=3）、肝炎（n=3）、脑炎（n=2）、肺炎（n=2）、重症肌无力（n=1）和干燥综合征（n=1）。JAKi作为二线治疗用于7名患者，三线治疗用于11名患者，四线或后续治疗用于6名患者。定义为irAE缓解至≤1级且在≤10 mg泼尼松当量下持续≥30天无复发的临床反应在17名患者（70.8%）中观察到，中位缓解时间为41天。心肌炎（75%）和关节炎（100%）的反应率最高。未发生机会性感染或JAKi相关的肝毒性；3名患者（10.3%）发生了血栓事件。

结论：这些发现表明JAKi是管理皮质类固醇无效或危及生命的irAEs的有前景且耐受性良好的选择。需要进一步的随机研究以确认其在此背景下的疗效和安全性。

### 第二部分 AI 大师评价

本研究旨在探讨JAK抑制剂（JAKi）在治疗免疫检查点抑制剂引起的皮质类固醇无效或危及生命的免疫相关不良事件（irAEs）中的应用价值。研究采用前瞻性队列设计，纳入了24名患者，结果显示JAKi在70.8%的患者中表现出良好的临床反应，尤其是心肌炎和关节炎患者。研究创新性在于为irAEs的治疗提供了新的选择，并证明了JAKi的安全性和耐受性。然而，小样本量和缺乏随机对照设计可能限制了结论的普适性，未来需要通过更大规模的随机试验进一步验证。这一研究为临床实践提供了重要参考，具有显著的临床和科研价值。

---

## 59. 转移性黑色素瘤联合免疫治疗序列的国际真实世界研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41314978](https://pubmed.ncbi.nlm.nih.gov/41314978)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41314978
**DOI：** 10.1136/jitc-2025-012225

### 第一部分 原文与翻译

**英文原标题：** International real-world study of combination immunotherapy sequences in metastatic melanoma.

**英文摘要原文：**
BACKGROUND: Immune checkpoint inhibitors (ICIs) have revolutionized melanoma treatment, with programmed cell death protein 1 (PD-1) inhibitors-alone or in combination with cytotoxic T-lymphocyte-associated protein 4 or lymphocyte-activation gene 3 inhibitors-demonstrating significant efficacy. However, there is a critical lack of robust data to determine the optimal sequencing of these therapies for individual patients. In particular, the role of relatlimab+nivolumab (rela/nivo) within treatment sequences remains poorly defined. Choosing the right sequence is strategic, as an inappropriate order may compromise the effectiveness of subsequent treatments and limit long-term benefits.

METHODS: This multicenter retrospective and prospective study evaluated 190 patients across three treatment arms: rela/nivo followed by ipilimumab+nivolumab (ipi/nivo) (arm A, N=40), ipi/nivo followed by rela/nivo (arm B, N=71), and anti-PD-1 followed by rela/nivo (arm C, N=79). The study assessed the impact of treatment sequencing on outcomes including response rate, progression-free survival, and overall survival (OS).

RESULTS: The overall response rate to second treatment was highest in arm C (30.4%), followed by arm B (28.1%) and arm A (17.5%). Patients with secondary resistance to first-treatment ICIs had better responses to second-treatment ICIs than those with primary resistance, particularly in arm B (p=0026). Median OS from date of first ICI treatment was significantly longer in arms B (40.9 months) and C (42.5 months) compared with arm A (16.3 months).

CONCLUSIONS: Our findings indicate that rela/nivo may remain active following anti-PD-1 or ipi/nivo therapy. Additionally, our results suggest that sequencing ipi/nivo before rela/nivo may yield better outcomes than starting with rela/nivo. Patients who respond to the first combination regimen appear to derive greater benefit from the second. Further efforts are needed to optimize sequencing strategies in advanced melanoma, and future studies should consider the impact of prior treatment outcomes.

**中文摘要译文：**
背景：免疫检查点抑制剂（ICIs）已经彻底改变了黑色素瘤的治疗方式，单独使用程序性细胞死亡蛋白1（PD-1）抑制剂或与细胞毒性T淋巴细胞相关蛋白4或淋巴细胞激活基因3抑制剂联合使用显示出显著的疗效。然而，目前严重缺乏可靠的数据来确定这些疗法对个体患者的最佳序列。特别是，relatlimab+nivolumab（rela/nivo）在治疗序列中的作用仍然不明确。选择合适的序列是战略性的，因为不当的顺序可能会影响后续治疗的效果并限制长期收益。

方法：这项多中心回顾性和前瞻性研究评估了190名患者，分为三个治疗组：rela/nivo后接ipilimumab+nivolumab（ipi/nivo）（A组，N=40）、ipi/nivo后接rela/nivo（B组，N=71）以及抗PD-1后接rela/nivo（C组，N=79）。研究评估了治疗序列对反应率、无进展生存期和总生存期（OS）等结局的影响。

结果：第二治疗的总反应率在C组最高（30.4%），其次是B组（28.1%）和A组（17.5%）。对第一治疗ICIs产生继发性耐药的患者对第二治疗ICIs的反应优于原发性耐药的患者，尤其在B组（p=0.026）。从首次ICI治疗日期开始的中位OS在B组（40.9个月）和C组（42.5个月）显著长于A组（16.3个月）。

结论：我们的研究结果表明，rela/nivo可能在抗PD-1或ipi/nivo治疗后仍然有效。此外，我们的结果提示，将ipi/nivo排在rela/nivo之前可能比从rela/nivo开始获得更好的结局。对第一联合治疗方案有反应的患者似乎能从第二治疗中获得更大的收益。需要进一步努力优化晚期黑色素瘤的序列策略，未来研究应考虑前期治疗结局的影响。

### 第二部分 AI 大师评价

本研究旨在探索转移性黑色素瘤患者中联合免疫治疗的最佳序列策略，通过多中心回顾性和前瞻性研究设计，评估了三种不同治疗序列的效果。研究发现，抗PD-1治疗后接rela/nivo（C组）的反应率最高，而ipi/nivo后接rela/nivo（B组）的总生存期显著优于其他组。这一结果为临床实践中选择治疗序列提供了重要依据，具有显著的临床价值。创新之处在于明确了rela/nivo在不同治疗序列中的作用，但其局限性在于样本量较小且为真实世界研究，未来需要更大规模的随机对照试验进一步验证。

---

## 60. 阻断PCSK9通过降低FLI1介导的SPP1和PD-L1表达抑制肝细胞癌免疫逃逸。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41314977](https://pubmed.ncbi.nlm.nih.gov/41314977)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41314977
**DOI：** 10.1136/jitc-2025-012586

### 第一部分 原文与翻译

**英文原标题：** Blocking PCSK9 suppresses hepatocellular carcinoma immune escape by decreasing FLI1-mediated SPP1 and PD-L1 expression.

**英文摘要原文：**
BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a newly identified immunosuppressive regulator, but its mechanism of suppressing antitumor immunity remains ambiguous. This study aims to uncover the underlying mechanism by which PCSK9 promotes hepatocellular carcinoma (HCC) immune escape and to explore potential intervention strategies.

METHODS: Co-culture assay assessed the cytotoxicity of CD8 T cells against PCSK9-knockout HCC cells. Hepa1-6, H22, and HepG2 cells were used to establish HCC mouse models. Tumor microenvironment changes were evaluated using flow cytometry and single-cell RNA sequencing. Additionally, we developed a CRISPR adenine base editing (ABE) base editor and screened small molecule inhibitors for PCSK9 inhibition in HCC treatment.

RESULTS: We found that PCSK9 was highly expressed and correlated with poor survival in patients with HCC. While PCSK9 deficiency did not affect HCC growth in vitro, it significantly enhanced CD8 T cell-mediated selective killing in vitro and in vivo. This selective killing of PCSK9-deficient HCC cells could not be explained by existing theories related to major histocompatibility complex-I and T-cell receptor (TCR) degradation. Instead, our study revealed that PCSK9 knockout inhibited the expression of secreted phosphoprotein 1 (SPP1) and programmed death-ligand 1 (PD-L1) in HCC cells, and identified friend leukemia virus integration 1 (FLI1) as their co-transcription factor. Overexpression of FLI1 reversed the PCSK9 knockout-induced downregulation of SPP1 and PD-L1, thereby promoting HCC immune escape. Furthermore, PCSK9 upregulated FLI1 expression through the neurogenic locus notch homolog protein 3 (NOTCH3) pathway. Additionally, we designed an all-in-one ABE base editor with thyroxine-binding globulin promoter (ABE-TBG-PCSK9) to knock down PCSK9 and identified parecoxib as a small molecule inhibitor. We confirmed both approaches enhanced CD8 T-cell antitumor activity, significantly inhibiting HCC tumor growth and prolonging mouse survival.

CONCLUSIONS: PCSK9 promoted HCC immune escape by upregulating SPP1 and PD-L1 via NOTCH3/FLI1 signaling. CRISPR ABE-mediated PCSK9 deficiency and PCSK9 inhibitor parecoxib may serve as effective strategies to inhibit HCC.

**中文摘要译文：**
背景：前蛋白转化酶枯草溶菌素9型（PCSK9）是一种新发现的免疫抑制调节因子，但其抑制抗肿瘤免疫的机制尚不明确。本研究旨在揭示PCSK9促进肝细胞癌（HCC）免疫逃逸的潜在机制，并探索可能的干预策略。

方法：通过共培养实验评估CD8 T细胞对PCSK9敲除的HCC细胞的杀伤作用。使用Hepa1-6、H22和HepG2细胞建立HCC小鼠模型。通过流式细胞术和单细胞RNA测序评估肿瘤微环境的变化。此外，我们还开发了一种CRISPR腺嘌呤碱基编辑器（ABE），并筛选了用于抑制PCSK9的小分子抑制剂，以用于HCC治疗。

结果：我们发现PCSK9在HCC患者中高表达，并与不良预后相关。虽然PCSK9缺失在体外不影响HCC的生长，但它在体外和体内显著增强了CD8 T细胞介导的选择性杀伤作用。这种对PCSK9缺失HCC细胞的选择性杀伤无法用现有的关于主要组织相容性复合物-I和T细胞受体（TCR）降解的理论解释。相反，我们的研究发现PCSK9敲除抑制了HCC细胞中分泌性磷蛋白1（SPP1）和程序性死亡配体1（PD-L1）的表达，并鉴定出Friend白血病病毒整合1（FLI1）是它们的共同转录因子。FLI1的过表达逆转了PCSK9敲除诱导的SPP1和PD-L1下调，从而促进HCC免疫逃逸。此外，PCSK9通过神经源性位点Notch同源蛋白3（NOTCH3）通路上调FLI1的表达。我们还设计了一种整合甲状腺素结合球蛋白启动子（ABE-TBG-PCSK9）的全合一ABE碱基编辑器来敲低PCSK9，并鉴定出帕瑞昔布作为一种小分子抑制剂。我们证实这两种方法增强了CD8 T细胞的抗肿瘤活性，显著抑制了HCC肿瘤的生长并延长了小鼠的生存期。

结论：PCSK9通过NOTCH3/FLI1信号通路上调SPP1和PD-L1的表达，从而促进HCC免疫逃逸。CRISPR ABE介导的PCSK9缺失和PCSK9抑制剂帕瑞昔布可能成为抑制HCC的有效策略。

### 第二部分 AI 大师评价

本研究旨在揭示PCSK9促进肝细胞癌（HCC）免疫逃逸的分子机制，并探索潜在的干预策略。通过CRISPR碱基编辑和小分子抑制剂筛选，研究发现PCSK9通过NOTCH3/FLI1信号通路上调SPP1和PD-L1的表达，从而抑制CD8 T细胞的抗肿瘤活性。这一发现不仅提供了PCSK9在HCC免疫逃逸中的新机制，还为开发基于PCSK9的靶向治疗（如CRISPR编辑和小分子药物）提供了理论依据。尽管研究揭示了重要的分子通路，但其临床转化仍需进一步验证，尤其是在人类患者中的应用。

---

## 61. 中性粒细胞胞外诱捕网-STC1正反馈环路促进膀胱癌免疫逃逸和转移。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41314976](https://pubmed.ncbi.nlm.nih.gov/41314976)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41314976
**DOI：** 10.1136/jitc-2025-012736

### 第一部分 原文与翻译

**英文原标题：** Neutrophil extracellular traps-STC1 positive feedback loop promotes immune evasion and metastasis in bladder cancer.

**英文摘要原文：**
BACKGROUND: Immune checkpoint inhibitors (ICIs) have transformed the treatment strategy for bladder cancer (BLCA), but primary resistance still occurs in most patients. Recent evidence suggests that neutrophil extracellular traps (NETs) play a key role in cancer therapy resistance, but their specific role in BLCA remains unclear. METHODS: An integrated analysis of multiple clinical cohorts receiving ICIs was performed to explore the link between NETs and patient outcomes. Immunofluorescence staining, in vitro co-culture system, scanning electron microscopy, and mouse lung metastasis model were used to evaluate the biological effects of NETs. Proteomics and single-cell transcriptomics analysis were further applied to elucidate the molecular mechanisms. RESULTS: Clinically, NETs abnormally accumulated in BLCA and promoted tumor metastasis and immunotherapy resistance in mice. Mechanistically, NETs upregulated the anti-phagocytic checkpoint STC1 in tumor cells through the TLR2-MAPK-FosL1 axis. Notably, STC1 inhibited antigen presentation by sequestering calreticulin, while its secreted form enhances NET formation, forming a self-reinforcing feedback loop. In addition, secreted STC1 impaired differentiation of CD14 precursors into mature dendritic cells, further exacerbating immune suppression. CONCLUSION: This study revealed the critical role of the NETs-STC1 feedback loop in BLCA immunoresistance. Targeting this axis could simultaneously enhance efficacy and safety of immunotherapy, providing a novel translational strategy for overcoming resistance in clinical settings.

**中文摘要译文：**
背景：免疫检查点抑制剂（ICIs）已经改变了膀胱癌（BLCA）的治疗策略，但原发性耐药仍然发生在大多数患者中。最近的研究表明，中性粒细胞胞外诱捕网（NETs）在癌症治疗耐药性中发挥着关键作用，但它们在BLCA中的具体作用仍不清楚。方法：通过整合分析多个接受ICI治疗的临床队列，探索NETs与患者预后的关联。采用免疫荧光染色、体外共培养系统、扫描电子显微镜和小鼠肺转移模型评估NETs的生物学效应。蛋白质组学和单细胞转录组学分析进一步用于阐明分子机制。结果：临床上，NETs在BLCA中异常积累并促进小鼠肿瘤转移和免疫治疗耐药。机制上，NETs通过TLR2-MAPK-FosL1轴上调肿瘤细胞中的抗吞噬检查点STC1。值得注意的是，STC1通过隔离钙网蛋白抑制抗原呈递，而其分泌形式增强NET的形成，形成一个自我强化的正反馈环路。此外，分泌型STC1损害CD14前体分化为成熟树突状细胞，进一步加剧免疫抑制。结论：本研究揭示了NETs-STC1正反馈环路在BLCA免疫耐药中的关键作用。靶向这一轴可能同时提高免疫治疗的疗效和安全性，为克服临床耐药提供了一种新颖的转化策略。

### 第二部分 AI 大师评价

本研究旨在探索中性粒细胞胞外诱捕网（NETs）在膀胱癌（BLCA）免疫治疗耐药中的作用机制。通过整合临床数据和多种实验手段，研究发现NETs通过上调STC1形成正反馈环路，促进肿瘤免疫逃逸和转移。这一发现不仅揭示了BLCA免疫耐药的新机制，还为靶向NETs-STC1轴的新型治疗策略提供了理论基础。研究的创新性在于明确了STC1的双重作用及其与NETs的互作关系，具有重要的临床转化潜力。然而，研究局限于小鼠模型和体外实验，未来需在更多临床样本中验证其适用性。

---

## 62. 非小细胞肺癌免疫治疗耐药机制的分类：如何做得更好？

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41314975](https://pubmed.ncbi.nlm.nih.gov/41314975)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41314975
**DOI：** 10.1136/jitc-2025-013110

### 第一部分 原文与翻译

**英文原标题：** Categorizing immunotherapy resistance mechanisms in non-small cell lung cancer: how can we perform better?

**英文摘要原文：**
The introduction of immune checkpoint inhibitors (ICI) has revolutionized the treatment of many solid tumors including advanced non-small cell lung cancer (NSCLC) without targetable driver alterations. Unfortunately, the majority of patients with NSCLC do not respond to ICI treatment or will eventually experience disease progression. A wide variety of resistance mechanisms is hypothesized as responsible for tumor immune escape. Also, at what stage they interfere in the anticancer immune response, and the possible complex interactions or overlap between these resistance mechanisms complicate the matter further. Although progress has been made, our current understanding of the resistance mechanisms underlying the failure of ICI treatment is still limited. This is reflected in the lack of positive phase III clinical trials for second-line treatment after failure of ICI in advanced NSCLC. This might be the result of inadequate patient selection. Here, we summarize the current available data on resistance mechanisms in NSCLC and propose a classification system to categorize patients based on resistance mechanisms present. By doing so, we could guide preclinical research and improve selection of patients for clinical trials, thereby ultimately improving outcomes for patients with advanced NSCLC who have progressed on ICI.

**中文摘要译文：**
免疫检查点抑制剂（ICI）的引入彻底改变了许多实体瘤的治疗方式，包括无靶向驱动基因改变的晚期非小细胞肺癌（NSCLC）。然而，遗憾的是，大多数NSCLC患者对ICI治疗无反应或最终会出现疾病进展。多种耐药机制被认为与肿瘤免疫逃逸有关。此外，这些耐药机制在抗癌免疫应答中干扰的阶段，以及它们之间可能的复杂相互作用或重叠，进一步使问题复杂化。尽管已取得一些进展，但目前我们对ICI治疗失败的潜在耐药机制的理解仍然有限。这一点在晚期NSCLC患者ICI治疗失败后缺乏积极的III期临床试验中得到了体现。这可能是由于患者选择不当所致。在此，我们总结了目前关于NSCLC耐药机制的可用数据，并提出了一种基于耐药机制的分类系统，以对患者进行分类。通过这种方式，我们可以指导临床前研究，并改进临床试验的患者选择，从而最终改善对ICI治疗进展的晚期NSCLC患者的预后。

### 第二部分 AI 大师评价

本研究旨在总结非小细胞肺癌（NSCLC）免疫治疗耐药机制的现有数据，并提出一种基于耐药机制的分类系统，以指导临床前研究和临床试验的患者选择。其创新性在于为耐药机制的分类提供了系统框架，有助于精准医疗的实践。研究的临床价值体现在其可能改善对ICI治疗进展的患者的预后。然而，研究也指出当前对耐药机制的理解仍有限，且患者选择不当可能是临床失败的原因之一，提示未来需进一步探索耐药机制的基础研究。

---

## 63. 对Van der Voort等人关于“直肠与结肠黏膜下癌发生率及大型非带蒂息肉手术结果：法国ESD登记数据”的回应

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41314787](https://pubmed.ncbi.nlm.nih.gov/41314787)
**期刊：** Gut
**PMID：** 41314787
**DOI：** 10.1136/gutjnl-2025-337415

### 第一部分 原文与翻译

**英文原标题：** Response to: 'Rectal versus colonic submucosal cancer rates and procedural outcomes in large non-pedunculated polyps: French ESD registry data' by Van der Voort .

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要。

### 第二部分 AI 大师评价

本研究是对Van der Voort等人研究的回应，关注直肠与结肠黏膜下癌的发生率及手术结果。虽然摘要不可用，但可以推测其可能探讨了不同部位息肉的手术效果差异及其临床意义。该研究可能为内镜黏膜下剥离术（ESD）在大型非带蒂息肉治疗中的应用提供了重要的数据支持，进一步强调了ESD在临床实践中的价值。然而，由于摘要缺失，研究的详细方法和具体发现无法评估，可能存在一定的局限性。

---

## 64. 用于转移性卵巢癌症诊疗一体化和治疗反应监测的NIR比率荧光抗体-药物偶联物

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41313802](https://pubmed.ncbi.nlm.nih.gov/41313802)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41313802
**DOI：** 10.1002/advs.202516607

### 第一部分 原文与翻译

**英文原标题：** NIR Ratiometric Fluorescent Antibody-Drug Conjugate for Metastatic Ovarian Cancer Theranostics and Treatment Response Monitoring.

**英文摘要原文：**
In vivo optical imaging advances antibody-drug conjugate (ADC) optimization by enabling real-time monitoring of biological stimulus-responsive drug behavior. Ratiometric probes, incorporating orthogonal wavelength-encoded multicolor detection and stimuli-cleavable linkages, are preferred over single-color strategies. Here, the synthesis of n501-CYMMAF (cyanine-decorated Monomethylauristatin F) is described as a novel ratiometric theranostic agent for dual efficacy in ovarian metastasis treatment and in situ treatment response monitoring. With low-dose administration (2.5 mg kg), exceptional target affinity (EC = 1.17 nm), and favorable biosafety (delivery to tumor-parts only), n501-CYMMAF enables experimental verification of treatment-evading metastatic cell populations through in situ fluorescent tracking, providing crucial insights into tumor recurrence pathways and judgement of treatment terminal point. In general, n501-CYMMAF represents a prototype for next-generation smart theranostics, integrating treatment and endpoint assessment to offer a platform for precision metastasis management.

**中文摘要译文：**
体内光学成像通过实时监测生物刺激响应性药物的行为，推动了抗体-药物偶联物（ADC）的优化。比率探针结合了正交波长编码的多色检测和刺激可切割连接子，相比于单色策略更受青睐。本文描述了n501-CYMMAF（氰基修饰的单甲基奥利司他汀F）的合成，作为一种新型比率诊疗剂，在卵巢转移治疗和原位治疗反应监测中具有双重功效。通过低剂量给药（2.5 mg/kg）、出色的靶点亲和力（EC = 1.17 nm）和良好的生物安全性（仅递送至肿瘤部位），n501-CYMMAF能够通过原位荧光追踪验证逃避治疗的转移性细胞群体，为肿瘤复发路径和治疗终点的判断提供了关键见解。总体而言，n501-CYMMAF代表了下一代智能诊疗一体化的原型，整合了治疗和终点评估，为精准转移管理提供了平台。

### 第二部分 AI 大师评价

本研究开发了一种新型NIR比率荧光抗体-药物偶联物n501-CYMMAF，旨在实现转移性卵巢癌症的治疗与诊疗一体化。通过低剂量给药和高靶向性，该药物不仅能够有效治疗肿瘤，还能通过荧光追踪监测治疗反应，揭示肿瘤复发机制。其创新性在于整合了治疗与实时监测功能，为精准医学提供了新工具。然而，研究可能局限于临床前模型的适用性，未来需进一步验证其临床效果。

---

## 65. W. Yang的研究文章"线粒体代谢受损是MYC抑制剂的关键癌症脆弱性"的更正

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41313782](https://pubmed.ncbi.nlm.nih.gov/41313782)
**期刊：** Science advances
**PMID：** 41313782
**DOI：** 10.1126/sciadv.aed8050

### 第一部分 原文与翻译

**英文原标题：** Erratum for the Research Article "Impaired mitochondrial metabolism is a critical cancer vulnerability for MYC inhibitors" by W. Yang .

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要。

### 第二部分 AI 大师评价

本研究为对W. Yang研究的更正，题目为"线粒体代谢受损是MYC抑制剂的关键癌症脆弱性"。该研究最初可能探讨了MYC抑制剂在癌症治疗中的作用，强调了线粒体代谢受损的重要性。虽然摘要不可用，但更正本身表明研究的严谨性和对细节的关注，这对科研的可信度至关重要。由于缺乏具体内容，无法进一步评估其创新性或临床价值。

---

## 66. 在多药化疗中加入JNK非依赖性药物可改善复发高危神经母细胞瘤的反应。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41313779](https://pubmed.ncbi.nlm.nih.gov/41313779)
**期刊：** Science advances
**PMID：** 41313779
**DOI：** 10.1126/sciadv.ady5599

### 第一部分 原文与翻译

**英文原标题：** Inclusion of JNK-independent drugs within multiagent chemotherapy improves response in relapsed high-risk neuroblastoma.

**英文摘要原文：**
The acquisition of a chemoresistant state underlies poor prognosis in many cancers, including neuroblastoma. We previously demonstrated that heterogeneity in apoptosis induction through c-Jun amino-terminal kinase (JNK) promotes a form of nongenetic chemoresistance in neuroblastoma observable at both patient and single-cell levels. As the maintenance of this JNK-impaired state in the relapse setting is a substantial barrier to the efficacy of many standard-of-care chemotherapy drugs, we combined a mechanistic, mathematical model of JNK activation with a pediatric-focused drug screen and identified approved oncology drugs capable of inducing apoptosis in a JNK-independent manner. Functional genomics further revealed that synergy between these JNK-independent drugs and standard-of-care chemotherapies emerged from differential utilization of apoptotic network components, rather than from their direct mechanistic targets. Efficacy studies with patient-derived xenograft models also confirmed that including a JNK-independent drug within existing chemotherapy backbones significantly improved response in the relapse setting, where new approaches are urgently needed.

**中文摘要译文：**
在许多癌症中，包括神经母细胞瘤，化疗耐药状态的获得是预后不良的基础。我们先前证明，通过c-Jun氨基末端激酶（JNK）诱导凋亡的异质性促进了在患者和单细胞水平上可观察到的一种非遗传性化疗耐药形式。由于在复发环境中维持这种JNK受损状态是许多标准护理化疗药物疗效的重大障碍，我们将JNK激活的机理数学模型与专注于儿科的药物筛选相结合，并鉴定出能够以JNK非依赖性方式诱导凋亡的已获批肿瘤药物。功能基因组学进一步揭示，这些JNK非依赖性药物与标准护理化疗之间的协同作用源于凋亡网络组分的差异性利用，而非它们的直接作用靶点。使用患者来源的异种移植模型进行的疗效研究也证实，在现有的化疗方案中加入一种JNK非依赖性药物显著改善了复发环境中的治疗反应，而这一领域迫切需要新方法。

### 第二部分 AI 大师评价

本研究旨在探索如何通过引入JNK非依赖性药物改善复发高危神经母细胞瘤的治疗反应。研究团队结合了机理模型和儿科药物筛选，鉴定出此类药物，并通过功能基因组学揭示了其协同作用的机制。关键发现表明，这种策略显著提高了复发环境中的治疗反应。本研究创新性地解决了化疗耐药问题，具有重要的临床价值，但其潜在局限性在于对其他类型癌症的普适性尚待验证。

---

## 67. 范可尼贫血中的代谢重编程：葡萄糖氧化受损、酮生成增强及代谢灵活性降低的证据

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41313766](https://pubmed.ncbi.nlm.nih.gov/41313766)
**期刊：** Science advances
**PMID：** 41313766
**DOI：** 10.1126/sciadv.ady6117

### 第一部分 原文与翻译

**英文原标题：** Metabolic reprogramming in Fanconi anemia: Evidence of compromised glucose oxidation, enhanced ketogenesis, and metabolic inflexibility.

**英文摘要原文：**
Fanconi anemia (FA) is a rare genetic disorder characterized by congenital abnormalities, bone marrow failure, and cancer predisposition. Approximately 80% of individuals with FA exhibit metabolic abnormalities, including failure to thrive and increased diabetes risk. Current management relies on physical examinations and glucose tolerance tests, which lack dynamic metabolic assessment. We used stable isotope labeling withC-glucose to track nutrient metabolism in individuals with FA. Unlike controls, persons with FA showed no postprandial increase in energy expenditure, sustained hyperglycemia accompanied by elevated glycolysis, and a markedly higher ketogenic response supporting a shift toward lipid utilization. Hormonal analysis revealed secretion of pancreatic hormones and ghrelin in individuals with FA, while incretins were unaffected. These results reflect a profound alteration in substrate utilization involving glucose intolerance, insulin resistance, and β-cell dysfunction. This innovative approach provides unprecedented insights into FA pathophysiology, which will inform more targeted nutritional and therapeutic interventions for this complex disorder.

**中文摘要译文：**
范可尼贫血（FA）是一种罕见的遗传性疾病，其特征包括先天畸形、骨髓衰竭和癌症易感性。约80%的FA患者表现出代谢异常，包括发育迟缓和糖尿病风险增加。目前的管理依赖于体格检查和葡萄糖耐量试验，这些方法缺乏动态代谢评估。我们使用稳定同位素标记的C-葡萄糖来追踪FA患者的营养代谢。与对照组不同，FA患者在餐后未显示出能量消耗的增加，表现为持续的高血糖伴随糖酵解水平升高，以及明显更高的酮生成反应，支持其向脂质利用的转变。激素分析显示FA患者中胰腺激素和生长素释放肽的分泌增加，但肠促胰岛素未受影响。这些结果反映了底物利用的深刻改变，涉及葡萄糖不耐受、胰岛素抵抗和β细胞功能障碍。这一创新方法为FA的病理生理学提供了前所未有的见解，将为这一复杂疾病的更有针对性的营养和治疗干预提供信息。

### 第二部分 AI 大师评价

本研究旨在通过稳定同位素标记技术，揭示范可尼贫血患者代谢异常的特异性机制。核心发现包括葡萄糖氧化受损、酮生成增强及代谢灵活性降低，为FA的病理生理学提供了新视角。研究方法创新性强，通过动态代谢评估填补了传统检查的不足，对临床实践和营养干预具有重要指导意义。然而，研究样本量较小，未来需要更大规模的验证。

---

## 68. 活细胞膜微区动态的可视化

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41313761](https://pubmed.ncbi.nlm.nih.gov/41313761)
**期刊：** Science advances
**PMID：** 41313761
**DOI：** 10.1126/sciadv.adv7001

### 第一部分 原文与翻译

**英文原标题：** Visualizing dynamics of membrane rafts on live cells.

**英文摘要原文：**
Membrane rafts are cellular portals to external stimuli that trigger signaling cascades for sophisticated yet remarkable biochemical activities. Visualization of the topographic evolution of membrane rafts remains unreported on live cells due to the nanosized and dynamic nature. Here, an imaging strategy involving atomic force microscopy and Hadamard product is developed to unveil membrane-raft features. Michigan Cancer Foundation-7 (MCF-7) cells were subjected to fibrinogen or manganese(II) (Mn)/resveratrol, both of which are ligands of integrin αβ embedded within membrane rafts; the former promotes metastasis, and the latter enables apoptosis. MCF-7 cellular membranes responded to the two stimulants markedly different. The size, height, spatiotemporal trajectory, and persistent time of ligand-activated nanodomains are revealed. This approach opens up a visualized platform toward the understanding of activation-associated signaling cascades.

**中文摘要译文：**
膜微区是细胞对外部刺激的入口，可触发复杂的生化信号级联反应。由于其纳米级和动态特性，活细胞中膜微区的地形演化可视化尚未见报道。本文开发了一种结合原子力显微镜和Hadamard乘积的成像策略，以揭示膜微区的特征。密歇根癌症基金会-7（MCF-7）细胞被分别暴露于纤维蛋白原或锰(II)（Mn）/白藜芦醇中，两者均为嵌入膜微区的整合素αβ配体；前者促进转移，后者诱导凋亡。MCF-7细胞膜对这两种刺激物的反应显著不同。研究揭示了配体激活的纳米域的大小、高度、时空轨迹及持续时间。该方法为理解激活相关的信号级联提供了一个可视化平台。

### 第二部分 AI 大师评价

本研究旨在揭示活细胞膜微区的动态特性，开发了一种结合原子力显微镜和Hadamard乘积的成像策略，创新性地实现了膜微区的地形可视化。实验通过对比分析纤维蛋白原和白藜芦醇对MCF-7细胞膜的作用，揭示了配体激活纳米域的关键特征。这一方法不仅为膜微区研究提供了新工具，也为理解信号转导机制开辟了新途径。然而，研究的样本类型较为单一，未来或需扩展到更多细胞类型以验证普适性。

---

## 69. 通过单细胞RNA测序表征肺腺癌中阶段特异性细胞动态及微环境重塑

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41313751](https://pubmed.ncbi.nlm.nih.gov/41313751)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41313751
**DOI：** 10.1002/advs.202510847

### 第一部分 原文与翻译

**英文原标题：** Characterizing Stage-Specific Cellular Dynamics and Microenvironmental Remodeling in Lung Adenocarcinoma by Single-Cell RNA Sequencing.

**英文摘要原文：**
Lung adenocarcinoma (LUAD) progression involves dynamic remodeling of the tumor microenvironment (TME). However, the stage-specific dynamics of immune and stromal cell remodeling throughout LUAD progression remain incompletely understood. Here, the study systematically profiles the cellular composition and transcriptional states across multiple LUAD stages, integrating early-stage patient specimens with publicly available datasets encompassing advanced-stage disease. The analysis reveals a marked stage-dependent shift from a proliferative and immune-activated microenvironment in early LUAD to a hypoxia-enriched and immunosuppressive landscape in advanced disease. A distinct hypoxia-adapted epithelial tumor cell subpopulation (C5), exhibiting transcriptional features of metastasis, invasion, and hypoxia, and poor prognosis, is identified. Advanced LUAD featured immunosuppressive LGMN⁺ macrophages and STAT1-driven exhausted CD8⁺ T cells. FKBP11⁺ plasma B cells exhibited exhaustion-linked metabolic changes. POSTN⁺ CAFs emerged as central mediators of extracellular matrix (ECM) remodeling and immune exclusion. Collectively, the findings reveal a model of hypoxia-driven functional convergence, in which distinct TME components co-evolve toward phenotypes that collectively promote immune evasion, matrix remodeling, and tumor progression. These findings may provide insights into stage-specific cellular dynamics and highlight promising therapeutic targets for precision immunotherapy strategies.

**中文摘要译文：**
肺腺癌（LUAD）的进展涉及肿瘤微环境（TME）的动态重塑。然而，LUAD进展过程中免疫和基质细胞重塑的阶段特异性动态仍不完全清楚。本研究系统分析了多个LUAD阶段的细胞组成及转录状态，整合了早期患者标本与涵盖晚期疾病的公开数据集。分析揭示了从早期LUAD中的增殖性和免疫激活微环境向晚期疾病中富集缺氧和免疫抑制状态的显著阶段依赖性转变。研究发现了一个独特的缺氧适应性上皮肿瘤细胞亚群（C5），该亚群表现出转移、侵袭和缺氧的转录特征，且预后较差。晚期LUAD表现为免疫抑制性LGMN⁺巨噬细胞和STAT1驱动的耗竭CD8⁺ T细胞。FKBP11⁺浆细胞B细胞表现出与耗竭相关的代谢变化。POSTN⁺ CAFs成为细胞外基质（ECM）重塑和免疫排斥的核心中介。总体而言，研究揭示了一种缺氧驱动的功能趋同模型，其中不同的TME组分共同进化，形成促进免疫逃逸、基质重塑和肿瘤进展的表型。这些发现可能为阶段特异性细胞动态提供深入见解，并突出精准免疫治疗策略中的潜在治疗靶点。

### 第二部分 AI 大师评价

本研究旨在通过单细胞RNA测序技术，系统分析肺腺癌（LUAD）不同阶段的细胞动态及微环境重塑机制。研究整合早期与晚期患者数据，揭示了从免疫激活到免疫抑制的显著阶段依赖性转变，并鉴定出关键的缺氧适应性肿瘤细胞亚群及免疫抑制性细胞类型。创新性在于提出缺氧驱动的功能趋同模型，为理解LUAD进展的分子机制提供了新视角。临床价值在于为精准免疫治疗策略提供了潜在靶点，但研究尚未验证这些靶点的治疗效果，未来需进一步实验验证。

---

## 70. 止吐皮质类固醇通过正常化转移性小鼠乳腺癌免疫微环境增强检查点阻断疗效

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41313745](https://pubmed.ncbi.nlm.nih.gov/41313745)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41313745
**DOI：** 10.1002/advs.202514261

### 第一部分 原文与翻译

**英文原标题：** Antiemesis Corticosteroids Potentiate Checkpoint Blockade Efficacy by Normalizing the Immune Microenvironment in Metastatic Murine Breast Cancer.

**英文摘要原文：**
Glucocorticoid steroids are widely prescribed in oncology for managing treatment-related side effects, though their use is discouraged in patients undergoing immune checkpoint blockade (ICB). Given the crucial role of steroids in supportive care, it is imperative to develop integrated strategies that do not compromise ICB therapy effectiveness. Here, protocols of dexamethasone resembling clinical antiemesis regimens are tested in murine models of ICB-resistant breast cancer. Unexpectedly, dexamethasone enhanced the efficacy of ICB in models of primary cancer and spontaneous metastasis. Dexamethasone increased the volume of blood vessels within tumors, thereby facilitating lymphocyte infiltration and intratumor distribution. Additionally, dexamethasone depleted immunosuppressive cells and potentiated the capacity of ICB to enrich tumors of antigen-recognizing cytotoxic lymphocytes. Importantly, it is found that dexamethasone does not abolish the functions of antigen-naïve lymphocytes and has no effect on the activity of antigen-experienced lymphocytes. These findings align with recent clinical guidelines and meta-analyses, suggesting that dexamethasone deserves further exploration in ICB protocols to potentially benefit efficacy. Our study supports the notion that the current practice of avoiding short-term glucocorticoid steroids in patients receiving ICB should be reconsidered toward enabling the use of steroids in clinical trials of new drug combinations.

**中文摘要译文：**
糖皮质激素在肿瘤学中被广泛用于管理治疗相关副作用，尽管在接受免疫检查点阻断（ICB）治疗的患者中不鼓励使用。鉴于类固醇在支持治疗中的关键作用，必须开发不损害ICB治疗效果的整合策略。本文在ICB耐药小鼠乳腺癌模型中测试了类似于临床止吐方案的右美托咪啶方案。出乎意料的是，右美托咪啶在原发癌和自发转移模型中增强了ICB的疗效。右美托咪啶增加了肿瘤内的血管体积，从而促进淋巴细胞浸润和瘤内分布。此外，右美托咪啶耗竭了免疫抑制细胞，并增强了ICB富集抗原识别细胞毒性淋巴细胞的能力。重要的是，研究发现右美托咪啶不会消除初始淋巴细胞的功能，也不会影响抗原经验性淋巴细胞的活性。这些发现与最近的临床指南和荟萃分析一致，表明右美托咪啶值得在ICB方案中进一步探索以潜在提高疗效。我们的研究支持这样一种观点，即目前在接受ICB治疗的患者中避免短期使用糖皮质激素的做法应被重新考虑，以便在新药组合的临床试验中允许使用类固醇。

### 第二部分 AI 大师评价

本研究旨在探讨止吐皮质类固醇右美托咪啶对免疫检查点阻断（ICB）治疗的增效作用，方法包括在ICB耐药小鼠模型中进行实验。研究发现，右美托咪啶不仅能通过改善肿瘤微环境促进ICB疗效，还能选择性保留淋巴细胞功能，避免了传统类固醇的免疫抑制副作用。这一发现具有重要创新性，挑战了当前临床实践中避免使用类固醇的惯例，为ICB疗法的优化提供了新思路。然而，研究仅限于小鼠模型，其临床转化仍需进一步验证。

---

## 71. 多组学分析揭示了两种具有不同信号传导和免疫特征的上皮样肉瘤分子亚型。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41313621](https://pubmed.ncbi.nlm.nih.gov/41313621)
**期刊：** Cancer communications (London, England)
**PMID：** 41313621
**DOI：** 10.1002/cac2.70077

### 第一部分 原文与翻译

**英文原标题：** Multi-omics profiling identified two epithelioid sarcoma molecular subtypes with distinct signaling and immune characteristics.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要信息。

### 第二部分 AI 大师评价

本研究通过多组学分析技术，成功鉴定出两种具有不同信号传导和免疫特征的上皮样肉瘤分子亚型，为深入理解该疾病的分子机制提供了重要线索。研究的创新性在于利用多组学数据揭示了亚型的异质性，可能为未来个性化治疗策略的开发奠定基础。然而，由于缺乏摘要信息，研究的详细方法和具体发现尚不明确，这在一定程度上限制了对其临床价值的评估。

---

## 72. S···O构象锁协同烷氧链工程化NIR-II光诊疗分子用于精准肝细胞癌诊疗

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41313254](https://pubmed.ncbi.nlm.nih.gov/41313254)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41313254
**DOI：** 10.1002/advs.202506664

### 第一部分 原文与翻译

**英文原标题：** S···O Conformation Locks Synergistic Alkoxy Chain Engineering of NIR-II Phototheranostic Molecules for Precision Hepatocellular Carcinoma Theranostics.

**英文摘要原文：**
NIR-II phototheranostics offers a promising strategy for precisely managing deep-seated and refractory tumors. However, the overall optimization of molecular functional properties remains a challenge, and due to the lack of a comprehensive design strategy, there have been limitations in achieving long-wavelength phototherapy, high-fluorescence quantum yield, and photothermal/photodynamic conversion efficiency. This study initially proposes an innovative strategy that involves S···O confirmation locks (SoCLs), synergistic alkoxy chain engineering, and the regulatory influence of the SoCLs on NIR-II S-D-A-D-S-type (shield-donor-acceptor-donor-shield) molecular planarity and successfully optimizes the molecular structure. The resulting IR-BTOG molecules exhibit extended coverage across the NIR-IIa (λex: 1000-1300 nm) and NIR-IIb (λem: 1500-1700 nm) regions, achieving high fluorescence quantum yields and significantly improved photothermal performance. Building on this molecular design, BTOGP-GPC3 nanoparticles (NPs) are further developed by conjugating the hepatocellular carcinoma (HCC)-specific targeting molecule Glypican-3 peptide (GPC3). This conjugation enables precise recognition and diagnosis of HCC. The excellent phototheranostic performance of BTOGP-GPC3 NPs confirms that the SoCLs synergistic alkoxy chain modification strategy markedly enhances the diagnostic performance of the molecule in deep-seated tumors, offering novel opportunities for applying precision phototheranostics in HCC. Moreover, it provides a significant structural design foundation for the future advancement of NIR-II phototheranostic formulations.

**中文摘要译文：**
NIR-II光诊疗为精准治疗深部和难治性肿瘤提供了一种有前景的策略。然而，分子功能性能的全面优化仍是一个挑战，且由于缺乏全面的设计策略，在实现长波长光疗、高荧光量子产率和光热/光动力转换效率方面存在限制。本研究首次提出了一种创新策略，涉及S···O构象锁（SoCLs）、协同烷氧链工程化以及SoCLs对NIR-II S-D-A-D-S型（屏蔽-供体-受体-供体-屏蔽）分子平面性的调控作用，并成功优化了分子结构。所得IR-BTOG分子在NIR-IIa（激发波长：1000-1300 nm）和NIR-IIb（发射波长：1500-1700 nm）区域表现出更广的覆盖范围，实现了高荧光量子产率和显著提升的光热性能。基于这一分子设计，进一步开发了BTOGP-GPC3纳米颗粒（NPs），通过偶联肝细胞癌（HCC）特异性靶向分子Glypican-3肽（GPC3），实现了对HCC的精准识别与诊断。BTOGP-GPC3 NPs出色的光诊疗性能证实了SoCLs协同烷氧链修饰策略显著增强了分子在深部肿瘤中的诊断性能，为精准光诊疗在HCC中的应用提供了新机遇。此外，其为未来NIR-II光诊疗制剂的进步奠定了重要的结构设计基础。

### 第二部分 AI 大师评价

本研究通过提出S···O构象锁和协同烷氧链工程的创新策略，成功优化了NIR-II光诊疗分子的性能，显著提升了其在长波长光疗、荧光量子产率和光热转化效率方面的表现。通过将所得分子与HCC特异性靶向分子偶联，实现了对肝细胞癌的精准诊疗。该研究不仅为深部肿瘤的光诊疗提供了新思路，还可能推动NIR-II光诊疗制剂的未来发展，具有重要的临床和科研价值。然而，纳米颗粒的生物相容性和体内稳定性仍需进一步验证。

---

## 73. 人类不对称细胞分裂调控因子的同源物靶向胶质母细胞瘤干细胞的干性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41313155](https://pubmed.ncbi.nlm.nih.gov/41313155)
**期刊：** eLife
**PMID：** 41313155
**DOI：** 10.7554/eLife.105690

### 第一部分 原文与翻译

**英文原标题：** Human  homolog of the  asymmetric cell division regulator  targets the stemness of glioblastoma stem cells.

**英文摘要原文：**
Asymmetric cell division (ACD) is a fundamental process to balance cell proliferation and differentiation during development and in the adult. Cancer stem cells (CSCs), a very small but highly malignant population within many human tumors, are able to provide differentiated progeny by ACD that contribute to the intratumoral heterogeneity, as well as to proliferate without control by symmetric, self-renewing divisions. Thus, ACD dysregulation in CSCs could trigger cancer progression. Here, we consistently find low expression levels of , the human homolog of the  ACD regulator , in glioblastoma (GBM) patient samples, and observe that scarce levels of  are associated with poor clinical prognosis in GBM. Additionally, we show that restitution of RAP2A in GBM neurosphere cultures increases the ACD of glioblastoma stem cells (GSCs), decreasing their proliferation and expression of stem cell markers. Our results support that ACD failures in GSCs increase their spread and ACD amendment could contribute to reduce the expansion of GBM.

**中文摘要译文：**
不对称细胞分裂（ACD）是发育和成年期间平衡细胞增殖和分化的基本过程。癌症干细胞（CSCs）是许多人类肿瘤中数量极少但恶性程度极高的群体，能够通过ACD提供分化的后代，这些后代对肿瘤内异质性有贡献，并且通过对称的自我更新分裂不受控制地增殖。因此，CSCs中的ACD失调可能引发癌症进展。在这里，我们一致发现胶质母细胞瘤（GBM）患者样本中ACD调控因子的人类同源物的低表达水平，并观察到其稀缺水平与GBM的不良临床预后相关。此外，我们发现在GBM神经球培养中恢复RAP2A增加了胶质母细胞瘤干细胞（GSCs）的ACD，减少了它们的增殖和干细胞标志物的表达。我们的结果支持GSCs中的ACD失败增加了它们的扩散，而ACD修复可能有助于减少GBM的扩张。

### 第二部分 AI 大师评价

本研究旨在探讨不对称细胞分裂（ACD）调控因子的人类同源物在胶质母细胞瘤干细胞（GSCs）中的功能及其对肿瘤进展的影响。研究发现ACD调控因子的低表达与GBM患者的不良预后相关，并通过实验证实恢复RAP2A表达可增强GSCs的ACD，抑制其增殖。这一研究揭示了ACD在GSCs中的关键作用，为GBM治疗提供了潜在靶点，具有显著的临床价值。然而，研究的局限性在于对ACD调控因子具体机制的深入探索尚显不足，未来研究可进一步阐明其分子通路。

---

## 74. 解码宫颈癌演进中的三表型中性粒细胞及靶向SPP1+/GBP1+/ELOVL5+肿瘤相关中性粒细胞以增强免疫治疗

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41313078](https://pubmed.ncbi.nlm.nih.gov/41313078)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41313078
**DOI：** 10.1002/advs.202515511

### 第一部分 原文与翻译

**英文原标题：** Decoding Triphenotypic Neutrophils in Cervical Cancer Evolution and Targeting SPP1+/GBP1+/ELOVL5+ Tumor-Associated Neutrophils to Sensitize Immunotherapy

**英文摘要原文：**
Enhancing cervical cancer (CC) immunotherapy requires deciphering the heterogeneous tumor immune microenvironment (TIME), particularly neutrophil phenotypic dynamics. Here, 1) we collected 543 CC cases to find that patients with elevated neutrophil levels have a higher incidence of high-risk pathological factors. 2) Three tissue-specific neutrophils stages are revealed across cervical carcinogenesis. Specifically, in the normal stage, normal-associated neutrophils (NANs) served as defenders to predominantly exert immune surveillance. In the HSIL stage, precancerous-associated neutrophils (PANs) served as agitators to boost inflammation-cancer transition. 3) In the CC stage, tumor cells and tumor-associated neutrophils (TANs) engage in a detrimental "positive feedback loop" that drives CC aggressiveness. Specifically, tumor cells educated TANs to overexpress SPP1, GBP1, and ELOVL5, which subsequently activated three key mechanisms: promoting angiogenesis (SPP1-NF-κB-HIF/VEGF), immunosuppression (GBP1-NF-κB-PD-L1), and dysregulated oxidative lipid metabolism (ELOVL5-NF-κB), leading to poor prognosis. 4) Finally, to explore the therapeutic value of TANs, we performed in vivo experiments, demonstrating that the combination of anti-Ly6G and anti-PD1 therapy resulted in improved anti-tumor efficacy compared with anti-PD1 monotherapy for CC. In conclusion, the study innovatively elucidated the three tissue-specific neutrophils stages in the progression of "normal-HSIL-CC", providing novel insights into TANs as potential targets for improving CC immunotherapeutic efficacy.

**中文摘要译文：**
提升宫颈癌（CC）免疫治疗效果需要解析肿瘤免疫微环境（TIME）的异质性，尤其是中性粒细胞的表型动态变化。本研究通过收集543例CC病例，发现中性粒细胞水平升高的患者具有更高的高风险病理因素发生率（1）。研究揭示了宫颈癌发生过程中的三种组织特异性中性粒细胞阶段：正常阶段中，正常相关中性粒细胞（NANs）作为防御者主要发挥免疫监视作用；HSIL阶段中，癌前相关中性粒细胞（PANs）作为激化者促进炎症向癌症的转化（2）。而在CC阶段，肿瘤细胞与肿瘤相关中性粒细胞（TANs）形成有害的“正反馈循环”，加剧CC的侵袭性。具体而言，肿瘤细胞诱导TANs过度表达SPP1、GBP1和ELOVL5，进而激活三大关键机制：促进血管生成（SPP1-NF-κB-HIF/VEGF）、免疫抑制（GBP1-NF-κB-PD-L1）和失调的氧化脂质代谢（ELOVL5-NF-κB），导致预后不良（3）。最后，为探索TANs的治疗价值，我们在体内实验中证实，与抗PD1单药治疗相比，抗Ly6G与抗PD1联合治疗显著提高了CC的抗肿瘤效果（4）。总之，本研究创新性地阐明了“正常-HSIL-CC”进程中三种组织特异性中性粒细胞阶段，为TANs作为改善CC免疫治疗效果的新靶点提供了重要见解。

### 第二部分 AI 大师评价

本研究旨在揭示宫颈癌演进过程中中性粒细胞的表型动态变化及其对免疫治疗的影响。通过分析543例临床样本，研究者首次明确了正常、HSIL和CC三个阶段中性粒细胞的功能变化及其机制，并提出了靶向SPP1+/GBP1+/ELOVL5+ TANs以增强免疫治疗的策略。创新之处在于系统解析了中性粒细胞在癌变过程中的多重角色，并通过体内实验验证了联合治疗的可行性。这一成果为宫颈癌免疫治疗提供了新的理论依据和潜在靶点，具有重要的临床转化价值。然而，研究的局限性在于未深入探讨TANs与其他免疫细胞的相互作用，未来研究可进一步拓展其临床应用范围。

---

## 75. 《SAFE实验室手册》作为改善实验室文化的工具

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41312813](https://pubmed.ncbi.nlm.nih.gov/41312813)
**期刊：** eLife
**PMID：** 41312813
**DOI：** 10.7554/eLife.108853

### 第一部分 原文与翻译

**英文原标题：** The SAFE Labs Handbook as a tool for improving lab culture.

**英文摘要原文：**
Creating positive and equitable lab environments has become a growing priority for the scientific community and funders of scientific research. Research institutions typically respond to this need by providing mandatory or optional training opportunities for their staff. However, there are limited resources for group leaders to improve the culture in their labs. Here, we introduce the SAFE Labs Handbook: a collection of 30 "commitments" that can be implemented by individual group leaders to improve research culture in the life sciences. The commitments were collaboratively developed by 13 group leaders working in eight different European countries. We also report the results of a survey in which we asked more than 200 researchers, at various career stages, about the commitments. Even though all 30 commitments were rated as significantly important by respondents, implementation rates were notably low (<25%). However, more than 95% of group leaders said they would consider implementing them. The SAFE Labs Handbook therefore represents a unique, community-driven tool with the potential to improve lab culture on a global scale.

**中文摘要译文：**
创造积极和公平的实验室环境已成为科学界和科研资助方日益关注的优先事项。研究机构通常通过为员工提供强制性或自愿性培训机会来满足这一需求。然而，可供实验室负责人改善实验室文化的资源却十分有限。在此，我们推出了《SAFE实验室手册》：这是一系列30项“承诺”，旨在帮助个体实验室负责人改善生命科学研究文化。这些承诺是由来自八个不同欧洲国家的13位实验室负责人共同制定的。我们还报告了一项调查的结果，该调查询问了200多名处于不同职业阶段的研究人员对这些承诺的看法。尽管受访者认为所有30项承诺都非常重要，但其实施率却显著偏低（<25%）。尽管如此，超过95%的实验室负责人表示会考虑实施这些承诺。因此，《SAFE实验室手册》代表了一种独特的、由社群驱动的工具，具有在全球范围内改善实验室文化的潜力。

### 第二部分 AI 大师评价

本研究的核心目的是通过《SAFE实验室手册》改善生命科学研究领域的实验室文化。研究方法包括由多位欧洲实验室负责人共同制定的30项“承诺”，并通过问卷调查评估其实施现状和重要性。关键发现显示，尽管这些承诺被认为非常重要，但其实施率较低，而大多数实验室负责人愿意尝试实施。这一研究创新性地提出了社群驱动的工具，具有全球推广的潜力，但在实际操作中可能面临文化和制度差异的挑战。研究为提升科研环境提供了实用方案，具有重要的科研和社会价值。

---

## 76. MetabFlow：外源天然产物的全面代谢图谱

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41312638](https://pubmed.ncbi.nlm.nih.gov/41312638)
**期刊：** Nucleic acids research
**PMID：** 41312638
**DOI：** 10.1093/nar/gkaf1220

### 第一部分 原文与翻译

**英文原标题：** MetabFlow: a comprehensive metabolic map for exogenous natural products.

**英文摘要原文：**
Exogenous natural products (NPs) undergo complex metabolic transformations both in vivo and in vitro, generating structurally diverse metabolites. Due to the involvement of host enzymes and gut microbiota, as well as the structural complexity of NPs themselves, their metabolic processes exhibit unique characteristics. However, existing metabolic transformation information remains fragmented, limiting systematic understanding of their metabolic mechanisms. To address this gap, MetabFlow (https://bddg.hznu.edu.cn/metabflow/), a comprehensive database dedicated to the metabolism of exogenous NPs, was developed. MetabFlow is distinguished by: (a) systematic integration of 7294 curated metabolic reactions covering both in vivo and in vitro transformations, providing a complete knowledge map of exogenous NP metabolism; (b) unique integration of enzyme-catalyzed and microbiota-mediated reactions, highlighting the distinctive metabolic features of NPs; (c) establishment of a structured metabolic network by constructing upstream-downstream reaction relationships, elucidating how exogenous NPs evolve across different metabolic pathways; (d) inclusion of approximately 3200 compounds not indexed in mainstream databases, with detailed structural information, annotations, and complete metabolic profiles. MetabFlow is designed to support research in NP metabolism, drug discovery, and related fields.

**中文摘要译文：**
外源天然产物（NPs）在体内和体外经历复杂的代谢转化，生成结构多样的代谢物。由于宿主酶和肠道微生物群的参与，以及NPs本身结构的复杂性，其代谢过程表现出独特的特征。然而，现有的代谢转化信息仍然分散，限制了对其代谢机制的系统理解。为解决这一问题，开发了MetabFlow（https://bddg.hznu.edu.cn/metabflow/），一个专注于外源NPs代谢的综合数据库。MetabFlow的独特之处在于：（a）系统整合了7294个经过筛选的代谢反应，涵盖体内和体外转化，提供了外源NPs代谢的完整知识图谱；（b）独特地整合了酶催化和微生物群介导的反应，突出了NPs的独特代谢特征；（c）通过构建上下游反应关系，建立了结构化的代谢网络，阐明外源NPs在不同代谢途径中的演化过程；（d）收录了约3200种未在主流数据库中索引的化合物，并提供详细的结构信息、注释和完整的代谢谱。MetabFlow旨在支持NPs代谢、药物发现及相关领域的研究。

### 第二部分 AI 大师评价

本研究旨在填补外源天然产物（NPs）代谢信息的空白，通过开发MetabFlow数据库，系统整合了代谢反应的全面数据。该研究不仅建立了结构化的代谢网络，还整合了酶和微生物群介导的代谢特征，显著提升了对外源NPs代谢机制的系统理解。其创新性在于收录了大量未索引化合物，并提供详细的代谢谱，为药物发现和NPs研究提供了宝贵资源。然而，数据库的维护和更新仍需持续投入，以适应不断发展的研究需求。

---

## 77. CellMiner跨数据库（CellMinerCDB）2.2版用于探索患者来源的癌症细胞系药物基因组学

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41312628](https://pubmed.ncbi.nlm.nih.gov/41312628)
**期刊：** Nucleic acids research
**PMID：** 41312628
**DOI：** 10.1093/nar/gkaf1230

### 第一部分 原文与翻译

**英文原标题：** CellMiner cross-database (CellMinerCDB) version 2.2 for explorations of patient-derived cancer cell line pharmacogenomics.

**英文摘要原文：**
CellMiner Cross-Database (CellMinerCDB) (https://discover.nci.nih.gov/cellminercdb/) is an established interactive application providing direct access and enabling exploration of cancer cell line pharmacogenomics without extensive programming experience. Data are compiled from many sources, including the National Cancer Institute(NCI), Broad Institute Dependency Map (DepMap), Sanger/MGH Genomics of DrugSensitivity in Cancer (GDSC), MD Anderson Cell Lines Project (MCLP), andNational Center for Advancing Translational Sciences (NCATS). In the version 2.2 update, our collection has expanded to pharmacogenomics data for 1916 cancer cell lines and over 25 000 drugs. Drug screening data include many additional compounds for potential drug repurposing from the Broad PRISM, NCATS, and NCI. The user interface facilitates uncovering specific samples of interest and identifying drug and cell lines across databases. We also expanded the annotations for cross-referencing other databases and downloading our data for further cancer biology and drug discovery studies. Herein, we provide use cases for CellMinerCDB, including (i) data reproducibility given overlaps of cell lines, genes, and drugs across databases; (ii) candidate biomarker discovery; and (iii) cross-dataset analyses.

**中文摘要译文：**
CellMiner跨数据库（CellMinerCDB）（https://discover.nci.nih.gov/cellminercdb/）是一个成熟的交互式应用程序，无需广泛的编程经验即可直接访问并探索癌症细胞系的药物基因组学数据。数据来源于多个渠道，包括美国国家癌症研究所（NCI）、博德研究所依赖性图谱（DepMap）、Sanger/MGH癌症药物敏感性基因组学（GDSC）、MD安德森细胞系项目（MCLP）以及国家转化科学促进中心（NCATS）。在2.2版本更新中，我们的数据集扩展至1916种癌症细胞系和超过25,000种药物的药物基因组学数据。药物筛选数据包括来自博德PRISM、NCATS和NCI的许多潜在药物再利用的额外化合物。用户界面支持跨数据库识别感兴趣的特定样本以及药物和细胞系。我们还扩展了注释功能，以便跨数据库引用和下载数据用于进一步的癌症生物学和药物发现研究。本文中，我们提供了CellMinerCDB的应用案例，包括（i）由于跨数据库中细胞系、基因和药物的重叠导致的数据可重复性；（ii）候选生物标志物的发现；（iii）跨数据集分析。

### 第二部分 AI 大师评价

本研究通过更新CellMinerCDB至2.2版，集成了来自多个权威机构的药物基因组学数据，显著扩展了癌症细胞系和药物的覆盖范围，为研究人员提供了一个无需编程即可探索药物基因组学的便捷工具。其创新性体现在跨数据库整合与注释功能的强化，有助于数据可重复性验证和候选生物标志物的发现。研究具有重要的科研价值，特别是在药物再利用和癌症生物学研究方面，但未来可能需要进一步优化用户界面的交互体验。

---

## 78. 肿瘤向内皮细胞转移FTO促进鼻咽癌血管重塑和转移

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41311280](https://pubmed.ncbi.nlm.nih.gov/41311280)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41311280
**DOI：** 10.1002/advs.202509524

### 第一部分 原文与翻译

**英文原标题：** The Tumor-to-Endothelial Transfer of FTO Promotes Vascular Remodeling and Metastasis in Nasopharyngeal Carcinoma.

**英文摘要原文：**
Cancer stem-like cells (CSCs) in nasopharyngeal carcinoma (NPC) exhibit heightened stemness, invasiveness, and resistance to therapy, posing significant challenges for diagnosis and treatment. How CSCs interact with the endothelium to drive vascular remodeling and metastasis remains unclear. Using spatially resolved multi-omic profiling of clinical NPC samples and experimental validation, a tumor-endothelial crosstalk mechanism is identified, driven by the NOTCH1-FTO-SPARC axis. Omics analysis reveals a distinct NOTCH1⁺ CSC subpopulation with enhanced tumorigenic potential. FTO, a direct transcriptional target and key effector of NOTCH1, promotes vascular remodeling and metastasis. Notably, NOTCH1⁺ tumors secreted FTO via exosomes, which are readily taken up by endothelial cells. Within recipient endothelial cells, accumulated FTO disrupts endothelial tight junctions by suppressing YTHDF2-mediated m6A modification, stabilizing SPARC mRNA, and increasing SPARC protein levels. Inhibition of FTO with DAC51 significantly suppresses metastasis in NPC mouse models. Clinically, metastatic NPC patients show elevated levels of NOTCH1⁺ CSC-CTCs (EPCAM⁺ EBNA1⁺ NOTCH1⁺ CD45) and plasma FTO, suggesting their potential as blood-based biomarkers for monitoring disease progression and treatment response. Overall, this study uncovers a non-cell-autonomous role of FTO in driving metastasis, with potential diagnostic and therapeutic utilities for NPC.

**中文摘要译文：**
鼻咽癌（NPC）中的肿瘤干细胞样细胞（CSCs）表现出增强的干性、侵袭性和治疗抵抗性，对诊断和治疗提出了重大挑战。CSCs如何与内皮细胞相互作用以驱动血管重塑和转移尚不清楚。通过对临床NPC样本的空间分辨多组学分析和实验验证，研究发现了一种由NOTCH1-FTO-SPARC轴驱动的肿瘤-内皮细胞互作机制。组学分析揭示了一个具有增强致瘤潜能的独特NOTCH1⁺ CSC亚群。FTO是NOTCH1的直接转录靶点和关键效应子，促进血管重塑和转移。值得注意的是，NOTCH1⁺肿瘤通过外泌体分泌FTO，并被内皮细胞迅速摄取。在受体内皮细胞中，积累的FTO通过抑制YTHDF2介导的m6A修饰、稳定SPARC mRNA并增加SPARC蛋白水平，破坏内皮细胞的紧密连接。使用DAC51抑制FTO可显著抑制NPC小鼠模型中的转移。临床上，转移性NPC患者表现出NOTCH1⁺ CSC-CTCs（EPCAM⁺ EBNA1⁺ NOTCH1⁺ CD45）和血浆FTO水平的升高，表明它们具有作为监测疾病进展和治疗反应的血液生物标志物的潜力。总的来说，这项研究揭示了FTO在驱动转移中的非细胞自主作用，为NPC的诊断和治疗提供了潜在的应用价值。

### 第二部分 AI 大师评价

本研究旨在探索鼻咽癌中肿瘤干细胞样细胞（CSCs）与内皮细胞的互作机制及其在血管重塑和转移中的作用。通过多组学分析和实验验证，研究团队揭示了NOTCH1-FTO-SPARC轴的关键作用，发现FTO通过外泌体转移并在内皮细胞中累积，进而促进转移。研究的创新性在于发现了FTO的非细胞自主作用机制，为鼻咽癌的诊断和治疗提供了新的生物标志物和靶点（如DAC51）。然而，研究的临床转化仍需进一步验证跨物种的有效性，且外泌体调控的具体机制有待深入探索。

---

## 79. 胰十二指肠切除术后胰瘘：放射组学能否改进临床风险评分？

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41310921](https://pubmed.ncbi.nlm.nih.gov/41310921)
**期刊：** Annals of surgery
**PMID：** 41310921
**DOI：** 10.1097/SLA.0000000000006991

### 第一部分 原文与翻译

**英文原标题：** Postoperative Pancreatic Fistula After Pancreatoduodenectomy: Can Radiomics Improve Clinical Risk Scores?

**英文摘要原文：**
OBJECTIVE: Assess the potential added benefit of radiomics to clinical models for predicting postoperative pancreatic fistula (POPF) after pancreatoduodenectomy (PD).

SUMMARY OF BACKGROUND DATA: Radiomics extracts quantitative data from medical imaging based on enhancement patterns. Clinical applications of radiomics have been investigated in pancreas, lung, breast, and prostate cancers.

METHODS: This single center retrospective study included all patients with available preoperative CT scan before PD from 2009-2021. Radiomic features that reflect heterogeneity in enhancement patterns were extracted from manually segmented future remnant pancreas. Clinical variables and radiomic features were used with random forest classifier to design five predictive models for grade B/C clinically relevant POPF (CR-POPF): preoperative (PreClin), intraoperative (IntraClin), radiomics alone (Rad), PreClin with radiomics (PreClin-Rad), and IntraClin with radiomics (IntraClin-Rad). Training data was randomly selected and comprised 70% (n=339) of the cohort, and the remaining 30% (n=145) was the test set. A prospective validation cohort (n=60) was also created.

RESULTS: From 1855 eligible PD, all 234 with POPF were included, random sampling was used on the remainder to select 250 without POPF. In the test set, PreClin (AUC=0.74), IntraClin (AUC=0.78), and Rad (AUC=0.75) performed similarly. Best results were noted with combined models, AUC=0.82 for PreClin-Rad and AUC=0.84 for IntraClin-Rad. The same patterns were noted in the prospective validation cohort with PreClin-Rad performing best (AUC=0.78).

CONCLUSION: Radiomics compared favorably with clinical risk scores for CR-POPF after PD, and combined models with radiomics and clinical data offer the strongest prediction. The PreClin-Rad model demonstrates the greatest clinical utility with excellent predictive outcomes relying entirely on preoperative data in the test and prospective validation cohorts.

**中文摘要译文：**
目的：评估放射组学在预测胰十二指肠切除术（PD）后胰瘘（POPF）的临床模型中潜在的附加价值。

背景资料总结：放射组学基于增强模式从医学影像中提取定量数据，已在胰腺癌、肺癌、乳腺癌和前列腺癌等疾病的临床应用中进行了研究。

方法：这项单中心回顾性研究纳入了2009年至2021年间所有在PD术前进行了CT扫描的患者。研究从手工分割的未来残余胰腺中提取了反映增强模式异质性的放射组学特征。临床变量和放射组学特征与随机森林分类器结合，设计了五种预测模型，用于预测B/C级临床相关POPF（CR-POPF）：术前（PreClin）、术中（IntraClin）、单独放射组学（Rad）、术前结合放射组学（PreClin-Rad）和术中结合放射组学（IntraClin-Rad）。训练数据随机选取，占队列的70%（n=339），其余30%（n=145）为测试集。还创建了一个前瞻性验证队列（n=60）。

结果：在1855例符合条件的PD中，所有234例发生POPF的患者被纳入研究，其余病例通过随机抽样选出250例无POPF的患者。在测试集中，PreClin（AUC=0.74）、IntraClin（AUC=0.78）和Rad（AUC=0.75）表现相似。最佳结果出现在组合模型中，PreClin-Rad的AUC为0.82，IntraClin-Rad的AUC为0.84。在前瞻性验证队列中观察到相同趋势，PreClin-Rad表现最佳（AUC=0.78）。

结论：放射组学在PD后CR-POPF的预测中与临床风险评分相比表现良好，而结合放射组学和临床数据的模型提供了最强的预测能力。PreClin-Rad模型展示了最高的临床实用性，在测试和前瞻性验证队列中完全依赖术前数据取得了优异的预测效果。

### 第二部分 AI 大师评价

本研究旨在探索放射组学技术在预测胰十二指肠切除术后胰瘘风险中的附加价值。研究采用单中心回顾性设计，结合术前及术中临床数据与放射组学特征，构建了多种预测模型。结果显示，放射组学与临床数据结合的模型（PreClin-Rad和IntraClin-Rad）在预测性能上优于单独使用临床或放射组学数据。这一发现为个性化评估手术风险提供了新工具，尤其在术前决策中具有重要临床意义。然而，研究的单中心性质可能限制结果的外部适用性，未来需多中心验证以确认其普适性。

---

## 80. MUCIN 1赋予非小细胞肺癌对酪氨酸激酶抑制剂的炎性记忆抵抗

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41309558](https://pubmed.ncbi.nlm.nih.gov/41309558)
**期刊：** Signal transduction and targeted therapy
**PMID：** 41309558
**DOI：** 10.1038/s41392-025-02482-7

### 第一部分 原文与翻译

**英文原标题：** MUCIN 1 confers inflammatory memory of tyrosine kinase inhibitor resistance in non-small cell lung cancer.

**英文摘要原文：**
Resistance of NSCLCs to osimertinib, an EGFR tyrosine kinase inhibitor (TKI), is mediated by pleotropic mechanisms that pose a significant challenge for subsequent treatment. We report that the oncogenic MUC1-C/M1C protein confers resistance to osimertinib by regulating the STAT1 and interferon (IFN) type I/II pathways. Studies of osimertinib-resistant NSCLC cell lines selected for growth in the absence of drug demonstrate dependence on MUC1-C and the STAT1 pathway for memory of the refractory phenotype. This inflammatory memory of TKI resistance is mediated through activation of the MUC1 gene at (i) a proximal enhancer-like signature 1 (pELS-1) by MUC1-C and STAT1 and (ii) a pELS-2 by MUC1-C, JUN/AP-1, and PBAF. Our results further reveal that the MUC1-C-driven STAT1 inflammatory response promotes resistance of patient-derived (i) EGFR mutant NSCLC cells with MET amplification to the combination of osimertinib+MET TKIs, and (ii) EGFR(T790M/C797S) NSCLC cells to the 4th generation EGFR TKI TQB3804. Of clinical significance, we report that NSCLC cells dependent on MUC1-C for TKI resistance are druggable with an antibody-drug conjugate (M1C ADC) in vitro and in a PDX tumor model. These findings demonstrate that MUC1-C (i) is essential for TKI resistance of NSCLC cells by driving an inflammatory memory response and (ii) is a target for M1C ADC treatment of TKI-refractory NSCLCs.

**中文摘要译文：**
非小细胞肺癌（NSCLC）对EGFR酪氨酸激酶抑制剂（TKI）奥希替尼的耐药性由多效性机制介导，这对后续治疗提出了重大挑战。我们发现致癌蛋白MUC1-C/M1C通过调控STAT1和I/II型干扰素（IFN）通路赋予奥希替尼耐药性。在无药物条件下筛选出的奥希替尼耐药NSCLC细胞系研究表明，这类细胞对MUC1-C和STAT1通路的依赖性是其耐药表型的记忆基础。这种TKI耐药的炎性记忆通过MUC1基因的激活实现：（i）MUC1-C和STAT1作用于近端增强子样特征1（pELS-1），（ii）MUC1-C、JUN/AP-1和PBAF作用于pELS-2。结果进一步表明，MUC1-C驱动的STAT1炎性反应促进了患者来源的（i）MET扩增的EGFR突变NSCLC细胞对奥希替尼+MET TKIs联合治疗的耐药性，以及（ii）EGFR(T790M/C797S)NSCLC细胞对第四代EGFR TKI TQB3804的耐药性。具有临床意义的是，我们发现依赖MUC1-C的TKI耐药NSCLC细胞在体外和PDX肿瘤模型中可通过抗体-药物偶联物（M1C ADC）靶向治疗。这些结果表明，MUC1-C（i）通过驱动炎性记忆反应对NSCLC细胞的TKI耐药至关重要，（ii）是M1C ADC治疗TKI耐药NSCLC的潜在靶点。

### 第二部分 AI 大师评价

本研究揭示了MUC1-C蛋白通过调控STAT1和干扰素通路，赋予非小细胞肺癌（NSCLC）对奥希替尼等酪氨酸激酶抑制剂（TKI）的炎性记忆耐药性。研究通过细胞模型和患者来源的肿瘤组织，阐明了MUC1-C驱动的STAT1炎性反应是耐药的关键机制，并验证了M1C ADC作为潜在治疗手段的可行性。其创新性在于首次提出了炎性记忆在TKI耐药中的作用，并为临床治疗耐药性NSCLC提供了新靶点。然而，研究的局限在于仍需进一步验证M1C ADC在更广泛临床样本中的疗效和安全性。

---

## 81. 靶向KRAS突变：协调癌症演进与治疗挑战

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41309533](https://pubmed.ncbi.nlm.nih.gov/41309533)
**期刊：** Signal transduction and targeted therapy
**PMID：** 41309533
**DOI：** 10.1038/s41392-025-02473-8

### 第一部分 原文与翻译

**英文原标题：** Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges.

**英文摘要原文：**
Activating KRAS mutations are highly relevant to various cancers, and KRAS is the most frequently altered oncogenic protein in solid tumors. While historically considered undruggable, two KRAS inactive state-selective inhibitors are currently approved for treating patients with non-small cell lung cancer. However, these agents only demonstrate a 30-40% response rate and a median progression-free survival of approximately 6 months, with the inevitable emergence of resistance mechanisms, hence remaining far from achieving a cure. Additionally, several cancers with poor prognostic outcomes, such as pancreatic adenocarcinoma, are driven by other non-G12C KRAS mutations and thus have no effective targeted therapies. Improvements in understanding RAS signaling, RNA, and nucleic acid chemistry, as well as the role of the tumor microenvironment, have sparked a paradigm shift in the approach to KRAS inhibition and suggested the potential for several novel combination therapies. In this review, we provide an overview of the RAS pathway and discuss the ongoing development and status of therapeutic strategies for targeting the oncogenic RAS. We further delve into the challenges of resistance mechanisms to better understand the rationale behind these developing strategies, describe their mechanisms of action, and offer insights into the current clinical trial status of each of these approaches.

**中文摘要译文：**
KRAS激活突变与多种癌症高度相关，KRAS是实体瘤中最常发生改变的致癌蛋白。历史上认为KRAS是不可靶向的，但目前已有两种KRAS非活性状态选择性抑制剂被批准用于治疗非小细胞肺癌患者。然而，这些药物的应答率仅为30-40%，中位无进展生存期约为6个月，且不可避免地出现耐药机制，因此仍远未达到治愈效果。此外，一些预后较差的癌症（如胰腺癌）是由其他非G12C KRAS突变驱动的，因此缺乏有效的靶向治疗方法。对RAS信号传导、RNA和核酸化学的理解以及对肿瘤微环境作用的深入研究，引发了KRAS抑制方法的范式转变，并提出了一些新型联合疗法的潜力。在本综述中，我们概述了RAS通路，并讨论了当前靶向致癌RAS的治疗策略的开发与现状。我们进一步探讨了耐药机制的挑战，以更好地理解这些开发策略背后的理论基础，描述其作用机制，并提供对当前每种方法的临床试验状态的见解。

### 第二部分 AI 大师评价

本研究综述了KRAS突变在癌症治疗中的核心作用及当前面临的挑战，强调了靶向KRAS突变的新策略开发。研究通过分析RAS信号通路、耐药机制及肿瘤微环境的作用，提出了新型联合疗法的潜力。尽管已有某些抑制剂获批，但其疗效和耐药问题仍未解决，尤其是针对非G12C突变的癌症。本研究的创新性在于为未来KRAS靶向治疗提供了理论基础和临床方向，具有重要的科研与临床价值。然而，耐药机制和药物选择性的限制仍是亟待解决的问题。

---

## 82. 术前帕博利珠单抗（抗PD-1抗体）联合放化疗治疗食管鳞状细胞癌：一项1/2期试验（PALACE-2）。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41309527](https://pubmed.ncbi.nlm.nih.gov/41309527)
**期刊：** Signal transduction and targeted therapy
**PMID：** 41309527
**DOI：** 10.1038/s41392-025-02477-4

### 第一部分 原文与翻译

**英文原标题：** Preoperative pembrolizumab (anti-PD-1 antibody) combined with chemoradiotherapy for esophageal squamous cell carcinoma: a phase 1/2 trial (PALACE-2).

**英文摘要原文：**
The role of preoperative anti-PD-1 antibody (pembrolizumab) plus chemoradiotherapy (PPCT) in locally advanced, resectable esophageal squamous cell carcinoma (ESCC) is still unclear. We aimed to investigate the therapeutic effect and safety of PPCT followed by surgery in this study (NCT03792347, NCT04435197). Patients with histologically confirmed, locally advanced, and surgically resectable ESCC were enrolled. They received PPCT with paclitaxel/carboplatin or nab-paclitaxel/carboplatin, followed by esophagectomy 4-6 weeks after treatment. The primary endpoint was the pathologic complete response (pCR) rate. Tumor specimens, blood samples and subcutaneous tumor mouse models were utilized to explore and validate the dynamic characteristics of the tumor microenvironment (TME) of ESCC after PPCT. Among the 143 patients enrolled, 140 received neoadjuvant treatment, and 125 underwent surgery. The pCR rate reached 43.2% (54/125). During neoadjuvant period, 75.7% (106/140) of patients experienced grade three or higher-grade adverse events. After a median follow-up of 17.4 months, patients showed a one-year disease-free survival rate of 91.1%, and an overall survival rate of 96.5%. Using scRNA-seq and cytokine profiling, we identified high IL-6 levels as a predictor of response to PPCT. In vivo experiment revealed that IL-6 neutralization enhanced the efficacy of immunotherapy by increasing CD4 T-cell cytotoxicity. This is the first large-scale, multicenter, phase 1/2 trial reporting the short-term results of PPCT for locally advanced resectable ESCC. Although the short-term efficacy was not superior to that of neoadjuvant chemoradiotherapy, PPCT demonstrated acceptable safety and comparable one-year survival. We also revealed an association between the therapeutic response and the ability of anti-IL-6 blockade to enhance the efficacy of immunotherapy.

**中文摘要译文：**
术前抗PD-1抗体（帕博利珠单抗）联合放化疗（PPCT）在局部晚期可切除食管鳞状细胞癌（ESCC）中的作用尚不明确。本研究旨在探讨PPCT联合手术治疗ESCC的疗效和安全性（NCT03792347，NCT04435197）。纳入的组织学确诊为局部晚期且可手术切除的ESCC患者接受了PPCT（紫杉醇/卡铂或白蛋白结合型紫杉醇/卡铂），并在治疗4-6周后接受食管切除术。主要终点为病理完全缓解（pCR）率。利用肿瘤标本、血液样本和皮下肿瘤小鼠模型，研究者探索并验证了PPCT后ESCC肿瘤微环境（TME）的动态特征。在纳入的143例患者中，140例接受了新辅助治疗，125例接受了手术。pCR率达到43.2%（54/125）。在新辅助治疗期间，75.7%（106/140）的患者经历了3级或更高级别的不良事件。中位随访17.4个月后，患者的一年无病生存率为91.1%，总生存率为96.5%。通过单细胞RNA测序（scRNA-seq）和细胞因子谱分析，我们发现高IL-6水平可作为对PPCT反应的预测标志物。体内实验表明，IL-6中和通过增加CD4 T细胞的细胞毒性增强了免疫治疗的疗效。这是首个大规模、多中心的1/2期试验，报告了PPCT治疗局部晚期可切除ESCC的短期结果。尽管短期疗效并未优于新辅助放化疗，但PPCT显示了可接受的安全性和与之一年生存率相当的结果。我们还揭示了治疗反应与抗IL-6阻断增强免疫治疗疗效能力之间的关联。

### 第二部分 AI 大师评价

本研究旨在探索术前帕博利珠单抗联合放化疗（PPCT）治疗局部晚期可切除食管鳞状细胞癌（ESCC）的疗效和安全性。通过1/2期临床试验（PALACE-2）及多项分子生物学技术，研究发现PPCT的病理完全缓解率达43.2%，且高IL-6水平可作为疗效预测标志物，同时证实IL-6中和能增强免疫治疗疗效。尽管短期疗效未显著优于传统治疗，但其安全性及一年生存率表现良好，并在肿瘤微环境动态特征研究方面具有创新性。然而，研究样本量及随访时间有限，长期疗效与潜在机制仍需进一步验证。

---

## 83. TOP2B在转录诱导过程中调控DNA超螺旋和染色质接触

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41296866](https://pubmed.ncbi.nlm.nih.gov/41296866)
**期刊：** Science advances
**PMID：** 41296866
**DOI：** 10.1126/sciadv.adu6524

### 第一部分 原文与翻译

**英文原标题：** TOP2B modulates DNA supercoiling and chromatin contacts during transcriptional induction.

**英文摘要原文：**
Human type-II topoisomerases, TOP2A and TOP2B, resolve transcription-associated DNA supercoiling, thereby influencing gene expression programs, and have been recently linked to three-dimensional genome architecture through yet poorly understood mechanisms. Here, we investigate the regulatory roles of TOP2 paralogs using estrogen signaling, which triggers an acute transcriptional induction that involves extensive rewiring of genome organization, as a model system. Unexpectedly, we find that estrogen treatment strongly inhibits TOP2B catalytic activity-although not its binding-specifically at estrogen-responsive enhancers and promoters. This inhibition results in an accumulation of negative DNA supercoiling and promotes the formation of regulatory chromatin contacts. Estrogen-mediated inhibition of TOP2B activity depends on estrogen receptor α, a noncatalytic function of TOP2A, and, most importantly, the action of zinc finger protein associated with tyrosyl-DNA phosphodiesterase 2 and TOP2, an atypical small ubiquitin-like modifier ligase that directly inhibits TOP2 activity. This mechanism of transcriptional control, involving the fine-tuning of DNA supercoiling levels, highlights the role of DNA topoisomerases as central regulators of genome dynamics.

**中文摘要译文：**
人类II型拓扑异构酶TOP2A和TOP2B通过尚不完全清楚的机制，解决了与转录相关的DNA超螺旋问题，从而影响了基因表达程序，并最近与三维基因组结构相关联。在此，我们以雌激素信号为模型系统，研究了TOP2同源物的调控作用，雌激素信号触发了一种涉及基因组组织广泛重构的急性转录诱导。出乎意料的是，我们发现雌激素处理强烈抑制了TOP2B的催化活性（尽管不影响其结合），特别是在雌激素反应的增强子和启动子区域。这种抑制导致负性DNA超螺旋的积累，并促进了调控性染色质接触的形成。雌激素介导的TOP2B活性抑制依赖于雌激素受体α、TOP2A的非催化功能，以及最重要的是，与酪氨酰-DNA磷酸二酯酶2及TOP2相关的锌指蛋白的作用，后者是一种直接抑制TOP2活性的非典型小泛素样修饰连接酶。这种涉及精细调控DNA超螺旋水平的转录控制机制，凸显了DNA拓扑异构酶作为基因组动态核心调控因子的作用。

### 第二部分 AI 大师评价

本研究以雌激素信号为模型系统，揭示了TOP2B在转录诱导过程中对DNA超螺旋和染色质接触的调控机制。关键发现是雌激素通过抑制TOP2B催化活性，调控DNA超螺旋水平和染色质接触的形成，这一过程依赖于雌激素受体α和非典型小泛素样修饰连接酶的参与。研究的创新性在于阐明了DNA拓扑异构酶在基因组动态调控中的核心作用，为理解转录控制的分子机制提供了新视角。然而，研究的局限性在于尚未完全揭示其临床应用的潜力，未来可进一步探索其在疾病治疗中的应用价值。

---

## 84. 三维光声和超声自动乳腺容积扫描仪（PAUS-ABVS）在乳腺癌患者中的应用

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41296862](https://pubmed.ncbi.nlm.nih.gov/41296862)
**期刊：** Science advances
**PMID：** 41296862
**DOI：** 10.1126/sciadv.adz8585

### 第一部分 原文与翻译

**英文原标题：** A three-dimensional photoacoustic and ultrasound automated breast volume scanner (PAUS-ABVS) for breast cancer patients.

**英文摘要原文：**
Breast cancer screening with mammography is less effective in women with dense breast tissue, prompting the use of ultrasound (US) imaging. While two- (2D) and three-dimensional (3D) US improve cancer detection, their low specificity leads to frequent unnecessary biopsies. Operator dependence on 2D US has led to the development of 3D automated breast volume scanners (ABVS), but challenges remain in distinguishing benign from malignant lesions. We developed a 3D photoacoustic and ultrasound (PAUS)-ABVS system that integrates a large field-of-view, 768-element transducer to improve diagnostic accuracy. In a clinical study of 61 patients with 36 benign and 30 malignant lesions, multispectral photoacoustic imaging was used to measure blood volume and oxygen saturation within lesions. When combined with standard US BI-RADS (breast imaging reporting and data system) scores, the system achieved a sensitivity of 96.7% and specificity of 66.7%. This performance matched the best outcomes of 2D PAUS and outperformed conventional US. Our results suggest that the PAUS-ABVS can support more accurate breast cancer diagnosis while reducing unnecessary biopsies.

**中文摘要译文：**
对于乳腺组织致密的女性，乳腺X线摄影在乳腺癌筛查中效果较差，因此超声（US）成像被广泛采用。虽然二维（2D）和三维（3D）超声提高了癌症检出率，但其低特异性导致了频繁的不必要活检。2D超声对操作者的依赖性推动了3D自动乳腺容积扫描仪（ABVS）的发展，但在区分良性和恶性病变方面仍存在挑战。我们开发了一种三维光声和超声（PAUS）-ABVS系统，该系统集成了大面积视场、768阵元的换能器以提高诊断准确性。在一项包含61名患者（36例良性病变和30例恶性病变）的临床研究中，多光谱光声成像被用于测量病变内的血容量和氧饱和度。在与标准超声BI-RADS（乳腺成像报告和数据系统）评分结合使用时，该系统的灵敏度达到96.7%，特异性为66.7%。这一性能与2D PAUS的最佳结果相当，并超越了传统超声。我们的结果表明，PAUS-ABVS可以支持更准确的乳腺癌诊断，同时减少不必要的活检。

### 第二部分 AI 大师评价

本研究旨在解决乳腺组织致密女性的乳腺癌筛查难题，开发了一种集成了光声和超声技术的三维自动扫描系统（PAUS-ABVS）。通过多光谱光声成像测量病变内的血容量和氧饱和度，结合传统超声评分，显著提高了诊断的灵敏度和特异性。该系统的创新性在于其大面积视场和高精度换能器设计，使诊断准确性超越传统超声，有效减少了不必要的活检。然而，66.7%的特异性仍有提升空间，未来可通过优化成像算法进一步改善性能。

---

## 85. CTCF-RNA相互作用协调细胞特异性的染色质环组织。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41296854](https://pubmed.ncbi.nlm.nih.gov/41296854)
**期刊：** Science advances
**PMID：** 41296854
**DOI：** 10.1126/sciadv.ady5507

### 第一部分 原文与翻译

**英文原标题：** CTCF-RNA interactions orchestrate cell-specific chromatin loop organization.

**英文摘要原文：**
CCCTC-binding factor (CTCF) is essential for chromatin organization. CTCF interacts with endogenous RNAs, and deletion of its ZF1 RNA binding region (∆ZF1) disrupts chromatin loops in mouse embryonic stem cells (ESCs). However, the functional significance of CTCF-ZF1 RNA interactions during cell differentiation is unknown. Using an ESC-to-neural progenitor cell (NPC) differentiation model, we show that CTCF-ZF1 is crucial for maintaining cell type-specific chromatin loops. Expression of CTCF-∆ZF1 leads to disrupted loops and dysregulation of genes within these loops, particularly those involved in neuronal development and function. We identified NPC-specific, CTCF-ZF1 interacting RNAs. Truncation of two such coding RNAs,  and , disrupted chromatin loops in cis, similar to the disruption seen in CTCF-∆ZF1-expressing NPCs. These findings underscore the inherent importance of CTCF-ZF1 RNA interactions in preserving cell-specific genome structure and cellular identity.

**中文摘要译文：**
CCCTC结合因子（CTCF）对染色质组织至关重要。CTCF与内源性RNA相互作用，其ZF1 RNA结合区域（∆ZF1）的缺失会破坏小鼠胚胎干细胞（ESC）中的染色质环。然而，CTCF-ZF1 RNA相互作用在细胞分化过程中的功能意义尚不清楚。通过ESC向神经祖细胞（NPC）分化的模型，我们发现CTCF-ZF1对维持细胞类型特异性的染色质环至关重要。表达CTCF-∆ZF1会导致染色质环的破坏和环内基因的失调，尤其是那些参与神经发育和功能的基因。我们鉴定出NPC特异性的CTCF-ZF1相互作用RNA。截断两个这样的编码RNA，即和，会导致顺式染色质环的破坏，类似于表达CTCF-∆ZF1的NPC中所见的破坏。这些发现强调了CTCF-ZF1 RNA相互作用在维持细胞特异性基因组结构和细胞身份中的固有重要性。

### 第二部分 AI 大师评价

本研究旨在探讨CTCF-ZF1 RNA相互作用在细胞分化过程中对染色质环组织的功能意义。通过ESC向NPC分化的模型，研究者揭示了CTCF-ZF1在维持细胞特异性染色质结构和基因表达调控中的关键作用，并鉴定了NPC特异性的CTCF-ZF1相互作用RNA。这一发现不仅为理解基因组三维结构的分子机制提供了新视角，还揭示了其在神经发育和功能中的潜在影响。研究的创新性在于明确了RNA介导的染色质组织调控机制，但其局限性在于尚未阐明相关RNA的具体功能及其在疾病中的潜在应用。

---

## 86. 脑源性细胞外囊泡circUsp32极化巨噬细胞导致创伤性脑损伤后的急性肾损伤

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41296848](https://pubmed.ncbi.nlm.nih.gov/41296848)
**期刊：** Science advances
**PMID：** 41296848
**DOI：** 10.1126/sciadv.adz1243

### 第一部分 原文与翻译

**英文原标题：** Brain-derived extracellular vesicles circUsp32 polarized macrophages causing acute kidney injury after traumatic brain injury.

**英文摘要原文：**
Brain-kidney cross-talk following traumatic brain injury (TBI) can induce acute kidney injury (AKI), but mechanisms remain unclear. Extracellular vesicles derived from injured brain tissue (TBI-EVs) may mediate brain-kidney interactions. In vivo experiments demonstrated that TBI-EVs causes AKI by promoting pro-inflammatory macrophage polarization. TBI-EVs markedly increased AKI markers and proportion of pro-inflammatory-polarized macrophages. Mechanistically, transcriptomics of TBI-EVs revealed high circUsp32 expression. Subsequent in vitro assays showed that circUsp32 competitively binds to the SH2 domain of suppressor of cytokine signaling 1 (Socs1), affecting interferon regulator factor 7 (IRF7) ubiquitination and promoting pro-inflammatory polarization. CircUsp32 knockdown reduced pro-inflammatory polarization and alleviated AKI in TBI mice. In addition, circUsp32 is homologous to hsa_circ_0044940, which may serve as a predicted biomarker of AKI after TBI. Notably, AKI following TBI may contribute to neuroinflammation via uremic toxins. Collectively, these findings suggest that circUsp32 mediates macrophage polarization through the Socs1/IRF7 axis and could be a potential biomarker for AKI following TBI.

**中文摘要译文：**
创伤性脑损伤（TBI）后脑肾之间的相互作用可导致急性肾损伤（AKI），但其机制尚不明确。来源于损伤脑组织的细胞外囊泡（TBI-EVs）可能介导脑肾相互作用。体内实验表明，TBI-EVs通过促进促炎性巨噬细胞极化引发AKI。TBI-EVs显著增加了AKI标志物及促炎性极化巨噬细胞的比例。机制上，TBI-EVs的转录组学分析显示circUsp32表达水平较高。随后的体外实验表明，circUsp32竞争性结合细胞因子信号传导抑制因子1（Socs1）的SH2结构域，影响干扰素调节因子7（IRF7）的泛素化，促进促炎性极化。敲低circUsp32可减少促炎性极化并缓解TBI小鼠的AKI。此外，circUsp32与hsa_circ_0044940同源，可能作为TBI后AKI的预测生物标志物。值得注意的是，TBI后的AKI可能通过尿毒症毒素加剧神经炎症。总之，这些发现表明，circUsp32通过Socs1/IRF7轴介导巨噬细胞极化，并可能成为TBI后AKI的潜在生物标志物。

### 第二部分 AI 大师评价

本研究旨在探究创伤性脑损伤（TBI）后脑源性细胞外囊泡（TBI-EVs）通过circUsp32调节巨噬细胞极化导致急性肾损伤（AKI）的机制。研究方法结合了体内实验、转录组学分析及体外功能验证，揭示了circUsp32通过Socs1/IRF7轴促进促炎性巨噬细胞极化。关键发现是circUsp32可作为TBI后AKI的潜在生物标志物，并可能通过尿毒症毒素加剧神经炎症。研究的创新性在于阐明了脑肾相互作用的具体分子机制，具有重要的临床和科研价值。然而，未来需进一步验证circUsp32在人体中的功能及其作为生物标志物的可行性。

---

速递结束，祝您工作愉快！